UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 10-K
_____________________
(Mark One)
☒
☐
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the transition period from to
Commission file number: 001-36310
_____________________
CONCERT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
65 Hayden Avenue, Suite 3000N
Lexington, Massachusetts
(Address of principal executive offices)
20-4839882
(I.R.S. Employer
Identification No.)
02421
(Zip code)
Securities registered pursuant to Section 12(b) of the Act:
(781) 860-0045
(Registrant’s telephone number, including area code)
Title of each class
Common Stock, par value $0.001 per share
Trading Symbol(s)
CNCE
Name of each exchange on which registered
Nasdaq Global Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes ☒ No ☐
1
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-
T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the
Exchange Act.
Large accelerated filer
Non-accelerated filer
Emerging growth company
☐
☐
☐
Accelerated filer
Smaller reporting company
x
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2019 was approximately $172,718,000
based on the closing price of the registrant’s common stock on the Nasdaq Global Market on that date.
The number of shares outstanding of the registrant’s common stock as of February 21, 2020: 29,636,994
2
CONCERT PHARMACEUTICALS, INC.
TABLE OF CONTENTS
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
PART I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II
Item 5.
Item 6.
Item 7.
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV
Item 15.
Item 16.
SIGNATURES
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Person Transactions, and Director Independence
Principal Accountant Fees and Services
Exhibits and Financial Statement Schedules
Form 10-K Summary
3
6
25
53
54
54
54
55
56
57
68
68
98
98
100
101
101
101
101
101
101
103
103
REFERENCES TO CONCERT
Throughout this Annual Report on Form 10-K, “Concert,” “the Company,” “we,” “us” and “our,” except where the context requires otherwise, refer to
Concert Pharmaceuticals, Inc. and its consolidated subsidiary, and “our board of directors” refers to the board of directors of Concert Pharmaceuticals, Inc.
FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward‑looking statements that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial
position, projected costs, prospects, plans and objectives of management, are forward‑looking statements. The words “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are
intended to identify forward‑looking statements, although not all forward‑looking statements contain these identifying words.
The forward‑looking statements in this Annual Report on Form 10-K include, among other things, statements about:
ongoing and planned clinical trials for our product candidates, whether conducted by us or by our collaborators, including the timing of initiation of
these trials and of the anticipated results;
our plans to identify, develop and commercialize novel small molecule drugs based on our knowledge of deuterium chemistry;
our plans to enter into collaborations for the development and commercialization of product candidates;
our expected benefits from our current and any future collaboration, development or license arrangements;
our ability to receive research and development funding and achieve anticipated milestones under our collaborations;
our expectations regarding any future milestone payments we may receive as part of our asset purchase agreement with Vertex Pharmaceuticals, Inc.
with respect to VX-561 and payments from our other collaboration and license arrangements;
the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
the rate and degree of market acceptance and clinical utility of our products;
our commercialization, marketing and manufacturing capabilities and strategy;
our intellectual property position and strategy;
the outcome of our inter partes review proceeding regarding U.S. Patent No. 9,249,149 covering CTP-543;
our freedom to operate with respect to third-party patents;
our expectations regarding our DCE Platform® and the potential advantages of our product candidates;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
developments relating to our competitors and our industry; and
the impact of government laws and regulations.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-
looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in
Part I, Item 1A. Risk Factors, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-
looking
4
statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments that we may
make.
You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely
and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any
forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
5
Item 1.
Business
OVERVIEW
Part I
We are a clinical stage biopharmaceutical company applying our extensive knowledge of deuterium chemistry to discover and develop novel small molecule
drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic
properties, thereby enhancing their clinical safety, tolerability or efficacy. Our approach typically starts with previously studied compounds, including
approved drugs, which we believe may be improved with deuterium substitution. Our technology provides the opportunity to develop products that may
compete with the non-deuterated drug in existing markets or to leverage its known activity to expand into new indications and may enable compounds not
otherwise well-suited for human drug development to be clinically developed. Our deuterated chemical entity platform, or DCE Platform®, has broad
potential across numerous therapeutic areas. Our proprietary pipeline includes clinical stage candidates targeting autoimmune and central nervous system, or
CNS, disorders and a number of preclinical compounds that we are currently assessing.
OUR STRATEGY
Our strategy is to apply our deuterium technology to previously studied molecules, including approved drugs, in which deuterium substitution has the
potential to enhance clinical safety, tolerability or efficacy. We select pipeline candidates based on the medical needs of patients, commercial opportunity,
regulatory considerations and competitive landscape. We use deuterium technology to develop deuterated product candidates that we believe are promising in
view of the known biology of previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical
safety, tolerability or efficacy. Our strategy includes potential commercialization of product candidates on our own, or with strategic partners.
Deuterium
Due to its natural abundance, the average adult human body contains approximately two grams of deuterium. While essentially identical to hydrogen in size
and shape, deuterium differs from hydrogen in that it contains an additional neutron. As a result, deuterium forms a more stable chemical bond with carbon
than does hydrogen. The deuterium-carbon bond is typically six to nine times more stable than the hydrogen-carbon bond. This has important implications for
drug development because drug metabolism often involves the breaking of hydrogen-carbon bonds.
6
Because deuterium forms more stable bonds with carbon, deuterium substitution can in some cases alter drug metabolism, including through improved
metabolic stability, reduced formation of toxins, increased formation of desired active metabolites or a combination of these effects. At the same time, these
improvements in drug metabolism are possible without materially altering the intrinsic biological activity of a compound. Deuterated compounds with
enhanced metabolic properties can generally be expected to retain biochemical potency and selectivity similar to their hydrogen analogs. The effects, if any,
of deuterium substitution on metabolic properties are highly dependent on the specific molecular positions at which deuterium is substituted for hydrogen. In
addition, the metabolic effects of deuterium substitution, if any, are unpredictable, even in compounds that have similar chemical structures.
Potential advantages of product candidates based on our DCE Platform
Using our DCE Platform, we create novel drugs designed to have superior properties - including enhanced clinical safety, tolerability or efficacy - based on
compounds that have established pharmacological activity. In many instances, Phase 1 clinical evaluation has the potential to demonstrate whether there will
be product differentiation.
Potential advantages of our DCE Platform include the following:
•
•
•
•
Improved metabolic profile. An improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug
interactions or increase efficacy. Metabolic profile refers to the relative amounts and exposure profile of the parent drug and its metabolites or
metabolic by-products in the body.
Increased half-life. A longer half-life may decrease the number of doses that a patient is required to take per day or provide more consistent exposure
of the compound in comparison to the corresponding non-deuterated compound, potentially improving the drug’s therapeutic profile. Half-life is
usually defined as the time it takes for the body to clear half of a given concentration of the drug from the plasma.
Avoidance of undesirable metabolism. By avoiding first pass metabolism, we may be able to improve oral bioavailability, which could potentially
lead to better efficacy at a lower dose of drug. First pass metabolism is metabolism that occurs before the drug reaches the circulatory system.
Improved biodistribution. Changes in the rate of drug metabolism in a specific organ can alter drug exposure in the organ, relative to plasma
concentrations. If a deuterated drug achieves higher organ levels relative to plasma levels than its non-deuterated analog, therapeutically-relevant
drug concentrations in that organ may be achieved by administering a smaller amount of the deuterated drug.
OUR PRODUCT CANDIDATES
Our pipeline is focused on leveraging our deuterium expertise and proprietary product platform to develop novel medications designed to enhance patient
outcomes in diverse therapeutic areas including autoimmune and CNS disorders. The discussion below highlights our most advanced development programs,
including those being developed by our collaborators.
CTP-543
Background on Alopecia Areata
Alopecia areata is a serious, chronic autoimmune disease affecting approximately 650,000 Americans at any given time that results in partial or complete loss
of hair on the scalp and/or body. Alopecia areata occurs when the immune system attacks the hair follicles and is characterized as non-scarring hair loss. It
presents in a number of patterns including:
•
•
•
Patchy: coin-sized or larger patch or patches of hair loss;
Totalis: no hair on the head; and
Universalis: no hair anywhere on the body.
Onset can occur at any age including childhood, and it affects both women and men equally. The average age of onset is between 25-35 years. The emotional
effect of alopecia areata can be considerable and may result in anxiety and depression or affect personal attributes such as self-esteem and confidence.
Alopecia areata may also be associated with other autoimmune conditions such as allergic rhinitis, asthma, atopic dermatitis, lupus, rheumatoid arthritis,
thyroid disease, ulcerative colitis and vitiligo. The most common form of treatment is corticosteroids including intralesional injections or topical application.
7
However, they are typically not well tolerated and often provide limited efficacy. There are currently no treatments approved by the U.S. Food and Drug
Administration, or FDA, for alopecia areata.
CTP-543 Opportunity
CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2 that we are developing for the treatment of moderate-to-severe alopecia areata. CTP-
543 was discovered by applying our deuterium chemistry technology to modify ruxolitinib, a Janus kinase, or JAK, inhibitor, which is commercially available
under the name Jakafi® in the United States for the treatment of certain blood disorders and for graft versus host disease. The FDA has granted Fast Track
designation for CTP-543 for the treatment of alopecia areata.
Clinical Development of CTP-543
We have completed two Phase 2 trials of CTP-543 for the treatment of moderate-to-severe alopecia areata. In September 2019, we announced topline results
from a Phase 2 double-blind, randomized, dose-ranging trial to evaluate three sequential doses of CTP-543 (4, 8 and 12 mg twice-daily) and a placebo control
in 149 patients with moderate-to-severe alopecia areata. Patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary
efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from
baseline at 24 weeks. The 8 mg twice-daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving ≥
75% and ≥ 90% relative change in Severity of Alopecia Tool, or SALT, score between baseline at 24 weeks. A numerically but not statistically greater
percentage of patients treated with the 4 mg twice-daily dose of CTP-543 met the primary efficacy endpoint. At 24 weeks, patients treated with 8 mg twice-
daily and 12 mg twice-daily compared to placebo also rated significantly greater improvement in their alopecia areata on the Patient Global Impression of
Improvement Scale. Treatment with CTP-543 was generally well tolerated. The most common side effects in the 8 mg or 12 mg twice-daily groups were
headache, nasopharyngitis, upper respiratory tract infection, acne, nausea and low-density lipoprotein increase. One serious adverse event of facial cellulitis
was reported in the 12 mg twice-daily group as possibly related to treatment; however, after a brief interruption, treatment continued and this patient
completed the trial. No thromboembolic events were reported during the trial.
8
Responders: 50% Change in SALT Relative to Baseline
Patient SALT Improvement Thresholds
Relative Change in SALT from Baseline to Week 24
In December 2019, we announced that we completed an open label Phase 2 trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-
543 in 57 patients with moderate-to-severe alopecia areata. Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily
results from our Phase 2 dose-ranging trial of CTP-543. The trial measured the relative change in SALT score between baseline and 24 weeks. Treatment was
generally well tolerated in both arms of the study. All but one of the patients who completed this trial elected to continue in an ongoing open label long-term
extension study. Based on the results observed, the twice-daily regimen is preferred, and we intend to utilize it in our clinical development program for CTP-
543 going forward. A second open label Phase 2 trial evaluating 12 mg twice-daily compared to 24 mg once-daily dosing of CTP-543 in patients with
moderate-to-severe alopecia areata is ongoing.
9
As of April 2019, all patients who complete efficacy and safety studies with CTP-543 are eligible to enroll into an open label long-term extension study.
We intend to conduct an end of Phase 2 meeting with the FDA during the first quarter of 2020 and advance CTP-543 into Phase 3 evaluation during the
second half of 2020.
CTP-692
Background on Schizophrenia
Schizophrenia is a chronic and devastating neuropsychiatric disorder that is a leading cause of disability worldwide. The disease is believed to afflict nearly
1% of the world’s population, affecting both men and women equally, and striking all ethnic and socioeconomic groups with a similar level of prevalence.
The illness is characterized by multiple symptoms that are categorized into three clusters known as positive symptoms (hallucinations and delusional
behaviors), negative symptoms (anhedonia, social withdrawal and apathy) and cognitive dysfunction (diminished capacity for learning, memory and
executive function). The theory underlying current antipsychotic therapies is that excessive dopaminergic neurotransmission and dysfunctional D2 receptor
signaling plays a key pathophysiological role in the disease, and consequently all typical and atypical antipsychotics in clinical practice possess some level of
D2 antagonist or partial agonist activity. Currently available antipsychotic drugs often exhibit efficacy for positive symptoms, but have been limited in their
capacity to treat negative symptoms and cognitive deficits.
There is an extensive body of evidence supporting N-methyl-D-aspartate, or NMDA, receptor hypofunction as a key underlying mechanism of schizophrenia.
The NMDA receptor comprises two binding domains and, in addition to requiring glutamate binding, activation with a co-agonist such as D-serine or glycine
is necessary for NMDA receptor activation. D-serine is believed to be the most important human NMDA synaptic co-agonist. It has been postulated for some
time that administration of NMDA co-agonists could benefit patients with schizophrenia since there is evidence that plasma and cerebral spinal fluid, or CSF,
levels of endogenous D-serine are reduced in patients with schizophrenia. In addition, evidence of both impaired D-serine synthesis and increased D-serine
metabolism have been reported in patients with schizophrenia relative to normal individuals.
CTP-692 Opportunity
CTP-692 is a selective deuterated analog of the endogenous amino acid, D-serine. Based on published nonclinical and clinical effects of D-serine, we believe
that CTP-692 has the potential to help restore NMDA receptor activity in key areas of the brain to improve clinical outcomes in patients with schizophrenia.
Clinical studies have shown that levels of D-serine measured in the plasma and CSF of patients with schizophrenia are significantly lower than healthy
controls. Genome-wide association studies demonstrate that genetic changes that alter glutamatergic transmission, including by reducing NMDA
neurotransmission and by reducing D-serine exposure, substantially increase the likelihood of becoming schizophrenic. Academic studies have demonstrated
that oral dosing of D-serine can result in dose-dependent improvement in positive, negative and cognitive symptoms in patients with schizophrenia when
added to D2-modulating antipsychotics. However, nonclinical studies have demonstrated that D-serine can cause nephrotoxicity in rats. In addition, in some
patients who received high doses of D-serine, clinical findings suggesting renal impairment were observed. As a result, the clinical development of D-serine
has historically been limited.
In nonclinical studies in rats, when administered at doses where D-serine resulted in causing significantly increased blood levels of serum creatinine and blood
urea nitrogen, indicating renal toxicity, CTP-692 did not cause changes in blood levels of those markers, suggesting that CTP-692 could have reduced toxicity
and a larger therapeutic window. In these studies, administration of CTP-692 also resulted in greater exposure than similar doses of D-serine. It therefore may
be better-suited for development as a human therapeutic agent. CTP-692 will initially be developed as an adjunctive therapy along with standard
antipsychotic medicines in patients with schizophrenia.
Clinical Development of CTP-692
The Phase 1 program was designed to assess CTP-692’s safety, tolerability and pharmacokinetics in healthy volunteers. The Phase 1 program included three
studies: a crossover comparison of CTP-692 versus D-serine, a single-ascending dose study that also assessed the effect of food on the pharmacokinetics of
CTP-692, and a multiple-ascending dose trial assessing CTP-692 dosed orally over seven days.
In the crossover study, a single dose of CTP-692 was found to result in greater plasma exposure than did the same amount of D-serine. In the single- and
multiple-ascending dose trials, CTP-692 was evaluated across doses ranging from 0.5 to 4 grams compared to placebo in a total of 72 volunteers. CTP-692
demonstrated a favorable safety, tolerability and pharmacokinetic
10
profile with no serious adverse events reported. Importantly, key blood and urine markers of kidney function did not indicate any signs of renal impairment.
In December 2019, we initiated a double-blind, randomized, placebo-controlled Phase 2 trial to evaluate the safety and efficacy of CTP-692 as an adjunctive
treatment for schizophrenia. Approximately 300 adult patients who are stable on an antipsychotic medication will be randomized to receive 1, 2 or 4 grams of
CTP-692 or placebo once-daily. The primary outcome measure is the change in the Positive and Negative Syndrome Scale (PANSS) total score at 12 weeks
compared to baseline. We expect to report topline data from this trial by year end 2020.
Preclinical Pipeline
We are currently assessing a number of preclinical assets as potential development candidates.
Collaboration Product Candidates
In addition to our wholly owned development programs, we have entered into collaborative arrangements with companies to develop deuterium-modified
versions of their marketed products. Our partners are currently responsible for all development and future commercialization activities under these
arrangements. In each of these collaborations, the deuterium-modified compound was independently discovered by us. For example, on February 24, 2012,
we entered into a development and license agreement with Avanir Pharmaceuticals, Inc., or Avanir, a subsidiary of Otsuka Pharmaceuticals Co., Ltd. for the
worldwide rights to develop, manufacture and commercialize AVP-786. AVP-786 is a combination of deudextromethorphan and an ultra-low dose of
quinidine being investigated for the treatment of neurologic and psychiatric disorders. In 2019, Avanir completed two Phase 3 trials evaluating AVP-786 for
the treatment of agitation associated with dementia of the Alzheimer’s type. The second of the Phase 3 trials did not meet its primary or key secondary
endpoints; however, following additional data analysis, Avanir decided to continue developing AVP-786 for the treatment of agitation associated with
dementia of the Alzheimer's type. A global Phase 3 trial and open label long-term extension study for Alzheimer’s agitation are ongoing. Additionally, Avanir
is conducting a Phase 2/3 trial evaluating AVP-786 for the treatment of negative symptoms of schizophrenia.
ASSET PURCHASE AGREEMENT WITH VERTEX PHARMACEUTICALS FOR CTP-656
In July 2017, we completed the sale of worldwide development and commercialization rights to CTP-656, and other assets related to the treatment of cystic
fibrosis, to Vertex Pharmaceuticals, Inc., or Vertex. CTP-656, now known as VX-561, is an investigational cystic fibrosis transmembrane conductance
regulator, or CFTR, potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the
underlying cause of cystic fibrosis. We received $160.0 million in cash upon closing, and if VX-561 is approved as part of a combination regimen to treat
cystic fibrosis, we are eligible to receive up to $90.0 million in additional milestones based on regulatory approval in the United States and agreement for
reimbursement in the first of the U.K., Germany or France.
INTELLECTUAL PROPERTY
We protect our product candidates through the use of patents, trade secrets and careful monitoring of our proprietary know-how. Our patents and patent
applications, if they issue as patents, for our lead programs expire between 2028 and 2038. The expected expiration dates are before any patent term extension
to which we may be entitled under the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the Hatch-Waxman
Amendments) or equivalent laws in other jurisdictions where we have issued patents.
CTP-543
We hold U.S. Patent No. 9,249,149, or the '149 patent, covering the composition of matter of deuterated analogs of ruxolitinib, including CTP-543, and have a
corresponding U.S. patent application. We have corresponding patent applications in Europe and a corresponding patent and patent application in Japan. Such
patents and patent applications, if issued, are expected to expire in 2033.
We also hold U.S. Patent No. 10,561,659 covering pharmaceutical compositions of CTP-543 and methods of treating hair loss, including alopecia areata, with
CTP-543. We have corresponding patent applications in Europe and Japan. Such patent and patent applications, if issued, are expected to expire in 2037.
In April 2018, the Patent Trial and Appeal Board, or PTAB, instituted an inter partes review, or IPR, brought against the '149 patent by Incyte Corporation, or
Incyte. In April 2019, the PTAB issued a final written decision in connection with the IPR that held that the claims of the '149 patent were unpatentable as
obvious. In January 2020, the U.S. Court of Appeals for the Federal Circuit, or Federal Circuit, granted our motion to vacate and remand the PTAB final
written decision in light of the recent
11
Federal Circuit ruling on the Constitution’s Appointments Clause (Arthrex, Inc. v. Smith & Nephew, Inc., No. 18-2140). As a result, the IPR will be remanded
for reconsideration by a new panel of PTAB judges. The Federal Circuit’s grant of our motion will take effect on March 16, 2020 unless Incyte or the Director
of the U.S. Patent and Trademark Office, or PTO, who intervened in the case, seeks rehearing of the Federal Circuit’s decision. If a request for rehearing were
to be denied, the Federal Circuit’s decision would ordinarily take effect seven days after the denial. The '149 patent remains valid and enforceable while the
IPR is being reconsidered by the PTAB and until any future appeals by us have been exhausted in the event that the PTAB reaches a similar decision to
invalidate the '149 patent.
We have retained all of the CTP-543 patent rights.
CTP-692
We have a U.S. patent application covering methods of use of CTP-692 and a corresponding Patent Cooperation Treaty application. Such patent applications,
if issued, are expected to expire in 2038. We have retained all of the CTP-692 patent rights.
AVP-786
We hold U.S. patents and pending applications covering the composition of matter and methods of use of deudextromethorphan and other deuterated
dextromethorphan analogs. Such U.S. patents and patent applications, if issued, are expected to expire between 2028 and 2030. We hold corresponding
patents and patent applications in Europe and Japan. Such foreign patents and patent applications, if issued, are expected to expire in 2028. We have granted
exclusive licenses under these patent rights to Avanir.
Other Product Candidates
We also have patent portfolios that are related to a number of other programs. These patent portfolios are wholly owned by us. These include issued patents or
patent applications that claim deuterated analogs of more than 90 non-deuterated drugs and drug candidates.
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In the United States and other countries
in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application.
Under U.S. patent law, the patent term may be extended by patent term adjustment due to certain failures of the PTO to act in a timely manner. The patent
term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for
the patent term lost during the FDA regulatory review process. The Hatch-Waxman Amendments permit a patent term extension of up to five years beyond
the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension
cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug
may be extended. Similar provisions are available in Europe and other non-U.S. jurisdictions to extend the term of a patent that covers an approved drug. In
the future, if and when our pharmaceutical products receive FDA approval, we expect to apply for patent term extensions on patents that we believe are
eligible for such extension. We also intend to seek patent term extensions in other jurisdictions where these are available. However, there is no guarantee that
the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of
such extensions.
We also rely on trade secrets and careful monitoring of our proprietary know-how to protect aspects of our business that are not amenable to, or that we do not
consider appropriate for, patent protection, including our DCE Platform.
MANUFACTURING AND SUPPLY
We currently rely, and expect to continue to rely, on third parties for the manufacture of product candidates for our clinical trials. We obtain these
manufacturing services, including both the manufacture of the active pharmaceutical ingredients and finished drug product, on a purchase order basis and
have not entered into long-term contracts with any of these third-party manufacturers. We expect to rely on third parties for commercial manufacturing for
any of our product candidates that receive marketing approval.
12
We believe that all of the deuterium that we use in manufacturing our product candidates is currently derived, directly or indirectly, from deuterium oxide. For
most of our deuterium supply we rely on bulk supplies of deuterium oxide, which we currently source from multiple suppliers, including two located in North
America, one of which is in the United States.
Certain of our manufacturing processes for our product candidates incorporate deuterium by using deuterated chemical intermediates or reagents that are
derived from deuterium oxide. For the deuterated chemical intermediates and reagents, we may be subject to the license requirements applicable to deuterium
oxide. In addition, the manufacturer of the deuterated chemical intermediate or reagent may themselves be required to obtain deuterium oxide under
applicable licensing requirements. Most of the manufacturers of these deuterated chemical intermediates and reagents are not located in countries that produce
bulk quantities of deuterium oxide. Therefore, our ability to source these deuterated chemical intermediates or reagents will depend on the ability of these
manufacturers to obtain deuterium oxide from other countries.
We purchase our raw materials on a purchase order basis and have not entered into long-term contracts with any of these third-party suppliers. We believe that
the raw materials for our product candidates are readily available and that the cost of manufacturing for our product candidates will not preclude us from
selling them profitably, if approved for sale.
COMMERCIALIZATION
We have not yet established a sales, marketing or product distribution infrastructure. We plan to use a combination of third-party collaboration, licensing and
distribution arrangements and a focused in-house commercialization capability to sell any of our products that receive marketing approval. With respect to the
United States, we plan to seek to retain full commercialization rights for products that we can commercialize with a specialized sales force and to retain co-
promotion or similar rights when feasible in indications requiring a larger commercial infrastructure. We plan to collaborate with third parties for
commercialization in the United States of any products that require a large sales, marketing and product distribution infrastructure. We also plan to collaborate
with third parties for commercialization outside the United States.
We plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our
own sales organization and to oversee and support our sales force. We expect the responsibilities of the marketing organization would include developing
educational initiatives with respect to approved products and establishing relationships with thought leaders in relevant fields of medicine.
COMPETITION
The development and commercialization of new drug products is highly competitive. We expect that we, and our collaborators, will face significant
competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to our product
candidates that we, or they, may seek to develop or commercialize in the future. Specifically, there are a number of large pharmaceutical and biotechnology
companies that currently market and sell products or are pursuing the development of product candidates for the treatment of autoimmune and CNS disorders,
which are key indications for our development programs. Our competitors may succeed in developing, acquiring or licensing technologies and drug products
that are more effective, simpler to use, have fewer or more tolerable side effects or are less costly than any product candidates that we are currently
developing or that we may develop or acquire, which could render our product candidates obsolete and noncompetitive.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer
or less severe side effects, are more convenient or are less expensive than any products that we, or our collaborators, may develop. Our competitors also may
obtain FDA or other marketing approval for their products before we, or our collaborators, are able to obtain approval for ours, which could reduce our ability
to utilize expedited regulatory pathways and could result in our competitors establishing a strong market position before we, or our collaborators, are able to
enter the market.
Many of our existing and potential future competitors may have significantly greater financial resources and expertise in research and development,
manufacturing, nonclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and
acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our
competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
13
Many pharmaceutical and biotechnology companies have begun to cover deuterated analogs of their product candidates in patent applications and may
develop these deuterated compounds. Some of these pharmaceutical and biotechnology companies may have significantly greater financial resources and
expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved
products than we do. In some cases, these competitors may be interested in developing deuterated compounds that we may be interested in developing for
ourselves. Our competitors may succeed in obtaining patents that dominate our products, preventing our operational freedom. In addition, these competitors
may enter into collaborative arrangements or business combinations that result in their ability to research and develop deuterated compounds more effectively
than us. Our potential competitors also include academic institutions, government agencies and other public and private research organizations.
CTP-543
CTP-543 is a deuterated analog of ruxolitinib, which is being developed for the treatment of moderate-to-severe alopecia areata, an autoimmune disease that
results in partial or complete loss of hair on the scalp and body. If CTP-543 receives marketing approval for this indication, it may face competition from a
number of other product candidates that are being studied for alopecia areata. A number of companies are pursuing development of oral JAK inhibitors with a
range of subtype selectivities for the treatment of alopecia areata, including Eli Lilly and Company and Pfizer Inc.
CTP-692
CTP-692 is a deuterated analog of D-serine, which is being developed for the adjunctive treatment of schizophrenia. A number of companies are pursuing
development of an adjunctive treatment for schizophrenia, including SyneuRx International [Taiwan] Corp.
GOVERNMENT REGULATIONS
Government authorities in the United States, at the federal, state and local level and in other countries and jurisdictions, including the European Union,
extensively regulate, among other things, the research, development, testing, manufacture, manufacturing changes, packaging, storage, recordkeeping,
labeling, advertising, promotion, sales, distribution, marketing and import and export of pharmaceutical products. The processes for obtaining regulatory
approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable federal, state, local and foreign
statutes and regulations, require the expenditure of substantial time and financial resources.
Review and Approval of Drugs in the United States
In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. Failure to comply
with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or
sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval,
imposition of a clinical hold, issuance of warning letters and other types of letters, voluntary product recalls, product seizures, total or partial suspension of
production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal investigations and
penalties brought by the FDA and the Department of Justice or other governmental entities.
An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:
•
•
•
•
•
completion of nonclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s good laboratory practices, or GLPs;
production of well-characterized drug substance and drug product, and potentially matching placebos;
submission to the FDA of an investigational new drug application, or IND application, which allows human clinical trials to begin unless the FDA
otherwise informs the drug’s sponsor within 30 days;
agreement by clinical investigators and their clinical trial sites, followed by approval by an independent institutional review board, or IRB, representing
each clinical site, before the clinical trial may be initiated at that site;
performance of adequate and well-controlled human clinical trials in accordance with the FDA’s good clinical practices, or GCPs, to establish the safety
and efficacy of the proposed drug product for each indication;
14
•
•
•
•
•
preparation and submission to the FDA of a New Drug Application, or NDA;
review of the NDA by an FDA advisory committee, where appropriate or if applicable;
satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active
pharmaceutical ingredient or active ingredients thereof, are produced to assess compliance with the FDA's current good manufacturing practices, or
cGMPs, and to assure that the facilities, methods and controls are adequate to ensure the product’s identity, strength, quality and purity;
payment of user fees and securing FDA approval of the NDA; and
compliance with any post-approval requirements, including a risk evaluation and mitigation strategy, or REMS, and post-approval studies required by
the FDA.
Nonclinical Studies and an IND
Nonclinical studies can include in vitro and animal studies to assess the potential for efficacy and adverse events and, in some cases, to establish a rationale
for human therapeutic use. The conduct of nonclinical studies is subject to federal regulations and requirements, including GLPs. Other studies include
laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or active pharmaceutical ingredient and the physical
properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the relevant nonclinical tests,
including all tests conducted under GLPs, together with manufacturing information, analytical data, any available clinical data or literature and plans for
clinical studies, among other things, to the FDA as part of an IND. Some nonclinical testing, such as longer-term toxicity testing, animal tests of reproductive
adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA,
unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold or partial clinical hold. In
such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may
not result in the FDA allowing clinical trials to commence.
Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to
the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of
the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so.
No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the
hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the
investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or
otherwise satisfying the FDA that the investigation can proceed.
Human Clinical Studies in Support of an NDA
Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with
GCPs, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any
clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in
monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted
to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any
clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must
review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in
compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institute of Health, or
NIH, for public dissemination on their ClinicalTrials.gov website. Human clinical trials are typically conducted in three sequential phases, which may overlap
or be combined:
15
Phase 1:
The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for
safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.
Phase 2:
Phase 3:
The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to
preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and dosage for Phase
3 studies.
The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in
well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to
establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.
Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to
the FDA and investigators for serious and unexpected suspected adverse events, any findings from other studies or animal or in vitro testing that suggests a
significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or
investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for
reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the
sponsor’s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at
all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research
subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an
institution it represents, if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with
unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial
sponsor, known as the data monitoring committee, or DMC, or board. This group provides recommendations for whether or not a trial may move forward at
designated check points based on review of certain data from the trial. The FDA will often inspect one or more clinical sites in late-stage clinical trials to
assure compliance with GCPs and the integrity of the clinical data submitted.
A manufacturer of an investigational drug for a serious disease or condition is required to make available, such as by posting on its website, its policy on
evaluating and responding to requests for individual patient access to such investigational drug. This requirement applies on the earlier of the first initiation of
a Phase 2 or Phase 3 trial of the investigational drug or, as applicable, 15 days after the drug receives a designation as a Breakthrough therapy, Fast Track
product or regenerative advanced therapy.
Submission of an NDA to the FDA
Assuming successful completion of required clinical testing and other requirements, the results of the nonclinical and clinical studies, together with detailed
information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA
requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to a user
fee.
Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less
than 500 employees, or its affiliate submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one
business entity controls, or has the power to control, the other business entity, or a third party controls, or has the power to control, both entities.
The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA’s receipt of the
submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather
than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject
to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has
agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of
filing, and most applications for “priority review” products are meant to be reviewed within six months of filing. The review process may be extended by the
FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the
FDA following the original submission.
Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with
16
cGMPs and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will
typically inspect one or more clinical sites to assure compliance with GCPs.
The FDA also may require submission and agreement of a REMS to mitigate any identified or suspected serious risks prior to approving an NDA. The REMS
could include medication guides, physician communication plans, assessment plans and elements to assure safe use, such as restricted distribution methods,
patient registries or other risk minimization tools.
The FDA may also refer an application for a novel drug to an advisory committee or explain why such referral was not required. Typically, an advisory
committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to
whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it
considers such recommendations carefully when making decisions.
The FDA’s Decision on an NDA
On the basis of the FDA’s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities and
clinical sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with
specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require
substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the
FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or
six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval.
If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be
included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug’s safety after
approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution
restrictions or other risk management mechanisms, including a REMS, which can materially affect the potential market and profitability of the product. The
FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, some types of
changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing
requirements and FDA review and approval.
The product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is
released for distribution. If the product is subject to official release, the manufacturer must submit samples of each lot, together with a release protocol
showing a summary of the history of manufacture of the lot and the results of all of the manufacturer’s tests performed on the lot, to the FDA. The FDA may
in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory
research related to the safety and effectiveness of drug products.
Expedited development and review programs
The FDA has various programs, including Fast Track designation, Breakthrough designation, priority review and accelerated approval, which are intended to
expedite or facilitate the development and review of new drugs that meet certain criteria and/or provide for approval on the basis of surrogate endpoints.
New drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address
an unmet medical need for the condition. Fast Track designation is intended to facilitate early and frequent meetings between the FDA and the sponsor
company during development and the FDA may agree to review sections of an NDA on a rolling basis before the complete NDA is submitted. A drug may be
eligible for Breakthrough designation if the drug is intended to treat a serious or life-threatening disease and preliminary clinical evidence indicates that the
drug may demonstrate substantial improvement over existing therapies. Breakthrough designation provides for frequent meetings between the sponsor and the
FDA, involving senior and experience review staff, as appropriate, in a collaborative, cross-functional review and the assignment of an FDA project lead to
facilitate efficient review of the development program and serve as a scientific liaison with the sponsor. Although Fast Track and Breakthrough designation do
not affect the regulatory standards for approval, the frequent interactions with the FDA may facilitate a more efficient development program. In addition, the
NDAs for drugs granted Fast Track and Breakthrough designation may become eligible for priority review. Priority review is designed for drug candidates
that offer significant improvements in safety or effectiveness or fill an unmet medical need and provides for an initial review within six months of acceptance
of the NDA for filing, as compared to a
17
standard review of ten months after acceptance for filing. Accelerated approval provides an earlier approval of drugs that treat serious diseases, and that fill an
unmet medical need, based on a surrogate endpoint that the FDA determines is reasonably likely to predict a clinical benefit. As a condition of approval, the
FDA may require that the sponsor of a drug receiving accelerated approval perform post-marketing confirmatory clinical trials.
Even if a drug candidate qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification
or that the time period for FDA review will not be shortened.
Section 505(b)(2) NDAs
NDAs for most new drug products are based on two adequate and well-controlled clinical trials which must contain substantial evidence of the safety and
efficacy of the proposed new product. These applications are generally submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to
approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This latter type of application allows the applicant to rely, in part, on the FDA’s
previous findings of safety and efficacy for a similar reference product, or may rely on published literature. Specifically, Section 505(b)(2) applies to NDAs
for a drug for which the applicant relies, as part of its application, on investigations made to show whether or not the drug is safe and effective for use “that
were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the
investigations were conducted.”
Thus, Section 505(b)(2) authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the applicant. NDAs filed
under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses
of previously approved products. If the 505(b)(2) applicant can establish that reliance on the FDA’s previous approval is scientifically appropriate, the
applicant may eliminate the need to conduct certain nonclinical or clinical studies of the new product. The FDA may also require companies to perform
additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of
the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.
If our partners submit NDAs for approval of deuterated analogs of marketed compounds for which they are the NDA holder, we believe that in certain cases
the FDA may allow referencing of data from the non-deuterated compound in support of the application for approval of the deuterated product. Since this
referencing by our partners would involve use of their own data and not require the use of another party’s data, it would constitute a Section 505(b)(1)
application.
Post-Approval Requirements
Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things,
requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences
with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA
review and approval. There also is an annual prescription drug user fee for any marketed products, as well as new application fees for supplemental
applications with clinical data.
In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments
with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMPs.
Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require
investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party
manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and
quality control to maintain compliance with cGMPs.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with
manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other
restrictions under a REMS. Other potential consequences include, among other things:
•
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
18
•
•
•
•
fines, warning letters or holds on post-approval clinical trials;
refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or withdrawal of product approvals;
product seizure or detention, or refusal to permit the import or export of products; or
injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the
approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.
In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the
distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states.
Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in
distribution.
Abbreviated New Drug Applications for Generic Drugs
In 1984, with the passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs
previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new
drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the nonclinical and clinical testing previously
conducted for a drug product previously approved under an NDA, known as the reference listed drug, or RLD. To reference that information, however, the
ANDA applicant must demonstrate, and the FDA must conclude, that the generic drug does, in fact, perform in the same way as the RLD it purports to copy.
Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients,
the route of administration, the dosage form and the strength of the drug. At the same time, the FDA must also determine that the generic drug is
“bioequivalent” to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if “the rate and extent of absorption of the generic drug do
not show a significant difference from the rate and extent of absorption of the reference listed drug. . .”
Upon approval of an ANDA, the FDA indicates that the generic product is “therapeutically equivalent” to the RLD and it assigns a therapeutic equivalence
rating to the approved generic drug in its publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” also referred to as the “Orange
Book.” Physicians and pharmacists consider the therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by
operation of certain state laws and numerous health insurance programs, the FDA’s designation of a therapeutic equivalence rating often results in substitution
of the generic drug without the knowledge or consent of either the prescribing physician or patient.
Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired.
The FDCA provides a period of five years of data exclusivity for new drug containing a new chemical entity. For the purposes of this provision, a new
chemical entity is a drug that contains no active moiety that has been previously approved by the FDA in any other NDA. An active moiety is the molecule or
ion responsible for the physiological or pharmacological action of the drug substance. In cases where such new chemical entity exclusivity has been granted,
an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which
case the applicant may submit its application four years following the original product approval.
The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than
bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year
exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or
indication. Three year exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement
for a new clinical investigation is satisfied. Unlike five year new chemical entity exclusivity, an award of three year exclusivity does not block the FDA from
accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product.
19
Hatch-Waxman Patent Certification and the 30 Month Stay
NDA sponsors are required to list with the FDA each patent with claims that cover the applicant’s product or a method of using the product. Each of the
patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to
certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the
ANDA applicant is not seeking approval.
Specifically, the applicant must certify with respect to each patent that:
•
•
•
•
the required patent information has not been filed;
the listed patent has expired;
the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or
the listed patent is invalid, unenforceable or will not be infringed by the new product.
A certification that the new product will not infringe the already approved product’s listed patents or that such patents are invalid or unenforceable is called a
Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the
ANDA application will not be approved until all the listed patents claiming the referenced product have expired.
If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA
and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in
response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV
certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a
decision in the infringement case that is favorable to the ANDA applicant.
To the extent that the Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the
FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a
505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for
obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired and, in the case of a Paragraph IV certification
and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the
Section 505(b)(2) applicant.
Pediatric Studies and Exclusivity
Under the Pediatric Research Equity Act of 2003, as amended, an NDA or supplement thereto must contain data that are adequate to assess the safety and
effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each
pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans within 60 days of an end of Phase 2
meeting, or as may be agreed between the sponsor and the FDA. Those plans must contain an outline of the proposed pediatric study or studies the applicant
plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The applicant, the FDA
and the FDA’s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the
applicant may request an amendment to the plan at any time.
The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after efficacy and safety
has been established in adults, or full or partial waivers from the pediatric data requirements. Generally, the pediatric data requirements do not apply to
products with orphan designation.
Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six
months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity
may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show
the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA’s request, the additional
protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or
regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively
extends the regulatory period during which the FDA cannot accept or approve another application.
20
Patent Term Restoration and Extension
A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments. Those Amendments permit
a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is
typically one-half the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and
ultimate approval. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product’s approval date.
Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the
expiration of the patent in question. The PTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA.
Review and Approval of Drug Products in the European Union
In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other
countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales
and distribution of its products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the
comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval
process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The
time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory
approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or
jurisdiction may negatively impact the regulatory process in others.
Pursuant to the European Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been implemented through national
legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member
state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial after a competent ethics committee has issued a
favorable opinion. Clinical trial applications must be accompanied by an investigational medicinal product dossier with supporting information prescribed by
the European Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable guidance documents.
To obtain marketing approval of a drug under European Union regulatory systems, an applicant must submit a marketing authorization application, or MAA,
either under a centralized or decentralized procedure.
The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union
member states. The centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes,
products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain
diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a
centralized process is in the interest of patients, the centralized procedure may be optional.
Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency, or
EMA, is responsible for issuing an Opinion following the initial assessment of an MAA. Under the centralized procedure, the maximum timeframe for the
evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in
response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major
interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the
opinion of the CHMP is given within 150 days. Following a positive Opinion by the CHMP, the final authorization is issued by the European Commission.
The decentralized procedure is available to applicants who wish to market a product in various European Union member states where such product has not
received marketing approval in any European Union member states before. The decentralized procedure provides for approval by one or more other, or
concerned, member states of an assessment of an application performed by one member state designated by the applicant, known as the reference member
state. Under this procedure, an applicant submits an application based on identical dossiers and related materials to the reference member state and concerned
member states. The reference member state prepares a draft assessment report and drafts of the related materials within 120 days after receipt of a valid
application. Within 90 days after receiving the reference member state’s assessment report and related materials, each concerned member state must decide
whether to approve the assessment report and related materials.
21
If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are
subject to a dispute resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states.
Data and Market Exclusivity in the European Union
In the European Union, new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market
exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator’s data to assess a generic
(abbreviated) application for eight years, after which generic marketing authorization can be submitted, and the innovator’s data may be referenced, but not
approved for two years. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the
marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their
authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical
entity and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if
such company can complete a full MAA with a complete database of pharmaceutical tests, nonclinical tests and clinical trials and obtain marketing approval
of its product.
Pharmaceutical Coverage, Pricing and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of
products will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and
Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for such products. The
process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that
the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged for medical products and
services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might
not include all of the approved products for a particular indication. In order to secure coverage and reimbursement for any product that might be approved for
sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the
product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor’s decision to provide coverage for a drug product
does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough
to realize an appropriate return on our investment in product development.
The containment of healthcare costs has also become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this
effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and
requirements for substitution of generic products and re-importation of products sold outside of the United States. Adoption of price controls and cost-
containment measures, including importation of drugs into the United States from lower-cost countries, and adoption of more restrictive policies in
jurisdictions with existing controls and measures, could adversely affect our net revenue and results.
Outside of the United States, ensuring adequate coverage and payment for products remains challenging. Pricing of prescription pharmaceuticals is subject to
governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing
approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of our product candidates or products to other
available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.
As a result, the marketability of any product which receives regulatory approval for commercial sale may suffer if the government and third-party payors fail
to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the United States has increased and will continue to
increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular,
the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the PPACA,
contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs,
extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on
pharmaceutical companies’ share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more
products that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
22
In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be
marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-
effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options for its member states to
restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for
human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on
the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but
monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result,
increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert
competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not
allow favorable reimbursement and pricing arrangements for any of our products.
Healthcare Law and Regulation
Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of drug products that are granted
marketing approval. Arrangements with third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which
we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:
•
•
•
•
•
•
•
the federal healthcare Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual
for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made, in whole or in part, under a
federal healthcare program such as Medicare and Medicaid;
the federal civil and criminal false claims laws, including the False Claims Act, which imposes civil monetary penalties, and provides for civil
whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal
government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the
federal government;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to
defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false
statement in connection with the delivery of or payment for healthcare benefits, items or services;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes
obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of
individually identifiable health information;
the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false
statement in connection with the delivery of or payment for healthcare benefits, items or services;
the federal transparency requirements under the PPACA, which requires certain manufacturers of covered drugs to report to the Department of Health
and Human Services information related to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals, as
well as physician ownership and investment interests; and
analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that
are reimbursed by non-governmental third-party payors, including private insurers.
Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to
physicians and other health care providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in
some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
23
EMPLOYEES
As of December 31, 2019, we had 70 employees, 50 of whom were primarily engaged in research and product development activities. A total of 20
employees have Ph.D. degrees. None of our employees are represented by a labor union and we believe that our relations with our employees are good.
FACILITIES
We lease approximately 56,000 square feet of office and laboratory space at our headquarters in Lexington, Massachusetts. The lease expires on January 1,
2029.
RESEARCH AND DEVELOPMENT
We have dedicated a significant portion of our resources to our efforts to develop our pipeline and product candidates. We incurred research and development
expenses of $59.8 million and $43.1 million during the years ended December 31, 2019 and 2018, respectively. We anticipate that a significant portion of our
operating expenses in future periods will continue to be related to research and development as we continue to advance our product candidates through
clinical development.
AVAILABLE INFORMATION
We file reports and other information with the Securities and Exchange Commission, or SEC, as required by the Securities Exchange Act of 1934, as
amended, or Exchange Act. You can review our electronically filed reports and other information that we file with the SEC on the SEC’s web site at
www.sec.gov.
We were incorporated under the laws of the State of Delaware on April 12, 2006 as Concert Pharmaceuticals, Inc. Our principal executive offices are located
at 65 Hayden Avenue, Suite 3000N, Lexington, Massachusetts 02421, and our telephone number is (781) 860-0045. Our website is www.concertpharma.com.
We make available free of charge through our website our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and
amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act. We make these reports available through our
website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. In addition, we regularly use our
website to post information regarding our business, product development programs and governance, and we encourage investors to use our website,
particularly the information in the section entitled “Investors,” as a source of information about us.
The foregoing references to our website are not intended to, nor shall they be deemed to, incorporate information on our website into this Annual Report on
Form 10-K by reference.
24
Item 1A.
Risk Factors.
Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those
expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the SEC, press releases,
communications with investors and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We
undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
RISKS RELATED TO OUR FINANCIAL POSITION AND NEED FOR ADDITIONAL CAPITAL
We have incurred significant losses since inception, expect to incur losses for at least the next several years and may never sustain profitability.
As of December 31, 2019, we had an accumulated deficit of $194.7 million. We have not generated any revenues from product sales and have financed our
operations to date primarily through the public offering of our common stock, private placements of our preferred stock, debt financings and funding from
collaborations or other agreements. We have not completed development of any product candidate and have devoted substantially all of our financial
resources and efforts to research and development, including nonclinical studies and our clinical development programs. We expect to continue to incur
significant expenses and increasing operating losses for at least the next several years. Our net losses may fluctuate significantly from quarter to quarter and
year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital.
We anticipate that our expenses will increase substantially if and as we:
•
•
•
•
•
continue to develop and conduct nonclinical studies and clinical trials with respect to our product candidates;
seek to identify additional product candidates;
in-license or acquire additional product candidates;
seek marketing approvals for our product candidates that successfully complete clinical trials;
establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which we may obtain
marketing approval;
require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;
•
• maintain, expand and protect our intellectual property portfolio;
•
•
•
hire additional personnel;
add equipment and physical infrastructure to support our research and development; and
continue to implement the infrastructure necessary to support our product development and help us comply with our obligations as a public company.
Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we
are, or one of our collaborators is, able to successfully commercialize one or more of our product candidates. Doing so will require success in a range of
challenging activities, including completing clinical trials of our product candidates, obtaining marketing approval for these product candidates,
manufacturing, marketing and selling those products for which we, or our collaborators, may obtain marketing approval, satisfying any post-marketing
requirements and obtaining reimbursement for our products from private insurance or government payors. We, and our collaborators, may never succeed in
these activities and, even if we do, or one of our collaborators does, we may never generate revenues that are large enough for us to achieve profitability. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain
profitable would decrease the value of our Company and could impair our ability to raise capital, expand our business, maintain our research and development
efforts, diversify our pipeline of product candidates or continue our operations. A decline in the value of our Company could cause our stockholders to lose all
or part of their investments in us.
We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for
our future viability.
We began operations in April 2006. Our operations to date have been limited to financing and staffing our Company, developing our technology and product
candidates and establishing collaborations. We have not yet demonstrated an ability to successfully conduct an international multi-center clinical trial, conduct
a large-scale pivotal clinical trial, obtain marketing approvals, manufacture product on a commercial scale or arrange for a third party to do so on our behalf,
or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or
25
viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing
pharmaceutical products.
We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product
development programs or commercialization efforts.
Developing pharmaceutical products, including conducting nonclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process
that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we initiate new clinical trials of,
initiate new research and nonclinical development efforts for and seek marketing approval for our product candidates, or if we in-license or acquire product
candidates. In addition, if we obtain marketing approval for any of our product candidates, we may incur significant commercialization expenses related to
product sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of one of our
collaborators. In particular, the costs that we may be required to incur for the manufacture of any product candidate that receives marketing approval may be
substantial. Manufacturing a drug at commercial scale may require specialized facilities, processes and materials. Furthermore, we will continue to incur costs
associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing
operations. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce or eliminate our research and development
programs or any future commercialization efforts.
In any event, our existing cash and cash equivalents and investments will not be sufficient to fund all of the efforts that we plan to undertake or to fund the
completion of development of any of our product candidates. Accordingly, we will be required to obtain further funding through a combination of equity
offerings, debt financings, collaboration and licensing arrangements and other sources. Adequate additional financing may not be available to us on
acceptable terms, or at all. Our failure to raise capital when needed would have a negative impact on our financial condition and our ability to pursue our
business strategy.
We believe that our cash and cash equivalents and investments as of December 31, 2019, together with the net proceeds of the public offering that we
received on January 30, 2020, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2021. Our estimate
as to how long we expect our cash and cash equivalents and investments to be able to continue to fund our operations is based on assumptions that may prove
to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital
significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.
Our future funding requirements, both short-term and long-term, will depend on many factors, including:
•
•
•
•
•
•
•
•
•
the progress, timing, costs and results of clinical trials of, and research and nonclinical development efforts for, our product candidates and potential
product candidates, including current and future clinical trials;
our current collaboration agreements and achievement of milestones under these agreements;
our ability to enter into and the terms and timing of any additional collaborations, licensing, product acquisition or other arrangements that we may
establish;
the number of product candidates that we pursue and their development requirements;
the outcome, timing and costs of seeking regulatory approvals;
our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against
intellectual property related claims;
potential litigation costs; and
the costs of operating as a public company.
Raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt
financings, collaboration and licensing arrangements and other sources. We do not have any committed external source of funds, other than potential
milestone payments under our Asset Purchase Agreement with Vertex, or the Vertex Agreement, as well as potential milestone payments and royalties under
our existing license agreements, each of which is subject to the achievement of development, regulatory and/or sales-based milestones with respect to our
product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the
ownership interests of our stockholders may be materially diluted, and the terms of these securities could include liquidation or other preferences and anti-
dilution protections that could adversely affect the rights of our
26
stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive
covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could
adversely impact our ability to conduct our business.
If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise
additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant
rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Any future indebtedness could adversely affect our ability to operate our business.
We could in the future incur indebtedness containing financial obligations and restrictive covenants, which could have significant adverse consequences,
including:
•
•
•
•
•
requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital,
capital expenditures, product development and other general corporate purposes;
increasing our vulnerability to adverse changes in general economic, industry and market conditions;
subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;
limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and
placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.
Any financial obligations or restrictive covenants could negatively impact our ability to conduct our business.
RISKS RELATED TO THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF OUR PRODUCT CANDIDATES
Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or
completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug
development, including failure to demonstrate efficacy in a clinical trial or across a broad or definable population of patients, the occurrence of severe or
medically or commercially unacceptable adverse events, fraudulent conduct by clinical investigators, failure to comply with protocols, applicable regulatory
requirements or other determinations made by the FDA, or any comparable foreign regulatory authority that a drug product is not approvable. It is possible
that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more
of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors,
our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical
trials, we may fail to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not
well tolerated when that is not in fact the case.
In addition to the risk of failure inherent in drug development, certain of the deuterated compounds that we, and our collaborators, are developing and may
develop in the future may be particularly susceptible to failure to the extent they are based on compounds that others have previously studied or tested, but did
not progress in development due to safety, tolerability or efficacy concerns or otherwise. Deuteration of these compounds may not be sufficient to overcome
the problems experienced with the corresponding non-deuterated compound.
We may not be able to continue further clinical development of our wholly owned development programs, including CTP-543 and CTP-692. If we are
unable to develop, obtain marketing approval for or commercialize our wholly owned development programs, ourselves or through a collaboration, or
experience significant delays in doing so, our business could be materially harmed.
We currently have no products approved for sale. The success of our wholly owned development programs will depend on several factors, including:
27
•
•
•
•
•
•
•
•
•
•
•
•
•
in the case of CTP-543, our ability to treat moderate-to-severe alopecia areata with acceptable safety and efficacy;
in the case of CTP-692, our ability to treat schizophrenia, in patients concurrently receiving antipsychotic medication, with acceptable safety and
efficacy;
successful and timely completion of clinical trials;
receipt of marketing approvals from applicable regulatory authorities;
the performance of our future collaborators, if any, for our programs;
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
establishment of supply arrangements with third-party raw materials suppliers and manufacturers;
our ability to manufacture or arrange for the manufacture of our active pharmaceutical ingredients and drug products
with sufficient quality, quantity and reproducibility to support clinical trials and potential future commercialization;
establishment of arrangements with third-party manufacturers to obtain finished drug products that are appropriately packaged for sale;
obtaining and maintaining patent, trade secret protection, regulatory exclusivity and freedom to operate, both in the United States and internationally;
amount of commercial sales, if and when approved;
a continued acceptable safety profile of our programs following any marketing approval; and
agreement by third-party payors to reimburse patients for the costs of treatment with our products, and the terms of such reimbursement.
If we are unable to successfully develop, receive marketing approval for and commercialize our wholly owned development programs, or experience delays
as a result of any of these factors or otherwise, our business could be materially harmed.
If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we, or our collaborators,
may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these
product candidates.
We, or our collaborators, must complete nonclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our
product candidates in humans in order to obtain marketing approval from regulatory authorities for the sale of our product candidates. Clinical testing is
expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. Further, the outcome of nonclinical
studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final
results. Moreover, nonclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we cannot be
certain that we will not face similar setbacks.
Any inability to successfully complete nonclinical and clinical development could result in additional costs to us, or our collaborators, and impair our ability
to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if (1) we, or our collaborators, are required to
conduct additional or larger clinical trials or other testing of our product candidates beyond the trials and testing that we, or they, contemplate, (2) we, or our
collaborators, are unable to successfully complete clinical trials of our product candidates or other testing, (3) the results of these trials or tests are
unfavorable, uncertain or are only modestly favorable, or (4) there are unacceptable safety concerns associated with our product candidates, we, or our
collaborators, in addition to incurring additional costs, may:
•
•
•
•
•
•
be delayed in obtaining marketing approval for our product candidates;
not obtain marketing approval at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;
be subject to additional post-marketing testing or other requirements; or
be required to remove the product from the market after obtaining marketing approval.
For instance, AVP-786 is being developed under a collaboration with Avanir. In 2019, Avanir completed two Phase 3 trials evaluating AVP-786 for the
treatment of agitation associated with dementia of the Alzheimer’s type. The second of the Phase 3 trials did not meet its primary or key secondary endpoints;
however, following additional data analysis, Avanir decided to continue developing AVP-786 for the treatment of agitation associated with dementia of the
Alzheimer's type in their ongoing global Phase 3 trial and open label long-term extension study. Additionally, Avanir is conducting a Phase 2/3 trial
evaluating AVP-786 for the treatment of negative symptoms of schizophrenia. However, given the results of Avanir’s second Phase 3 trial
28
of AVP-786 for the treatment of agitation associated with dementia of the Alzheimer's type, there is no guarantee that any future trials of AVP-786 will meet
their primary or key secondary endpoints.
Even if we, or our collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable
foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.
If we, or our collaborators, experience any of a number of possible unforeseen events in connection with clinical trials of our product candidates,
potential marketing approval or commercialization of our product candidates could be delayed or prevented.
We, or our collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent marketing approval
of our product candidates, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
toxicity or serious adverse effects may be observed in our nonclinical studies causing us to delay or abandon clinical trials;
clinical trials of our product candidates may produce unfavorable or inconclusive results;
unexpectedly high placebo response rates;
rater variability in the assessment of clinical endpoints;
we, or our collaborators, may decide, or regulators may require us or them, to conduct additional clinical trials and or develop and or validate new
clinical endpoints for our clinical trials, or abandon product development programs;
the number of patients required for clinical trials of our product candidates may be larger than we, or our collaborators, anticipate, patient enrollment in
these clinical trials may be slower than we, or our collaborators, anticipate or participants may drop out of these clinical trials at a higher rate than we,
or our collaborators, anticipate;
our third-party contractors, or those of our collaborators, including those manufacturing our product candidates or components or ingredients thereof or
conducting clinical trials on our behalf or on behalf of our collaborators, may fail to comply with regulatory requirements or meet their contractual
obligations to us or our collaborators in a timely manner or at all;
criminal or unauthorized misuse of computer systems may result in disruption to our, or our partners' or vendors', clinical trials, nonclinical activities or
manufacturing, or may compromise data from our, or our partners' or vendors', clinical or nonclinical studies;
regulators or institutional review boards may not authorize us, our collaborators or our or their investigators to commence a clinical trial or conduct a
clinical trial at a prospective trial site;
we, or our collaborators, may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with
prospective trial sites;
patients that enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in
the need to drop the patients or the sites from the clinical trial, increase the needed enrollment size for the clinical trial, extend the clinical trial’s
duration or cause spurious results;
investigators may provide inaccurate or false data, resulting in spurious clinical results, an inadequate data set or regulators’ unwillingness to approve a
product;
regulators, institutional review boards or data monitoring committees may require that we, or our collaborators, or our or their investigators suspend or
terminate clinical research for various reasons, including noncompliance with regulatory requirements or their standards of conduct, a finding that the
participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate or
findings of undesirable effects caused by a chemically or mechanistically similar drug or drug candidate;
the FDA or comparable foreign regulatory authorities may disagree with our, or our collaborators’, clinical trial design or our or their interpretation of
data from nonclinical studies and clinical trials;
the FDA or comparable foreign regulatory authorities may change their requirements for approvability for a given product or for an indication after we
have initiated work based on their previous guidance;
the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product
candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;
we, or our manufacturing vendors, may not produce, or may not consistently produce material, that meets necessary specifications for
commercialization;
the FDA or comparable foreign regulatory authorities may determine that our, or our manufacturing vendors, manufacturing or quality control
processes fail to meet their specifications or guidelines; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our
clinical data insufficient to obtain marketing approval.
29
Product development costs for us, or our collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or
they, may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We, and our
collaborators, do not know whether any nonclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule,
or at all. Significant nonclinical or clinical trial delays also could shorten any periods during which we, or our collaborators, may have the exclusive right to
commercialize our product candidates or allow our competitors, or the competitors of our collaborators, to bring products to market before we, or our
collaborators, do and impair our ability, or the ability of our collaborators, to successfully commercialize our product candidates and may harm our business
and results of operations. In addition, many of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of marketing approval of
any of our product candidates.
If we, or our collaborators, experience delays or difficulties in the enrollment of patients in clinical trials, our, or their, receipt of necessary regulatory
approvals could be delayed or prevented.
We, or our collaborators, may not be able to initiate or continue clinical trials for any of our product candidates if we, or they, are unable to locate and enroll a
sufficient number of eligible patients to participate in clinical trials as required by the FDA or comparable foreign regulatory authorities, such as the European
Medicines Agency. Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
the size and nature of the patient population;
the severity of the disease under investigation;
the availability or interest of clinical sites to enroll patients into our trials;
the proximity of patients to clinical sites;
the eligibility criteria for the trial;
the design of the clinical trial, including any requirement to halt current therapy in connection with the trial;
the potential need to discontinue investigational treatment at the completion of the study;
the availability of other effective treatments for the indication we are assessing;
access to relevant clinical trial sites;
efforts to facilitate timely enrollment;
competing clinical trials;
support by relevant industry or patient organizations with influence over clinical trial sites; and
clinicians’ and patients’ perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including
any new drugs that may be approved or used for the indications we are investigating.
Our inability, or the inability of our collaborators, to enroll a sufficient number of patients for our, or their, clinical trials could result in significant delays or
may require us or them to abandon one or more clinical trials altogether. Enrollment delays in our, or their, clinical trials may result in increased development
costs for our product candidates, delay or halt the development of and approval processes for our product candidates and jeopardize our, or our collaborators’,
ability to commence sales of and generate revenues from our product candidates, which could cause the value of our Company to decline and limit our ability
to obtain additional financing, if needed.
Fast Track designation by the FDA may not lead to a faster development, regulatory review or approval.
Although CTP-543 has been granted Fast Track designation by the FDA for the treatment of alopecia areata, Fast Track designation does not necessarily lead
to a faster development pathway or regulatory review process and does not increase the likelihood of regulatory approval. The FDA may later withdraw the
designation if it believes the designation is no longer supported by the data from our clinical development program.
Serious adverse events, undesirable side effects or other unexpected properties of our product candidates, including those that we have licensed to
collaborators, may be identified during development that could delay or prevent the product candidate’s marketing approval.
All of our product candidates are in nonclinical and clinical development stages and their risk of failure is high. Serious adverse events or undesirable side
effects caused by our product candidates, or competitor products with similar mechanisms of action, could cause us, one of our collaborators, an institutional
review board, data monitoring committee or regulatory authorities to interrupt, amend, delay or halt clinical trials of one or more of our product candidates
and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. A dose of a
deuterated compound could, in comparison to an equal dose of the corresponding non-deuterated compound, result in altered exposure levels, distribution and
half-life in the body and alter the levels of particular metabolites that are present in the body.
30
These changes may cause serious adverse events or undesirable side effects that we, or our collaborators, did not anticipate, whether based on the
characteristics of the corresponding non-deuterated compound or otherwise. If any of our product candidates is associated with serious adverse events or
undesirable side effects or have properties that are unexpected, we, or our collaborators, may need to abandon development or limit development of that
product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more
acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause
undesirable or unexpected side effects that prevented further development of the compound. In addition, unexpected adverse clinical effects of a deuterated
product candidate, including either those identified by us or deuterated analogs of approved drugs being developed by any third parties, may create general
concerns regarding deuteration technology that could delay the development of our product candidates.
High placebo rates are common in neuropsychiatric clinical trials, which may result in failed clinical trials.
Placebo responses are common in clinical trials of many neuropsychiatric agents, and the rate of such responses has generally been increasing for decades in
the United States and Europe. High placebo response rates can cause even effective agents to fail to achieve statistical significance on key endpoints, resulting
in failed clinical trials. Even if our compounds demonstrate efficacy in Phase 2 studies, higher than expected placebo response rates may result in their failure
in pivotal studies and our inability to obtain regulatory approval.
Even if one of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-
party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller
than we estimate.
Even if one of our product candidates, including those licensed to our collaborators, is approved by the appropriate regulatory authorities for marketing and
sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, formulary decision-makers and others in the
medical or patient communities. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially
more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to
switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. If
any of our product candidates receive negative publicity, patients may choose not to request them even if approved, or may not comply with taking them as
prescribed.
Efforts to educate the medical community, patients, formulary decision-makers and third-party payors on the benefits of our product candidates may require
significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we
may not generate significant revenues and we may not become profitable. The degree of market acceptance of our product candidates, including those
licensed to our collaborators, if approved for commercial sale, will depend on a number of factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
the efficacy and safety of the product;
the potential advantages of the product compared to alternative treatments;
the prevalence and severity of any side effects;
the clinical indications for which the product is approved;
whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy;
limitations or warnings, including distribution or use restrictions or burdensome prescription requirements contained in the product’s approved labeling;
our ability, or the ability of our collaborators, to offer the product for sale at commercially acceptable prices;
the product’s convenience and ease of administration compared to alternative treatments;
the willingness of the target patient population to try, and of physicians to prescribe, the product;
the strength of sales, marketing and distribution support;
the approval of other new products for the same indications;
the extent and success of counter-detailing efforts by our competitors;
the pricing, extent of discounts or bundled products offered by our competitors;
the organization stability of our collaborators, if any;
changes in the standard of care for the targeted indications for the product;
the timing of market introduction of our approved products as well as competitive products; and
the availability and amount of reimbursement from government payors, managed care plans and other third-party payors.
31
The potential market opportunities for our product candidates are difficult to precisely estimate. Our estimates of the potential market opportunities are
predicated on many assumptions, including industry knowledge and publications, third-party research reports and other surveys. While we believe that our
internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain
and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual
markets for our product candidates could be smaller than our estimates of the potential market opportunities.
If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less pure, homogeneous or stable than
believed, less effective than previously believed, or causes undesirable side effects that were not previously identified or at a higher rate than was projected
during clinical development, our ability to market the drug, or that of our collaborators, could be compromised.
Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is
possible that these individuals are not representative of the actual patient population or that our clinical trials may indicate an apparent positive effect of a
product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a
product candidate, we, or others, discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously
identified, any of the following adverse events could occur:
•
•
•
•
•
•
•
regulatory authorities may withdraw their approval of the drug and/or seize the drug;
we, or our collaborators, may need to recall the drug or change the way the drug is administered;
additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug, including the addition of labeling
statements, such as a “black box” warning or a contraindication;
we may be subject to fines, injunctions or the imposition of civil or criminal penalties;
we, or our collaborators, may be required to operate under a REMS;
we, or our collaborators, could be sued and held liable for harm caused to patients; and
the drug may become less competitive.
Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price.
If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution arrangements with third parties,
we may not be successful in commercializing any product candidates that we develop if and when those product candidates are approved.
We do not have a sales, marketing or distribution infrastructure and as a company have no experience in the sale, marketing or distribution of pharmaceutical
products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to
third parties. We expect to use a combination of third-party collaboration, licensing and distribution arrangements and a focused in-house commercialization
capability to sell any products that receive marketing approval.
We generally plan to seek to retain full commercialization rights for the United States for products that we can commercialize with a specialized sales force
and to retain co-promotion or similar rights for the United States when feasible in indications requiring a larger commercial infrastructure. The development
of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming and could delay any product launch. If the
commercial launch of a product candidate for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur
for any reason, we could have prematurely or unnecessarily incurred these commercialization costs. This may be costly, and our investment could be lost if
we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire or retain a sales force in the United States that is
sufficient in size or has adequate expertise in the medical markets that we plan to target. If we are unable to establish or retain a sales force and marketing and
distribution capabilities, our operating results may be adversely affected. If a potential partner has development or commercialization expertise that we
believe is particularly relevant to one of our products, then we may seek to collaborate with that potential partner even if we believe we could otherwise
develop and commercialize the product independently.
We currently expect to collaborate with third parties for commercialization in the United States of any products that require a large sales, marketing and
product distribution infrastructure. We also expect to commercialize our product candidates outside the United States through collaboration, licensing and
distribution arrangements with third parties, if at all. As a result of entering into arrangements with third parties to perform sales, marketing and distribution
services, our product revenues or the profitability of these product revenues may be lower, perhaps substantially lower, than if we were to directly market and
sell
32
products in those markets. Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be unable to do so on
terms that are favorable to us. In addition, we may have little or no control over such third parties, and any of them may fail to devote the necessary resources
and attention to sell and market our products effectively, or may actively sell a competing product at the expense of selling ours.
If we do not establish sales and marketing capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing
any of our product candidates that receive marketing approval.
We face substantial competition from other pharmaceutical and biotechnology companies and our operating results may suffer if we fail to compete
effectively.
The development and commercialization of new drug products is highly competitive. We expect that we, and our collaborators, will face significant
competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to our product
candidates that we, or they, may seek to develop or commercialize in the future. Specifically, there are a number of large pharmaceutical and biotechnology
companies that currently market and sell products or are pursuing the development of product candidates for the treatment of autoimmune and CNS disorders,
which are key indications for our development programs. Our competitors may succeed in developing, acquiring or licensing technologies and drug products
that attain preferred reimbursement by payors or are more effective, simpler to use, have fewer or more tolerable side effects or are less costly than any
product candidates that we are currently developing or that we may develop or acquire, or which are marketed more effectively, which could render our
product candidates obsolete and noncompetitive.
We are developing CTP-543 as an oral agent for the treatment of moderate-to-severe alopecia areata. If CTP-543 receives marketing approval for this
indication, it may face competition from a number of other product candidates that are being studied for alopecia areata. A number of companies are pursuing
development of oral JAK inhibitors with a range of subtype selectivities for the treatment of alopecia areata, including Eli Lilly and Company and Pfizer Inc.
We are developing CTP-692 as an oral adjunctive treatment of schizophrenia. A number of companies are pursuing development for adjunctive treatment of
schizophrenia, exploring cognitive or negative symptoms of the disease, including SyneuRx International [Taiwan] Corp.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer
or less severe side effects, are more convenient or are less expensive than any products that we, or our collaborators, may develop. Our competitors also may
obtain FDA or other marketing approval for their products before we, or our collaborators, are able to obtain approval for ours, which could reduce our ability
to utilize expedited regulatory pathways and could result in our competitors establishing a strong market position before we, or our collaborators, are able to
enter the market.
Many of our existing and potential future competitors have significantly greater financial resources and expertise in research and development,
manufacturing, nonclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and
acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our
competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
We also face competition in the development of deuterated compounds.
Many pharmaceutical and biotechnology companies have begun to cover deuterated analogs of their product candidates in patent applications and may
develop these deuterated compounds. Some of these pharmaceutical and biotechnology companies may have significantly greater financial resources and
expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved
products than we do. In addition, other companies are utilizing deuterium substitution for drug development. In some cases, these competitors may be
interested in developing deuterated compounds that we may be interested in developing for ourselves. In addition, these competitors may enter into
collaborative arrangements or business combinations that result in their ability to research and develop deuterated compounds more effectively than us. Our
potential competitors also include academic institutions, government agencies and other public and private research organizations.
33
If our competitors in the development of deuterated compounds are able to grow their intellectual property estates and create new and successful deuterated
compounds more effectively than us, our ability to identify additional compounds for nonclinical and clinical development and obtain product revenues in
future periods could be compromised, which could result in significant harm to our operations and financial position.
If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such
authorities do not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products
could be adversely affected.
Once an NDA is approved, the product covered thereby becomes an RLD in the FDA’s publication, “Approved Drug Products with Therapeutic Equivalence
Evaluations.” Manufacturers may seek approval of generic versions of reference listed drugs through submission of ANDAs in the United States. In support
of an ANDA, a generic manufacturer need not conduct clinical studies. Rather, the applicant generally must show that its product has the same active
ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is
bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly
less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices.
Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the
generic product.
The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The
FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. Specifically, in cases where such exclusivity
has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV
certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may
submit its application four years following approval of the reference listed drug. While we believe that our product candidates contain active ingredients that
would be treated as new chemical entities by the FDA and, therefore, if approved, should be afforded at least five years of data exclusivity, the FDA may
disagree with that conclusion and may approve generic products after a period that is less than five years. Manufacturers may seek to launch these generic
products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product.
Competition that our products may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash
flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.
To the extent we, or our collaborators, market products that are deuterated analogs of generic drugs that are approved or will be approved while we
market our products in territories in which the generic drug is available, our products may compete against these generic products and the sales of our
products could be adversely affected.
We anticipate that some of the products that we, or our collaborators, may develop will be deuterated analogs of approved drugs that are or will then be
available on a generic basis. In addition, if we develop a product that is a deuterated analog of a non-generic approved drug, the FDA or comparable foreign
regulatory authorities may also approve generic versions of the corresponding non-deuterated drug. If approved, we expect that our deuterated products will
compete against these generic non-deuterated compounds if they are used in the same indications. Even if the approved indications are different for the
deuterated and non-deuterated drugs, the generic non-deuterated drug may be used off-label, negatively affecting sales of our product. Efforts to educate the
medical community and third-party payors on the benefits of any product that we develop as compared to the corresponding non-deuterated compound, or
generic versions of it, may require significant resources and may not be successful. If physicians, rightly or wrongly, do not believe that a product that we, or
our collaborators, develop offers substantial advantages over the corresponding non-deuterated compound, or generic versions of the corresponding non-
deuterated compound, or that the advantages offered by our product as compared to the corresponding non-deuterated compound, or its generic versions, are
not sufficient to merit the increased price over the corresponding non-deuterated compound, or its generic versions, that we, or our collaborators, would seek,
physicians might not prescribe that product. In addition, third-party payors may refuse to provide reimbursement for a product that we, or our collaborators,
develop when the corresponding non-deuterated compound, or generic versions of the corresponding non-deuterated compound, offer a cheaper alternative
therapy in the same indication, or may otherwise encourage use of the corresponding non-deuterated compound, or generic versions of the corresponding non-
deuterated compound, over our product, even if our product possesses favorable pharmaceutical properties or is labeled for a different indication.
Competition that our product candidates may face from any generic non-deuterated product on which our product candidate is based or a later-approved
generic version of a branded non-deuterated product on which our product is based, could materially
34
and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in
those product candidates.
Even if we, or our collaborators, are able to commercialize any product candidate that we, or they, develop, the product may become subject to
unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives that could harm our business.
The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product
candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations or reimbursed by
government health administration authorities, private health coverage insurers and other third-party payors. Government authorities and third-party payors,
such as private health insurers and health maintenance organizations, decide which medications they will cover and establish reimbursement levels. The
healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have
attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of our
collaborators to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement
may not be available to our customers, or those of our collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive
basis. Cost-control initiatives could cause us, or our collaborators, to decrease the price we, or they, might establish for products, which could result in lower
than anticipated product revenues. If reimbursement is not available, or is available only to limited levels, we, or our collaborators, may not be able to
successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us,
or our collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our, or their, investments.
There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and
reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be
marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription
pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or our collaborators, might
obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly
for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing
limitations may hinder our ability, or the ability of our collaborators, to recoup our, or their, investment in one or more product candidates, even if our product
candidates obtain marketing approval.
Third-party payor coverage of newly approved drugs may be more limited than the indications for which the drugs are approved by the FDA or comparable
foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the
drug and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be
incorporated into existing payments for other services.
In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies, requiring
burdensome comparison studies with currently approved drugs and challenging the prices charged. We, and our collaborators, cannot be sure that coverage
will be available for any product candidate that we, or they, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net
reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries
where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both
government-funded and private payors for any product candidates for which we, or our collaborators, obtain marketing approval could have a material
adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.
We may not be successful in our efforts to identify or discover additional potential product candidates.
A significant portion of our research involves the development of new deuterated compounds using our DCE Platform. These efforts may not be successful in
creating compounds that have commercial value or therapeutic utility beyond the corresponding non-deuterated compound, or at all. Our research programs
may initially show promise in creating potential product candidates, yet fail to yield viable product candidates for clinical development for a number of
reasons, including:
35
•
•
•
deuterated analogs of existing non-deuterated compounds or newly designed deuterated compounds may not demonstrate satisfactory efficacy or other
benefits, such as convenience of dosing, increased tolerability, enhanced formation of desirable active metabolites or reduced formation of toxic
metabolites;
potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to
be products that will receive marketing approval and achieve market acceptance; and
pharmaceutical and biotechnology companies have begun to claim deuterated analogs of their compounds in patent filings, resulting in otherwise
promising deuterated product candidates already being covered by patents or patent applications.
If we are unable to identify suitable additional compounds for nonclinical and clinical development, our ability to develop product candidates and obtain
product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock
price.
Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that
we may develop.
We face an inherent risk of product liability claims as a result of the clinical testing of our product candidates despite obtaining appropriate informed consents
from our clinical trial participants. We will face an even greater risk if we, or our collaborators, commercially sell any product that we may, or they may,
develop. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit
commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:
•
•
•
•
•
•
•
•
•
•
decreased demand for our product candidates or products that we may develop;
injury to our reputation and significant negative media attention;
withdrawal of clinical trial participants;
significant costs to defend litigation;
distraction to our management diverting focus from business operations and strategy;
initiation of investigations by regulators;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
substantial monetary awards to trial participants or patients;
loss of revenue; and
the inability to commercialize any products that we may develop.
Although we maintain product liability insurance coverage, it may not fully cover potential liabilities that we may incur. The cost of any product liability
litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if and when we begin
selling any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain
or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the
development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of
operations and prospects.
The increasing use of social media platforms presents risks and challenges.
The increasing use of social media platforms presents risks and challenges. Social media increasingly is being used by third parties to communicate about our
product candidates and the diseases they are designed to treat. We believe that members of the alopecia areata community may be more active on social media
as compared to other patient populations due to the demographics of this patient population. Social media practices in the pharmaceutical and biotechnology
industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients in clinical
trials may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product candidate, which could result in reporting
obligations. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social
networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive
regulatory actions or incur other harm to our business.
RISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES
We depend on collaborations with third parties for the development and commercialization of some of our product candidates and expect to continue to do
so in the future. Our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.
36
We have entered into collaborations for the development and commercialization of certain of our product candidates and expect to enter into additional
collaborations in the future. We have limited control over the amount and timing of resources that our collaborators dedicate to the development or
commercialization of our product candidates, and our ability to generate revenues from these arrangements will depend on our collaborators’ abilities to
successfully perform the functions assigned to them in these arrangements. In addition, our collaborators have the right to abandon research or development
projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms.
Collaborations involving our product candidates pose a number of risks, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
collaborators may not perform their obligations as expected;
collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or
commercialization programs, based on clinical trial results, changes in the collaborators’ strategic focus or available funding or external factors, such as
an acquisition, that divert resources or create competing priorities;
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate,
repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
collaborators may conduct their clinical trials poorly or inadequately, harming our products, including our products’ development in other territories;
product candidates developed in collaboration with us, including in particular product candidates based on deuteration of a collaborator’s marketed
drugs or advanced clinical candidates, may be viewed by our collaborators as competitive with their own product candidates or products, which may
cause collaborators to cease to devote resources to the commercialization of our product candidates;
a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of
such product or products;
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might
cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us
with respect to product candidates or might result in litigation or arbitration, any of which would be time-consuming and expensive;
collaborators may steal our trade secrets or may hire valuable employees from us;
collaborators may fail to protect our trade secrets;
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of
the applicable product candidates.
Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of
ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate
licensed to it by us.
We expect to seek to establish additional collaborations, and if we are not able to establish them on commercially reasonable terms, we may have to alter
our development and commercialization plans.
Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We
may seek one or more collaborators for the development and commercialization of one or more of our product candidates.
We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for collaboration will depend, among other
things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed
collaborator’s evaluation of a number of factors. Those factors may include the potential differentiation of our product candidate from its corresponding non-
deuterated analog, design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory
pathway for any such approval, the potential market for the product candidate, the proposed collaborator’s perception of our freedom to operate in a particular
market or markets without challenge, the costs and complexities of manufacturing and delivering the
37
product to patients and the potential of competing products. The collaborator may also consider alternative product candidates or technologies that may be
available for collaboration and whether such collaboration could be more attractive than the one with us for our product candidate.
Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business
combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We are also restricted under the
terms of certain of our existing collaboration agreements from entering into collaborations regarding or otherwise developing specified compounds that are
similar to the compounds that are subject to those agreements and collaboration agreements that we enter into in the future may contain further restrictions on
our ability to enter into potential collaborations or to otherwise develop specified compounds.
We may not be able to negotiate collaborations for our product candidates on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may
have to limit the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of
our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or increase our expenditures
and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not
have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. In cases where we
seek a collaborator for a product compound that is a deuterated analog of a compound that has been previously developed, failure to enter into a collaboration
with the developer of the corresponding non-deuterated compound may result in a loss of the potential to obtain clearance from the FDA to follow expedited
development programs that reference and rely on findings previously obtained from the developer’s prior nonclinical or clinical studies of the corresponding
non-deuterated compound.
We rely on third parties to conduct our clinical trials and some aspects of our research and nonclinical testing. If they terminate their relationships with
us or do not perform satisfactorily, our business may be materially harmed.
We do not independently conduct clinical trials of any of our product candidates. We rely on third parties, such as contract research organizations, clinical
data management organizations, medical institutions and clinical investigators, to conduct these clinical trials and expect to rely on these third parties to
conduct clinical trials of any other product candidate that we develop. We also rely on third parties to conduct some aspects of our research and nonclinical
testing and expect to rely on these third parties in the future. Any of these third parties may terminate their engagements with us under certain circumstances.
If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially
reasonable terms, or at all. Switching to or adding additional third parties would involve additional cost and require management time and focus. In addition,
there is a natural transition period when a new third party commences work, which could result in delays in our product development activities. Although we
seek to carefully manage our relationships with our contract research organizations, any such challenges or delays could have a material adverse impact on
our business, financial condition and prospects.
Our reliance on these third parties for clinical development activities limits our control over these activities but we remain responsible for ensuring that each
of our studies is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. For example,
notwithstanding the obligations of a contract research organization for a trial of one of our product candidates, we remain responsible for ensuring that each of
our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with
GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights,
integrity and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of trial sponsors, principal
investigators, clinical trial sites and institutional review boards. If we or our third-party contractors fail to comply with applicable GCPs, the clinical data
generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product
candidates, which would delay the marketing approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical
trials comply with GCPs.
Furthermore, these third parties are not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control
whether or not they devote sufficient time, skill and resources to our ongoing development programs. These contractors may also have relationships with
other commercial entities, including our competitors, which could impede their ability to devote appropriate time to our clinical programs. If these third
parties do not successfully carry out their contractual duties, meet expected deadlines or conduct their services in accordance with our contracts, regulatory
requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates. If that
occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our
38
product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed,
our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed.
We also rely on other third parties to store, label and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors
could delay clinical development or marketing approval of our product candidates or commercialization of any resulting products, producing additional losses
and depriving us of potential product revenue.
We are also required to register clinical trials and post the results of completed clinical trials on a government-sponsored database, such as ClinicalTrials.gov,
within certain timeframes. Failure to do so can result in the inability to report our clinical results in certain publications, fines, adverse publicity and civil and
criminal sanctions.
Because there are limited sources of deuterium, we, and our collaborators, are exposed to a number of risks and uncertainties associated with our
deuterium supply.
We believe that all of the deuterium that we use in manufacturing our product candidates is currently derived, directly or indirectly, from deuterium oxide. For
most of our deuterium supply, we rely on bulk supplies of deuterium oxide which we currently source from multiple suppliers, including two located in North
America, one of which is in the United States.
In order to internationally transport any deuterium oxide that we purchase from our current or potential future foreign suppliers, we, or our suppliers, may be
required to obtain an export license from the country of origin and we may be required to obtain an International Import Certificate or other governmental
approvals or assurances from the country of destination. We are also required to obtain an export license from the Nuclear Regulatory Commission before
shipping deuterium oxide from the United States to any contract manufacturer in another country. Export licenses and certain other required documents may
specify the maximum amount of deuterium oxide that we, or our suppliers, are permitted to either import or export. In order for us to obtain supplies of
deuterium oxide from foreign suppliers, they may be required to obtain an export license from the country of origin and we may be required to obtain
domestic governmental approvals or assurances. In addition, our current U.S. export licenses may be insufficient to meet our future requirements. We, or our
suppliers, may not be able to obtain such licenses, approvals or assurances in a timely manner or at all.
Certain of our manufacturing processes for our product candidates incorporate deuterium by using deuterated chemical intermediates or reagents that are
derived from deuterium oxide. For the deuterated chemical intermediates and reagents, we are not subject to the license requirements applicable to deuterium
oxide; however, the manufacturer of the deuterated chemical intermediate or reagent may themselves be required to obtain deuterium oxide under applicable
licensing requirements. Most of the manufacturers of these deuterated chemical intermediates and reagents are not located in countries that produce bulk
quantities of deuterium oxide. Therefore, our ability to source these deuterated chemical intermediates will depend on the ability of these manufacturers to
obtain deuterium oxide from other countries. Certain countries may also limit or prohibit the export of deuterium-containing products or intermediates. In the
future we may arrange for supplies of deuterated chemical intermediates or reagents from manufacturers located in countries from which they can source
deuterium oxide in bulk. However, contract manufacturers in these countries may not represent a viable alternative to our current suppliers. We do not have
long-term agreements with our suppliers of deuterated chemical intermediates or reagents and we obtain some of these deuterated chemical intermediates or
reagents from single sources, putting us at risk of uncontrolled cost increases or supply interruptions if we cannot establish alternative sourcing arrangements.
Deuterated chemical intermediates may be expensive or difficult to obtain or may be produced by specialized techniques that are not widely practiced, and we
may not be able to enter into arrangements for larger scale supply of deuterated chemical intermediates on acceptable terms, or at all.
We estimate that our current sources of deuterium oxide will be sufficient to meet our anticipated requirements; however, we do not have long-term
agreements with our current suppliers. If we are not able to establish or maintain supply arrangements, or any relevant foreign governments decide to
withhold authorizations for the export of deuterium oxide that we seek, we may be unable to secure alternative sources. If we are unable to obtain sufficient
supplies of deuterium oxide from our current suppliers or our potential future foreign supplier, we would be forced to either seek alternative suppliers of
deuterium oxide, likely in other countries, or alternative sources of deuterium. Such alternative supplies may not be available to us on acceptable terms, or at
all.
If we are unable to obtain sufficient supplies of deuterium, our ability to produce our product candidates would be impeded and our business, financial
condition and prospects could be harmed. In particular, certain of our manufacturing processes are projected to require particularly large quantities of
deuterium for late-stage clinical trials and for commercialization. Consequently, any adverse impact on our ability to obtain deuterium oxide from our current
suppliers, import deuterium oxide
39
into the United States or export deuterium oxide to our contract manufacturers could have a particularly severe impact on our ability to develop or
commercialize those product candidates.
Similarly, to develop and commercialize any of our licensed product candidates, our collaborators will need to obtain supplies of deuterium and will be
subject to risks and requirements in connection with sourcing deuterium that are similar to the ones that we face. In addition, if any of our product candidates
is approved by the FDA, then the FDA will also have regulatory jurisdiction over the manufacture and use of deuterium oxide and deuterated chemical
intermediates or reagents in such products. Any adverse impact on our, or our collaborators’, ability to obtain deuterium could delay or prevent the
development or commercialization of our product candidates, which could have a material adverse effect on our business.
We contract with third parties for the manufacture and distribution of our product candidates for nonclinical and clinical testing and expect to continue
to do so in connection with our future development and commercialization efforts. This reliance on third parties increases the risk that we will not have
sufficient quantities of our product candidates or such quantities at an acceptable cost, or that the product candidates will not be of sufficient quality or
reproducibility or produced on our desired schedule, which could delay, prevent or impair our development or commercialization efforts.
We currently rely, and expect to continue to rely, on third-party contractors to manufacture nonclinical and clinical supplies of our product candidates and to
package, label and ship these supplies. We expect to rely on third-party contractors to manufacture, formulate, package, label and distribute commercial
quantities of any product candidate that we commercialize following approval for marketing by applicable regulatory authorities. Reliance on such third-party
contractors entails risks, including:
• manufacturing delays, including if our third-party contractors give greater priority to the supply of other products over our product candidates or if they
otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
potentially incorrect data analysis, resulting in falsely-positive, falsely-negative or misleading or uninterpretable results;
potential industrial accidents such as fires or explosions that compromise our product candidates or the ability of the contractors to timely deliver them;
the possible termination or non-renewal of agreements by our third-party contractors at a time that is costly or inconvenient for us;
potentially limited numbers of available contractors due to the need for uncommon equipment or expertise, or pre-existing conflicts of interest;
the possible breach by the third-party contractors of our agreements with them;
possible theft of intellectual property or trade secrets;
possible theft of our materials, including starting materials, intermediates, active pharmaceutical ingredients or drug products;
the failure of third-party contractors to comply with applicable regulatory requirements;
the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being
properly identified;
possible contamination, or non-conformance with product or packaging specifications, of our product during or after its manufacture;
possible interruptions in our contractors’ operations, including departure of key personnel, disruption due to merger and acquisitions activities or supply
chain disruptions;
the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being
distributed to commercial vendors in a timely manner, resulting in lost sales; and
the possible misappropriation of our proprietary information, including our trade secrets and know-how.
•
•
•
•
•
•
•
•
•
•
•
•
•
If any of our product candidates are approved by any regulatory agency, we plan to enter into agreements with third-party contract manufacturers for the
commercial production and distribution of those products. It may be difficult for us to reach agreement with a contract manufacturer on satisfactory terms or
in a timely manner, especially if the manufacturer believes it is uniquely suited to use our deuterium chemistry manufacturing processes or otherwise has
unusual market power, or that our deuterium chemistry manufacturing processes bear greater production risks than manufacture of non-deuterated
compounds. In addition, we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating
under cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers
on satisfactory terms, which could delay our commercialization efforts.
Third-party manufacturers are required to comply with cGMPs and similar regulatory requirements outside the United States. Facilities used by our third-
party manufacturers must be inspected by the FDA after we submit an NDA and before potential approval of the product candidate. Similar regulations apply
to manufacturers of our product candidates for use or sale in
40
foreign countries. We do not directly control the manufacturing process and are completely dependent on our third-party manufacturers for compliance with
the applicable regulatory requirements for the manufacture of our product candidates. If our manufacturers fail to consistently manufacture material that
conforms to the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, or if they unacceptably deviate from standard
operating procedures in the production of our product candidates, they will not be able to secure the applicable approval for or a regulatory authority may find
deficiencies with their manufacturing facilities. If deficiencies are found at these facilities or if these facilities are not approved for commercial manufacture,
we may need to find alternative manufacturing facilities, which could result in delays in obtaining approval for the applicable product candidate.
In addition, our manufacturers are subject to ongoing periodic inspections by the FDA and corresponding state and foreign agencies for compliance with
cGMPs and similar regulatory requirements both prior to and following the receipt of marketing approval for any of our product candidates. Some of these
inspections may be unannounced. Failure by any of our manufacturers to comply with applicable cGMPs or other regulatory requirements could result in
sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions,
interruptions in supply and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and have a material
adverse impact on our business, financial condition and results of operations.
Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and
our ability to commercialize any products that receive marketing approval on a timely and competitive basis.
RISKS RELATED TO OUR INTELLECTUAL PROPERTY
If we are unable to obtain and maintain sufficient patent protection for our product candidates, or if the scope of the patent protection is not sufficiently
broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product
candidates may be adversely affected.
Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our
proprietary product candidates. If we do not adequately protect our intellectual property, competitors may be able to erode or negate any competitive
advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in
the United States and abroad related to our novel product candidates that are important to our business. The patent application and approval process is
expensive, uncertain and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a
timely manner. Neither deuterium itself, nor the general concept of selective substitution of deuterium for hydrogen in existing pharmaceutical compounds, is
patentable; therefore, we usually seek patents on a compound-by-compound basis or on a relatively narrow genus of compounds. We are not guaranteed that
patents will issue protecting any particular deuterated compound for which we seek patent protection. We also cannot guarantee that another company will not
be able to find a different pattern of deuterium substitution that is equally or more effective in improving the characteristics of a non-deuterated compound,
then patenting that deuterated compound and competing with us.
Our ability to obtain and maintain patent protection for our product candidates may be limited if disclosures of non-deuterated compounds are held to
anticipate or make obvious claims of deuterated analogs of the same or similar compounds in any given territory. In addition, several large pharmaceutical
and biotechnology companies have begun to pursue patent protection for deuterated analogs of their products and product candidates, and may in the future
obtain patent protection that covers deuterated analogs of those product candidates. If patents directed primarily to non-deuterated compounds are deemed to
protect deuterated analogs of those compounds or patent claims on deuterated analogs of compounds become common in the biotechnology and
pharmaceutical industries, these factors may substantially limit our ability to seek and obtain patent protection for new product candidates based on deuterium
modification of compounds. It may also limit our ability to develop new product candidates based on deuterium modification of such compounds without
obtaining a license from those patent holders. In certain cases, a company that owns the patent on a non-deuterated compound may be able to file a
continuation or divisional patent on deuterated analogs of their compounds that successfully claims priority to the original filing date of the non-deuterated
composition, causing their patent to have priority over ours, even if filed later than ours was.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims
allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination
of patent rights with respect to pharmaceutical compounds commonly involves complex legal and factual questions, which has in recent years been the
subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.
41
Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to
March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the
actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases
not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were
the first to file for patent protection of such inventions.
We may also become involved in opposition, derivation, reexamination, post grant review, or PGR, IPR or interference proceedings, in the United States or
elsewhere, challenging our patent rights or the patent rights of others. For example, in April 2018, the PTAB instituted an IPR brought against the '149 patent
by Incyte. The '149 patent covers the composition of matter of deuterated analogs of ruxolitinib, including CTP-543. In April 2019, the PTAB issued a final
written decision in connection with the IPR that held that the claims of the '149 patent were unpatentable as obvious. In January 2020, the Federal Circuit
granted our motion to vacate and remand the PTAB final written decision in light of the recent Federal Circuit ruling on the Constitution’s Appointments
Clause (Arthrex, Inc. v. Smith & Nephew, Inc., No. 18-2140). As a result, the IPR will be remanded for reconsideration by a new panel of PTAB judges. The
Federal Circuit’s grant of our motion will take effect on March 16, 2020 unless Incyte or the Director of the PTO, who intervened in the case, seeks rehearing
of the Federal Circuit’s decision. If a request for rehearing were to be denied, the Federal Circuit’s decision would ordinarily take effect seven days after the
denial. The '149 patent remains valid and enforceable while the IPR is being reconsidered by the PTAB and until any future appeals by us have been
exhausted in the event that the PTAB reaches a similar decision to invalidate the '149 patent. Adverse determinations in any such submission, proceeding or
litigation such as this could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and
compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent
rights.
Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively
prevent others from commercializing competitive products. Changes in either the patent laws or interpretation of the patent laws in the United States and
other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect
our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law restricts the patentability of methods
of treatment of the human body more than U.S. law does.
Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from
competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or
alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or otherwise
competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs to the
FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or
assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with
jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. In certain territories, losses to an
infringing product may not be sufficiently great to justify the costs of challenging the infringer and asserting our rights. In some situations, governments have
allowed or enabled the sale of competing products that infringe a company’s intellectual property. Thus, even if we have valid and nominally enforceable
patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the
courts or patent offices in the United States and abroad, including challenges through the PTO's PGR proceedings. Such challenges may result in loss of
exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using
or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition,
given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized.
If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business
would be harmed.
While we have obtained composition of matter patents with respect to our most advanced product candidates, our DCE Platform is not patented. In seeking to
develop and maintain a competitive position through our DCE Platform and as to other aspects of our business, we rely on trade secrets, including unpatented
know-how, technology and other proprietary information. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality
agreements with
42
parties who have access to them, such as our consultants, independent contractors, advisors, corporate collaborators, outside scientific collaborators, contract
manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain
consultants. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our
trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a
trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, if any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, we would have no right to prevent such third party, or those to whom they communicate such technology or
information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a
competitor, our business and competitive position could be harmed.
Third parties may sue us alleging that we are infringing their intellectual property rights, and such litigation could be costly and time consuming and
could prevent or delay us from developing or commercializing our product candidates.
Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual
property and other proprietary rights of third parties. Our CTP-543 compound is based, and potential future product candidates may be based, on products that
are covered by issued patents or patent applications, the holders of which may attempt to assert claims against us. To date, we are not aware of any judicial
decision holding that a patent that covers a non-deuterated compound should be construed to also cover deuterated analogs thereof, absent specific claims
with respect to the deuterated analogs. However, any such judicial decision, or legal proceedings asserting such claims, could increase the likelihood of
potential infringement claims being asserted against us. If any third-party patents or patent applications are found to cover our product candidates or their
methods of use, we may not be free to manufacture or market our product candidates as planned without obtaining a license, which may not be available on
commercially reasonable terms, or at all.
For example, CTP-543 is a deuterated analog of ruxolitinib. Incyte owns patents covering ruxolitinib that may be unexpired if and when we seek marketing
approval for CTP-543. Incyte also owns a U.S. patent that broadly claims deuterated analogs of ruxolitinib. On June 27, 2017, we filed a PGR with the PTAB
seeking to invalidate all claims of Incyte's U.S. patent that covers deuterated analogs of ruxolitinib. In January 2018, the PTAB did not grant our petition to
challenge the validity of Incyte's patent. In May 2018, our request for reconsideration was denied.
In addition, Columbia University is the assignee of patents licensed to Aclaris Therapeutics, Inc. claiming the use of ruxolitinib, isotopic forms of ruxolitinib
and other named JAK inhibitors for the treatment of hair loss disorders, including alopecia areata, which may be unexpired if and when we seek marketing
approval for CTP-543.
There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or
threatened with, litigation or other adversarial proceedings with respect to our product candidates. Third parties may assert infringement claims against us
based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately
quantified in advance. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent
infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the relevant patent claims or that these
patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving
invalidity under most circumstances requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.
We may also assert that a patent claim for a corresponding non-deuterated compound does not cover our product. Even if we are successful in these
proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these
proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful
conclusion.
If we are found to infringe a third party’s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or
commercializing the infringing product candidate or product and could be required to pay potentially significant damages. Alternatively, we may be required
to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product
candidate. However, we may not be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it
could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary
damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from
commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have
misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.
43
We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and
unsuccessful.
Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required
to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. In any
patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not
have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity and enforceability of such patents is
upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on
the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to
assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or
competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.
Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary
damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no
assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are
concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and
scientific personnel could outweigh any benefit we receive as a result of the proceedings.
RISKS RELATED TO REGULATORY APPROVAL AND OTHER LEGAL COMPLIANCE MATTERS
Even if we complete the necessary nonclinical studies and clinical trials, the marketing approval process is expensive, time consuming and uncertain and
we may not obtain approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which
territories, we, or our collaborators, will obtain marketing approval to commercialize a product candidate.
The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drug products are subject to extensive regulation by
the FDA and comparable foreign regulatory authorities, which regulations differ from country to country. Failure to obtain marketing approval for a product
candidate in a given territory will prevent us, and our collaborators, from commercializing the product candidate in that territory. Our product candidates are
in various stages of development and are subject to the risks of failure inherent in drug development. We, and our collaborators, have not submitted an
application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have limited experience
in filing and supporting the applications necessary to gain marketing approvals.
The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval
is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved.
This is the case even though the deuterated compounds that we produce and seek to develop can have similar pharmacological properties as their
corresponding non-deuterated compounds. Even if, as a result of any such similarities, we, or our collaborators, obtain clearance from the FDA and other
regulatory authorities to follow expedited development programs for some deuterated compounds that reference and rely on previous findings for non-
deuterated compounds, the review and approval of our product candidates may still take a substantial period of time. Conversely, in certain countries
regulators may consider our deuterated compounds to be equivalent to non-deuterated compounds that possess regulatory exclusivity and therefore refuse to
approve our compounds until the expiration of that exclusivity.
In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes,
regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an
application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data
are insufficient for approval and require additional nonclinical, clinical or other studies. In addition, varying interpretations of the data obtained from
nonclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or our collaborators,
ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.
44
Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability, or that of our collaborators, to generate revenue
from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.
Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.
In order to market and sell our products in the European Union and many other jurisdictions, we, or our collaborators, must obtain separate marketing
approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional
testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the
United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many territories outside the United States, it is
required that the product be approved for reimbursement before the product can be approved for sale in that territory. Our products may not receive
commercially feasible prices in any given territory, or the price offered for our products in a territory may have an adverse effect on their prices in other
territories if we were to accept. We, and our collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if
at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority
outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.
Even if we, or our collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products
may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.
Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation.
We, and our collaborators, must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or
they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions
and must be consistent with the information in the product’s approved labeling. Thus, we, and our collaborators, will not be able to promote any products we
develop for indications or uses for which they are not approved.
In addition, manufacturers of approved products and those manufacturers’ facilities are required to comply with extensive FDA requirements, including
ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance
as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, our collaborators and
their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.
Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators, and our and
their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production,
product surveillance and quality control.
If we, and our collaborators, are not able to comply with post-approval regulatory requirements, we, and our collaborators, could have the marketing
approvals for our products withdrawn by regulatory authorities and our, or our collaborators’, ability to market any future products could be limited, which
could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect
on our operating results and financial condition.
Any of our product candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions
or withdrawal from the market and we, or our collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory
requirements or if we, or they, experience unanticipated problems with our products following approval.
Any of our product candidates for which we, or our collaborators, obtain marketing approval in the future, as well as the manufacturing processes, post-
approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to continual requirements
of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and
reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of
records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product
candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval,
including the requirement to implement a REMS.
45
The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The
FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure
that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The
FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use and if we, or our collaborators, do not market any of our
product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or
enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and
advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state
consumer protection laws.
In addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes, or
failure to comply with regulatory requirements, may yield various results, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
restrictions on such products, manufacturers or manufacturing processes;
restrictions on the indication, patient population or other parameters for which the drug is approved;
restrictions on the labeling or marketing of a product;
restrictions on product distribution or use;
requirements to conduct post-marketing studies or clinical trials;
warning letters or untitled letters;
withdrawal of the products from the market;
refusal to approve pending applications or supplements to approved applications that we submit;
recall of products;
fines, restitution or disgorgement of profits or revenues;
reputational damage;
suspension or withdrawal of marketing approvals;
refusal to permit the import or export of products;
product seizure; or
injunctions or the imposition of civil or criminal penalties.
Recently enacted and future legislation may increase the difficulty and cost for us and our collaborators to obtain marketing approval of and
commercialize our product candidates and affect the prices we, or they, may obtain.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability,
or the ability of our collaborators, to profitably sell any products for which we, or they, obtain marketing approval.
In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and
pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement
methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs
that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we
receive for any approved products. While the MMA only addresses drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage
policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in
a similar reduction in payments from private payors.
In March 2010, President Obama signed into law the PPACA.
Among the provisions of the PPACA of potential importance to our product candidates are the following:
•
•
•
•
•
•
an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and
enhanced penalties for noncompliance;
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices;
extension of manufacturers’ Medicaid rebate liability;
expansion of eligibility criteria for Medicaid programs;
46
•
•
•
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program new requirements to report financial
arrangements with physicians and teaching hospitals;
a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along
with funding for such research.
In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. These changes included aggregate reductions to
Medicare payments to providers of up to 2% per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer
Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the
government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other
healthcare funding.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical
products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be
changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S.
Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us and our collaborators to more stringent
product labeling and post-marketing testing and other requirements.
Our future relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and
regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future
earnings.
Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain
marketing approval. Our future arrangements with third-party payors and customers, if any, will subject us to broadly applicable fraud and abuse and other
healthcare laws and regulations. The laws and regulations may constrain the business or financial arrangements and relationships through which we market,
sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations in the
United States include the following:
•
•
•
•
•
Anti-Kickback Statute. The federal Healthcare Anti-Kickback statute prohibits, among other things, persons and entities from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral
of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made, in whole or in
part, under a federal healthcare program such as Medicare and Medicaid;
False Claims Act. The federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against
individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal
healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to
pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;
HIPAA. HIPAA imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or knowingly and willfully
falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services and, as amended by the Health Information Technology for Economic and Clinical Health Act and its
implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the
privacy, security and transmission of individually identifiable health information;
Transparency Requirements. Federal transparency laws require certain manufacturers of covered drugs to report payments and other transfers of value
to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and other healthcare
providers and their immediate family members; and
Analogous State and Foreign Laws. Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, can apply to
sales or marketing arrangements and claims involving healthcare items or services. In addition, some state laws require pharmaceutical companies to
comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or
marketing expenditures and govern the privacy and security of health information in certain circumstances, many of
47
which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of
value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health
information in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating
compliance efforts.
Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.
It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment,
exclusion of products from government funded healthcare programs, such as Medicare and Medicaid and the curtailment or restructuring of our operations. If
any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they
may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
have a material adverse effect on our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use,
storage, treatment and disposal of hazardous materials and wastes. From time to time, our operations may involve the use of hazardous materials, including
chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials
and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury
resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.
We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.
We maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of
hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental
liability or toxic tort claims that may be asserted against us.
In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future
environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial
condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other
sanctions.
Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
In some countries, such as the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these
countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain
reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness
of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory
levels, our business could be materially harmed.
RISKS RELATED TO DATA PROTECTION AND CYBERSECURITY
Our failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity
and could negatively affect our operating results and business.
We are subject to data protection laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection
continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the United States, numerous federal and
state laws and regulations, including state data breach notification laws,
48
state health information privacy laws and federal and state consumer protection laws govern the collection, use, disclosure and protection of health-related
and other personal information. Failure to comply with data protection laws and regulations could result in government enforcement actions, which could
include civil or criminal penalties, private litigation and/or adverse publicity and could negatively affect our operating results and business. In addition, we
may obtain health information from third parties that are subject to privacy and security requirements under HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act. We could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable
health information in a manner that is not authorized or permitted.
The collection and use of personal health data in the European Union is governed by the provisions of the General Data Protection Regulation, or GDPR,
which came into effect in May 2018. This regulation imposes several requirements relating to the consent of the individuals to whom the personal data
relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the
security and confidentiality of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United
States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States may result
in significant fines and other administrative penalties.
Significant disruptions of information technology systems or security breaches could adversely affect our business.
We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we
collect, store and transmit large amounts of confidential information (including, among other things, trade secrets or other intellectual property, proprietary
business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential
information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors who may or
could have access to our confidential information. The size and complexity of our information technology systems, and those of third-party vendors with
whom we contract, and the large amounts of confidential information stored on those systems, make such systems vulnerable to service interruptions or to
security breaches from inadvertent or intentional actions by our employees, consultants, third-party vendors, and/or business partners, or from cyber-attacks
by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect.
Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service
reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks could also include phishing attempts or e-mail fraud to
cause payments or information to be transmitted to an unintended recipient.
Significant disruptions of our information technology systems, or those of our third-party vendors, or security breaches could adversely affect our business
operations and/or result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information,
including, among other things, trade secrets or other intellectual property, proprietary business information and personal information, and could result in
financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal
information, including personal information regarding our patients or employees, could harm our reputation, require us to comply with federal and/or state
breach notification laws and foreign law equivalents, and otherwise subject us to liability under laws and regulations that protect the privacy and security of
personal information. Security breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased
harm of the type described above. While we have implemented security measures to protect our information technology systems and infrastructure, there can
be no assurance that such measures will prevent service interruptions or security breaches that could adversely affect our business.
RISKS RELATED TO EMPLOYEE MATTERS AND MANAGING GROWTH
Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified
personnel.
Our industry has experienced a high rate of turnover of management personnel in recent years. Our ability to compete in the highly competitive biotechnology
and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and clinical personnel. We are highly
dependent on the pharmaceutical research and development and business development expertise of Roger D. Tung, our President and Chief Executive Officer,
as well as the other principal members of our management, scientific and development team. Although we have formal employment agreements with our
executive officers, these agreements do not prevent them from terminating their employment with us at any time. In addition, although we maintain a key-
man insurance policy with respect to Dr. Tung, we do not carry key-man insurance on any of our other executive officers or employees and may not carry any
key-man insurance in the future.
49
If we lose one or more of our executive officers, our ability to implement our business strategy successfully could be seriously harmed. Furthermore,
replacing executive officers may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the
breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully. Competition to hire from this
limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition
among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in
formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and
may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract
and retain high quality personnel, our ability to develop and commercialize product candidates will be limited.
We expect to grow our organization and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
As our pipeline grows and matures, we expect to experience significant growth in the number of our employees and the scope of our operations, including in
the areas of drug manufacturing, regulatory affairs and sales, clinical development, marketing and distribution. Our management may need to divert a
disproportionate amount of its attention away from our day-to-day activities to devote time to managing these growth activities. To manage these growth
activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and
train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with
such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
Moreover, the expected expansion of our operations may lead to significant costs and may divert our business development resources. Any inability to
manage growth could delay the execution of our business plans or disrupt our operations.
RISKS RELATED TO OUR COMMON STOCK
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
The trading price of our comment stock has been, and may continue to be, volatile and could be subject to wide fluctuations in response to various factors,
some of which are beyond our control. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular
have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common
stock may be influenced by many factors, including:
the success or failure of existing or new competitive products or technologies;
the timing, advancement of and results of nonclinical studies and clinical trials of any of our product candidates;
commencement or termination of collaborations for our development programs;
failure, delays, changes to or discontinuation of any of our development programs;
regulatory or legal developments in the United States and other countries;
regulatory actions relating to our product candidates;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel;
disclosures by our collaborators relating to our product candidates or competitive programs;
•
•
•
•
•
•
•
•
•
• merger or acquisition activity of our collaborators;
•
•
•
•
•
•
•
•
•
•
•
the level of expenses related to any of our product candidates or clinical development programs;
the results of our efforts to develop additional product candidates or products;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
announcement or expectation of additional financing efforts;
receipt or expectation of receipt of revenues such as milestones, royalties, grants and license fees;
sales of our common stock by us, our insiders or other stockholders;
programmed trading based on technical stock chart or other inputs;
portfolio restructuring by large stockholders or decisions by stockholders to rapidly acquire or sell our shares;
addition or removal of our stock from stock indices;
variations in our financial results or those of companies that are perceived to be similar to us;
changes in estimates or recommendations by securities analysts that cover our stock;
50
actions by short-sellers or supporters of our stock, including social media postings or reports;
changes in the structure of healthcare payment systems;
•
•
• market conditions in the pharmaceutical and biotechnology sectors;
•
•
•
•
legalization or the anticipation of possible legalization of drug reimportation from other countries;
actual or anticipated changes in FDA practices;
general economic, industry and market conditions; and
the other factors described in this “Risk Factors” section.
An active trading market for our common stock may not be sustained.
Although we have listed our common stock on the Nasdaq Global Market, an active trading market for our common stock may not be sustained. In the
absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the price at which they acquired
their shares or at the times that they would like to sell. An inactive trading market may also impair our ability to raise capital to continue to fund operations by
selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.
We have broad discretion in the use of our cash reserves and may not use them effectively.
Our management has broad discretion to use our cash reserves and could use our cash reserves in ways that do not improve our results of operations or
enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a
material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their
use, we may invest our cash reserves in a manner that does not produce income or that loses value.
We are a “smaller reporting company,” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock
less attractive to investors.
We are a smaller reporting company under applicable SEC regulations. For so long as we remain a smaller reporting company, we are permitted and plan to
rely on exemptions from certain disclosure requirements, including reduced disclosure obligations regarding executive compensation. We cannot predict
whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a
result, there may be a less active trading market for our common stock and our stock price may be more volatile.
We will continue to incur increased costs as a result of operating as a public company.
As a public company, we are incurring and expect to continue to incur significant legal, accounting and other expenses. We expect that these expenses will
further increase now that we are no longer an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, as of January 1, 2020.
Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or SOX, we are required to evaluate the effectiveness of our internal control over financial
reporting as of the end of each fiscal year and to report on this evaluation in our Annual Report on Form 10-K for the year. As an emerging growth company,
we had previously not been required to include an attestation report on internal control over financial reporting issued by our independent registered public
accounting firm. However, now that we are no longer an emerging growth company, we have included in this Annual Report on Form 10-K our first
attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We will need to continue to
dedicate internal resources, engage outside consultants and maintain a detailed work plan to assess and document the adequacy of our internal control over
financial reporting, continue to improve control processes as appropriate, validate through testing that controls are functioning as documented and maintain a
continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that in the future we will not be
able to conclude that our internal control over financial reporting is effective as required by SOX Section 404. If we identify one or more material
weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common
stock to decline significantly, even if our business is doing well.
Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the
holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.
51
In addition, as of February 21, 2020, there were 5,470,485 shares subject to outstanding options and restricted stock units under our equity compensation
plans, all of which shares are registered under the Securities Act. These shares will be able to be freely sold in the public market upon exercise, as permitted
by any applicable vesting requirements, except to the extent they are held by our affiliates, in which case such shares will become eligible for sale in the
public market as permitted by Rule 144 under the Securities Act. Furthermore, as of February 21, 2020, there were 1,861,273 shares subject to outstanding
warrants to purchase common stock, 1,800,000 shares of which are registered under the Securities Act. The remaining 61,273 shares will become eligible for
sale in the public market, to the extent such warrant is exercised, as permitted by Rule 144 under the Securities Act.
We do not anticipate paying any cash dividends on our capital stock in the foreseeable future, accordingly, stockholders must rely on capital appreciation,
if any, for any return on their investment.
We have never declared or paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to finance the operation,
development and growth of our business. Furthermore, any future debt agreements may preclude us from paying dividends. As a result, capital appreciation,
if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.
Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to substantially influence all matters submitted
to stockholders for approval.
Our executive officers and directors, combined with our stockholders who own more than 5% of our outstanding common stock, and all affiliates, in the
aggregate, beneficially own a substantial percentage of our capital stock. As a result, if these stockholders were to choose to act together, they would be able
to substantially influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they
choose to act together, would substantially influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our
assets. This concentration of ownership control may:
•
•
•
delay, defer or prevent a change in control;
entrench our management or the board of directors; or
impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.
Future sales of a substantial number of our common shares by our principal stockholders could depress the trading price of our common stock.
If our principal stockholders sell substantial amounts of shares of our common stock in the public market or if the market anticipates that these sales could
occur, the market price of shares of our common stock could decline. These sales may make it more difficult for us to sell equity or equity-related securities in
the future at a time and price that we deem appropriate, or to use equity as consideration for future acquisitions.
Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our corporate charter and our by-laws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders
may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also
limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock.
In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any
attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of
directors. Among other things, these provisions:
•
•
•
•
•
•
establish a classified board of directors such that all members of the board of directors are not elected at one time;
allow the authorized number of our directors to be changed only by resolution of our board of directors;
limit the manner in which stockholders can remove directors from the board;
establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder
meetings;
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
limit who may call a special meeting of stockholders;
52
•
•
authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work
to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors;
and
require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions
of our charter or by-laws.
Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which
prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of
the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed
manner. This could discourage, delay or prevent someone from acquiring us or merging with us, whether or not it is desired by, or beneficial to, our
stockholders.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading
volume could decline.
The trading market for our common stock depends on the research and reports that securities or industry analysts publish about us or our business. We do not
have any control over these analysts. There can be no assurance that analysts will cover us, or provide favorable coverage. If one or more analysts downgrade
our stock or change their opinion of our stock, our share price may decline. In addition, if one or more analysts cease coverage of our Company or fail to
regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.
Changes in tax law could adversely affect our business and financial condition or holders of our common stock.
The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the
Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely
affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future.
Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge stockholders
to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.
ITEM 1B. Unresolved Staff Comments
None.
53
ITEM 2. Properties
We lease our principal facilities, which consist of approximately 56,000 square feet of office and laboratory space located at 65 Hayden Avenue,
Lexington, Massachusetts. The lease expires on January 1, 2029. We believe that our facilities are sufficient for our current needs for the foreseeable future.
ITEM 3. Legal Proceedings
In April 2018, the PTAB instituted an IPR brought against the '149 patent by Incyte. The '149 patent covers the composition of matter of deuterated analogs of
ruxolitinib, including CTP-543. In April 2019, the PTAB issued a final written decision in connection with the IPR that held that the claims of the '149 patent
were unpatentable as obvious. In January 2020, the Federal Circuit granted our motion to vacate and remand the PTAB final written decision in light of the
recent Federal Circuit ruling on the Constitution’s Appointments Clause (Arthrex, Inc. v. Smith & Nephew, Inc., No. 18-2140). As a result, the IPR will be
remanded for reconsideration by a new panel of PTAB judges. The Federal Circuit’s grant of our motion will take effect on March 16, 2020 unless Incyte or
the Director of the PTO, who intervened in the case, seeks rehearing of the Federal Circuit’s decision. If a request for rehearing were to be denied, the Federal
Circuit’s decision would ordinarily take effect seven days after the denial. The '149 patent remains valid and enforceable while the IPR is being reconsidered
by the PTAB and until any future appeals by us have been exhausted in the event that the PTAB reaches a similar decision to invalidate the '149 patent.
ITEM 4. Mine Safety Disclosures
Not applicable.
54
Part II
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities
MARKET INFORMATION
Our common stock has been publicly traded on the Nasdaq Global Market under the symbol “CNCE” since February 13, 2014.
HOLDERS
As of January 31, 2020, there were 12 holders of record of our common stock. This number does not include beneficial owners whose shares are held by
nominees in street name.
DIVIDENDS
We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth
and development of our business. We do not intend to pay any cash dividends to the holders of our common stock in the foreseeable future.
55
ITEM 6.
Selected Financial Data
We are not required to provide the information required by this Item because we are a smaller reporting company.
56
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements
and the related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth
elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking
statements that involve risks and uncertainties. You should read the “Risk Factors” section in Part I, Item 1A. of this Annual Report on Form 10-K for a
discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements
contained in the following discussion and analysis.
OVERVIEW
We are a clinical stage biopharmaceutical company applying our extensive knowledge of deuterium chemistry to discover and develop novel small molecule
drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic
properties, thereby enhancing their clinical safety, tolerability or efficacy. Our approach typically starts with previously studied compounds, including
approved drugs, that we believe may be improved with deuterium substitution. Our technology provides the opportunity to develop products that may
compete with the non-deuterated drug in existing markets or to leverage its known activity to expand into new indications and may enable compounds not
otherwise well-suited for human drug development to be clinically developed. Our deuterated chemical entity platform, or DCE Platform®, has broad
potential across numerous therapeutic areas. As discussed in detail in Part I, Item 1. above, we have a robust pipeline of wholly owned programs which
includes clinical stage candidates targeting autoimmune and CNS disorders, and a number of preclinical compounds that we are currently assessing.
Since our inception in 2006, we have devoted substantially all of our resources to our research and development efforts, including activities to develop our
DCE Platform and our core capabilities in deuterium chemistry, identify potential product candidates, undertake nonclinical studies and clinical trials,
manufacture clinical trial material in compliance with cGMPs, provide general and administrative support for these operations and establish our intellectual
property. We have generated an accumulated deficit of $194.7 million since inception through December 31, 2019 and will require substantial additional
capital to fund our research and development. We do not have any products approved for sale and have not generated any revenue from product sales.
We have funded our operations primarily through the public offering and private placement of our equity, debt financing and funding from collaborations,
patent assignments and other arrangements. In March 2015, we sold 3,300,000 shares of common stock at a price to the public of $15.15 per share, resulting
in net proceeds to us of $46.7 million, after deducting the underwriting discounts, commissions and offering-related transaction costs. During January 2020,
we completed an underwriting public offering pursuant to which we sold 5,735,283 shares of common stock at the public offering price of $9.92 per share. In
addition, we sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 1,800,000 shares of common stock at a purchase price of
$9.919 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each
pre-funded warrant. The aggregate gross proceeds we received from the public offering was $74.7 million, before deducting underwriting discounts and
commissions and other offering related expenses of $4.8 million.
On March 3, 2017, we entered into the Vertex Agreement with Vertex, pursuant to which we agreed to sell and assign to Vertex CTP-656, now known as VX-
561, and other cystic fibrosis assets of ours for up to $250.0 million, subject to the satisfaction of certain closing conditions. On July 25, 2017, the transaction
contemplated by the Vertex Agreement closed, and Vertex paid us $160.0 million in cash consideration, with $16.0 million initially held in escrow, which was
released to us in February 2019. Additional information concerning the sale of CTP-656 is discussed in Note 12 to the consolidated financial statements
appearing elsewhere in this Annual Report on Form 10-K.
Our operating results may fluctuate significantly from year to year, depending on the timing and magnitude of cash payments received pursuant to
collaboration and licensing arrangements and other agreements and the timing and magnitude of clinical trial and other development activities under our
current development programs. We generated net losses of $78.2 million and $56.0 million for the years ended December 31, 2019 and 2018, respectively.
We expect to continue to incur significant expenses and operating losses for at least the next several years. We expect our expenses will increase substantially
in connection with our ongoing activities as we continue research and development efforts and develop and conduct additional nonclinical studies and clinical
trials with respect to our product candidates.
57
We do not expect to generate revenue from product sales unless and until we, or our collaborators, obtain marketing approval for one or more of our product
candidates, which we expect will take a number of years and is subject to significant uncertainty. If we obtain, or believe that we are likely to obtain,
marketing approval for any product candidates for which we retain commercialization rights, and intend to commercialize a product, we expect to incur
significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We expect to seek to fund our operations through
a combination of equity offerings, debt financings, collaboration and licensing arrangements and other sources for at least the next several years. However, we
may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter
into such other arrangements as and when needed would force us to delay, limit, reduce or terminate our research and development programs and could have a
material adverse effect on our financial condition and our ability to develop our products. We will need to generate significant revenues to achieve sustained
profitability and we may never do so.
COLLABORATIONS
We have entered into a number of collaborations for the research, development and commercialization of deuterated compounds. To date, our collaborations
have provided us with significant funding for both our specific development programs and our DCE Platform. Our collaborators also have applied their
considerable scientific, development, regulatory and commercial capabilities to the development of our compounds. In addition, in some instances, where we
develop and seek to collaborate with respect to deuterated analogs of marketed drugs or of drug candidates that are more advanced in clinical trials, our
collaborators may be eligible for an expedited development or regulatory pathway by relying on previous clinical data regarding their corresponding non-
deuterated compound. We believe that our collaborations have contributed to our ability to progress our product candidates and build our DCE Platform.
Our collaborations are discussed further in Note 12 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
ASSET PURCHASE AGREEMENT
On March 3, 2017, we entered into the Vertex Agreement pursuant to which we sold and assigned to Vertex CTP-656, now known as VX-561, and other
cystic fibrosis assets of ours. On July 25, 2017, the transaction contemplated by the Vertex Agreement closed, and Vertex paid us $160.0 million in cash
consideration, with $16.0 million initially held in escrow, which was released to us in February 2019. Additional information concerning the sale of CTP-656
is discussed in Note 12 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
Additionally, upon the achievement of certain milestone events, Vertex has agreed to pay us an aggregate of up to $90.0 million. Of this amount, $50.0
million will become payable to us upon receipt of FDA marketing approval for a combination treatment regimen containing CTP-656 for patients with cystic
fibrosis, and $40.0 million will become payable to us upon completion of a pricing and reimbursement agreement in the first of the United Kingdom,
Germany or France with respect to a combination treatment regimen containing CTP-656 for patients with cystic fibrosis.
FINANCIAL OPERATIONS OVERVIEW
Revenue
We have not generated any revenue from the sales of products. All of our revenue to date has been generated through collaboration, license and research
arrangements with collaborators and nonprofit organizations for the development and commercialization of product candidates, a patent assignment
agreement and an asset sale. On January 1, 2018, we adopted Financial Accounting Standards Board, or FASB, Accounting Standards Update, or ASU, 2014-
09, Revenue from Contracts with Customers, which is also referred to as Accounting Standards Codification, or ASC, 606. We adopted ASC 606 using the
modified retrospective approach. For detailed information regarding the adoption of ASC 606 and the impact on our consolidated financial statements, see
Note 2 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
The terms of these agreements may include one or more of the following types of payments: non-refundable license fees, payments for research and
development activities, payments based upon the achievement of specified milestones, payment of license exercise or option fees relating to product
candidates and royalties on any net product sales. To date, we have received non-refundable upfront payments, several milestone payments, payments for
research and development services provided to our collaborators, a change in control payment pursuant to a patent assignment agreement and a payment for
the sale of an
58
asset. However, we have not yet earned any license exercise or option fees, sales-based milestone payments or royalty revenue as a result of product sales.
In the future, we will seek to generate revenue from a combination of product sales and milestone payments and royalties on product sales in connection with
our current collaborations, our asset sale with Vertex or other collaborations we may enter into.
Research and development expenses
Research and development expenses consist primarily of costs incurred for the development of our product candidates, which include:
•
•
•
•
•
•
•
employee-related expenses, including salary, benefits, travel and stock-based compensation expense;
expenses incurred under agreements with contract research organizations and investigative sites that conduct our clinical trials;
the cost of acquiring, developing and manufacturing clinical trial materials;
facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other
supplies;
platform-related lab expenses, which includes costs related to synthesis, analysis and in vitro and in vivo characterization of deuterated compounds to
support the selection and progression of potential product candidates;
expenses related to consultants and advisors; and
costs associated with nonclinical activities and regulatory operations.
Research and development costs are expensed as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to
completion of specific tasks using information and data provided to us by our vendors and our clinical sites.
A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis. These external costs
include fees paid to investigators, consultants, central laboratories and contract research organizations in connection with our clinical trials, and costs related
to acquiring and manufacturing clinical trial materials. Our internal research and development costs are primarily personnel-related costs, depreciation and
other indirect costs. We do not track our internal research and development expenses on a program-by-program basis, as they are deployed across multiple
projects under development.
The successful development of any of our product candidates is highly uncertain. As such, at this time, we cannot reasonably predict with certainty the
duration and completion costs of the current or future clinical trials of any of our product candidates or if, when or to what extent we will generate revenues
from the commercialization and sale of any of our product candidates that obtain marketing approval. We may never succeed in achieving regulatory approval
for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of
factors, including:
•
•
•
•
•
•
•
the scope and rate of progress of our ongoing as well as any additional clinical trials and other research and development activities;
conduct of and results from ongoing as well as any additional clinical trials and research and development activities;
significant and changing government regulation;
the terms and timing and receipt of any regulatory approvals;
the performance of our collaborators;
our ability to manufacture any of our product candidates that we are developing or may develop in the future; and
the expense and success of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, including potential
claims that we infringe other parties' intellectual property.
A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the cost and
timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct
clinical trials or other research and development activities beyond those that we currently anticipate will be required for the completion of clinical
development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend
significant additional financial resources and time on the completion of clinical development.
59
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher
development costs than those in earlier stages of clinical development, due to the increased size and duration of later-stage clinical trials and the
manufacturing that is typically required for those later-stage clinical trials. We expect research and development costs to increase significantly for the
foreseeable future as our product candidate development programs progress, but we do not believe that it is possible at this time to accurately project total
program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product
candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our
stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.
General and administrative expenses
General and administrative expenses consist primarily of salaries and related costs for personnel, including stock-based compensation and travel expenses for
our employees in executive, operational, finance, legal, business development and human resource functions. Other general and administrative expenses
include facility-related costs, depreciation and other expenses not allocated to research and development expense and professional fees for directors,
accounting and legal services and expenses associated with obtaining and maintaining patents. In both 2019 and 2018, we incurred expenses for intellectual
property matters related to CTP-543.
We anticipate that our general and administrative expenses will increase in the future as our pipeline grows and matures. Additionally, if and when we believe
that a regulatory approval of the first product candidate that we intend to commercialize on our own appears likely, we anticipate an increase in payroll and
related expenses as a result of our preparation for commercial operations, especially as it relates to the sales, marketing and distribution of our product
candidates.
Investment income
Investment income consists of interest income earned on cash equivalents and investments. The amount of investment income earned in any particular period
may vary primarily as a result of the amount of cash equivalents and investments held during the period and the types of securities included in our portfolio
during the period. Our current investment policy is to maintain a diversified investment portfolio of U.S. government-backed securities and money market
mutual funds consisting of U.S. government-backed securities.
Unrealized loss on marketable equity securities
Unrealized loss on marketable equity securities consists of changes in the fair value of shares of common stock of Processa held by us, as discussed further in
Note 12 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
Income taxes
We record a provision or benefit for income taxes on pre-tax income or loss based on our estimated effective tax rate for the year. We had a pre-tax net loss of
$78.2 million and recorded no income tax provision or benefit during the year ended December 31, 2019. We recorded $0.3 million in income tax provision
during the year ended December 31, 2018 as a result of taxes assessed on the $16.0 million initially held in escrow under the Vertex Agreement.
CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES
Our management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have
been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments
and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our
financial statements. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable
under the circumstances. Actual results may differ from these estimates. On an ongoing basis, we evaluate our judgments and estimates in light of changes in
circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements
prospectively from the date of change in estimates.
60
While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual
Report on Form 10-K, we believe that the following accounting policies used in the preparation of our financial statements require the most significant
judgments and estimates:
•
•
•
revenue recognition;
prepaid and accrued research and development expenses; and
stock-based compensation.
Revenue recognition
We have primarily generated revenue through arrangements with collaborators for the development and commercialization of product candidates.
We adopted ASC 606 effective January 1, 2018. ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts
with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The revenue standard is based on the
principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those goods or services. The revenue standard also requires additional disclosure about the nature, amount,
timing and uncertainty of revenue and cash flows arising from customer contracts and costs to obtain or fulfill contracts. We applied ASC 606 on January 1,
2018 to all contracts using the modified retrospective approach. For additional details regarding our adoption of ASC 606 and our associated accounting
policies, refer to Notes 2 and 12 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
Prepaid and accrued research and development expenses
As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process
involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and
estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the
actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make
estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We
periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and
development expenses include fees paid to:
•
•
•
•
contract research organizations in connection with clinical trials;
investigative sites in connection with clinical trials;
vendors in connection with nonclinical development activities; and
vendors related to product manufacturing, development and distribution of clinical supplies.
We generally accrue expenses related to research and development activities based on the services received and efforts expended pursuant to contracts with
multiple contract research organizations that conduct and manage clinical trials on our behalf as well as other vendors that provide research and development
services. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There
may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense.
Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In
accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual
timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Non-refundable advance
payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when
the goods have been received rather than when the payment is made.
Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services
performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date,
there have been no material differences from our estimates to the amounts actually incurred.
Stock-based compensation
Since our inception in April 2006, we have applied the fair value recognition provisions of FASB ASC Topic 718, Compensation-Stock Compensation, or
ASC 718, to account for stock-based compensation arrangements with our employees.
61
Stock-based compensation arrangements with non-employees has not been significant. We use the Black-Scholes-Merton option pricing model for
determining the estimated fair value for stock-based awards on the date of grant, which requires the use of subjective assumptions to determine the fair value
of stock-based awards, including the award’s expected term and the price volatility of the underlying stock. We recognize the value of the portion of the
awards that is ultimately expected to vest as expense over the requisite vesting periods on a ratable basis for the entire award. Our stock option awards granted
to employees generally have a ten-year term and typically vest over a four-year period.
Expected volatility was estimated using a weighted average of our historical volatility of our common stock and the historical volatility of the common stock
of a representative group of publicly traded companies from the biopharmaceutical industry with similar characteristics as us, including stage of product
development and therapeutic focus. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our
own stock price becomes available.
The expected term of awards represents the period of time that the awards are expected to be outstanding. We use the simplified method as prescribed by the
SEC Staff Accounting Bulletin, or SAB, No. 107, Share-Based Payment, as we do not have sufficient historical exercise data to provide a reasonable basis
upon which to estimate the expected term of stock options granted to employees.
We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention of paying cash dividends. The risk-
free interest rate was estimated using an average of treasury bill interest rates over a period commensurate with the expected term of the option at the time of
grant. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
We have computed the fair value of employee stock options at the date of grant using the following weighted-average assumptions:
Expected volatility
Expected term
Risk-free interest rate
Expected dividend yield
Year ended December 31,
2019
2018
76.83%
6.0 years
2.16%
—%
77.22%
6.0 years
2.64%
—%
We have granted restricted stock units and performance stock units to our employees and members of our senior management team. We recognize
compensation expense for restricted stock units ratably over the required service period. For awards with performance conditions in which the award does not
vest unless the performance condition is met, we recognize expense only if we estimate that achievement of the performance condition is probable. If we
conclude that vesting is probable, we recognize expense from the date that we reach this conclusion through the estimated vesting date using an accelerated
attribution method.
PENDING AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
For detailed information regarding recently issued accounting pronouncements and the expected impact on our consolidated financial statements, see Note 2
to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
RESULTS OF OPERATIONS
Discussion of the year ended December 31, 2019
The following table summarizes our results of operations for the year ended December 31, 2019.
62
(in thousands)
Revenue:
License and research and development revenue
Total revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Investment income
Other income
Unrealized loss on marketable equity securities
Net loss
License and research and development revenue
Year ended December 31,
2019
$
$
1,077
1,077
59,816
20,276
80,092
(79,015)
2,987
12
(2,150)
(78,166)
License and research and development revenue was $1.1 million for the year ended December 31, 2019. The revenue recognized in 2019 was primarily a
result of the License Agreement, or the Cipla Agreement, entered into in the first quarter of 2019 with Cipla Technologies LLC, or Cipla. We recognized $1.0
million in revenue associated with this arrangement for the year ended December 31, 2019. For additional details related to the Cipla Agreement, see Note 12
to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
The decrease in license and research and development revenue compared to $10.5 million for the year ended December 31, 2018 is due to the upfront
consideration received from Processa of 2,090,301 shares of its common stock with a fair value of $10.5 million on the date of the transaction, which was
recorded in fiscal year 2018. For additional details related to the transaction with Processa, see Note 12 to the consolidated financial statements appearing
elsewhere in this Annual Report on Form 10-K.
As of December 31, 2019, we had deferred revenue of:
•
•
$7.8 million related to our collaboration with Celgene Corporation, or Celgene, consisting of $1.3 million related to the R&D Services Performance
Obligation, $0.1 million related to the Supply Performance Obligation and $6.4 million related to the First and Second Discount Performance
Obligations; and
$2.8 million related to a payment received from GlaxoSmithKline, or GSK.
Research and development expenses
The following table summarizes our external research and development expenses, by program, for the year ended December 31, 2019, with our internal
research expenses separately classified by category.
(in thousands)
CTP-543 external costs
CTP-692 external costs
External costs for other programs
Employee and contractor-related expenses
Facility and other expenses
Total research and development expenses
Year ended December 31,
2019
$
$
17,388
14,126
3,279
19,498
5,525
59,816
Research and development expenses were $59.8 million for the year ended December 31, 2019. CTP-543 expenses primarily related to clinical development,
including multiple Phase 2 clinical trials. CTP-692 expenses were attributable to the Phase 1 clinical trials completed in 2019 and manufacturing costs to
support the advancement of the CTP-692 program into a Phase 2
63
clinical trial. Employee-related expenses consisted primarily of cash and non-cash stock-based compensation expenses. Facility-related expenses consisted
primarily of rent and maintenance of our premises. External costs for other programs includes a $0.5 million payment to the nonprofit organization Fast
Forward in the first quarter of 2019 under an existing agreement related to CTP-354 between us and Fast Forward, which was triggered by the upfront
payment pursuant to the Cipla Agreement, and costs incurred to develop our research pipeline.
The $16.7 million increase in research and development costs for the year ended December 31, 2019 compared to the year ended December 31, 2018 is due to
multiple CTP-543 Phase 2 clinical trials, multiple CTP-692 Phase 1 clinical trials and manufacturing costs to support the continued development of CTP-692.
General and administrative expenses
The following table summarizes our general and administrative expenses for the year ended December 31, 2019.
(in thousands)
Employee salaries and benefits
External professional service and legal expenses
Facility, technology and other expenses
Depreciation and amortization
Total general and administrative expenses
Year ended December 31,
2019
$
$
11,000
5,173
3,797
306
20,276
General and administrative expenses for the year ended December 31, 2019 consisted primarily of salaries and related costs for personnel, including non-cash
stock-based compensation. Other general and administrative expenses included accounting and legal services, office and facility-related costs.
Total general and administrative expenses for the year ended December 31, 2019 decreased by $2.7 million compared to the year ended December 31, 2018.
Salaries and benefits decreased $1.7 million and legal costs decreased $0.8 million compared to the year ended December 31, 2018. These decreases are
slightly offset by an increase of $0.2 million in audit and other professional fees compared to the year ended December 31, 2018.
Investment income
Investment income was $3.0 million for the year ended December 31, 2019 and consisted of interest income earned on cash equivalents and investments.
Unrealized loss on marketable equity securities
We recorded an unrealized loss on marketable equity securities of $2.2 million during the year ended December 31, 2019. Unrealized loss on marketable
equity securities consists of changes in the fair value of shares of common stock of Processa held by us, as discussed further in Note 12 to the consolidated
financial statements appearing elsewhere in this Annual Report on Form 10-K.
Discussion of the year ended December 31, 2018
The following table summarizes our results of operations for the year ended December 31, 2018.
64
(in thousands)
Revenue:
License and research and development revenue
Total revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Investment income
Other income
Unrealized loss on marketable equity securities
Loss before income taxes
Provision for income taxes
Net loss
License and research and development revenue
Year ended December 31,
2018
$
$
10,505
10,505
43,149
22,940
66,089
(55,584)
2,787
12
(2,926)
(55,711)
313
(56,024)
License and research and development revenue was $10.5 million for the year ended December 31, 2018. In 2018, we granted Processa an exclusive,
worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-499 in exchange for upfront consideration of 2,090,301 shares of
common stock of Processa with a fair value of $10.5 million on the date of the transaction, which was recorded as license and research and development
revenue during fiscal year 2018. For further details related to our transaction with Processa, refer to Note 12 to the consolidated financial statements
appearing elsewhere in this Annual Report on Form 10-K.
Research and development expenses
The following table summarizes our external research and development expenses, by program, for the year ended December 31, 2018, with our internal
research expenses separately classified by category.
(in thousands)
CTP-543 external costs
CTP-692 external costs
External costs for other programs
Employee and contractor-related expenses
Facility and other expenses
Total research and development expenses
Year ended December 31,
2018
$
$
9,254
7,417
3,147
17,876
5,455
43,149
Research and development expenses were $43.1 million for the year ended December 31, 2018. CTP-543 expenses primarily related to ongoing Phase 2
clinical study and manufacturing costs to support continued advancement of the CTP-543 program. CTP-692 expenses were attributable to costs incurred
related to Phase 1 clinical trials and manufacturing activities to support the development of CTP-692. Employee-related expenses consisted primarily of cash
and non-cash stock-based compensation expenses for the year ended December 31, 2018. Facility-related expenses consisted primarily of rent and other
office costs. External costs for other programs consisted of costs incurred to develop our research pipeline.
General and administrative expenses
The following table summarizes our general and administrative expenses for the year ended December 31, 2018.
65
(in thousands)
Employee salaries and benefits
External professional service and legal expenses
Facility, technology and other expenses
Depreciation and amortization
Total general and administrative expenses
Investment income
Year ended December 31,
2018
$
$
12,662
5,805
4,307
166
22,940
Investment income was $2.8 million for the year ended December 31, 2018 and consisted of interest income earned on cash equivalents and investments.
Unrealized loss on marketable equity securities
The unrealized loss on marketable equity securities of $2.9 million consisted of changes in the fair value of shares of common stock of Processa held by us, as
discussed further in Note 12 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
Provision for income taxes
We recorded $0.3 million in income tax expense during the year ended December 31, 2018. The provision for 2018 primarily consisted of interest owed to
federal and state tax authorities due to the deferral of $16.0 million in income from Vertex for cash initially held in escrow but received in February 2019.
LIQUIDITY AND CAPITAL RESOURCES
We have incurred cumulative losses and negative cash flows from operations since our inception in April 2006, and as of December 31, 2019, we had an
accumulated deficit of $194.7 million. We anticipate that we will continue to incur losses for at least the next several years. We expect that our research and
development and general and administrative expenses will continue to increase and, as a result, we will need additional capital to fund our operations, which
we may raise through a combination of equity offerings, debt financings, collaboration and licensing arrangements and other sources.
We have financed our operations to date primarily through the public offering and private placement of our equity, debt financing and funding from
collaborations and patent assignments. During February 2014, we completed our initial public offering, or IPO, whereby we sold 6,649,690 shares of common
stock at a price to the public of $14.00 per share, raising aggregate net proceeds of $83.1 million. During March 2015, we sold 3,300,000 shares of common
stock through an underwritten public offering at a price to the public of $15.15 per share, raising aggregate net proceeds of $46.7 million. During January
2020, we completed an underwriting public offering pursuant to which we sold 5,735,283 shares of common stock at the public offering price of $9.92 per
share. In addition, we sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 1,800,000 shares of common stock at a
purchase price of $9.919 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise
price for each pre-funded warrant. The aggregate gross proceeds we received from the public offering was $74.7 million, before deducting underwriting
discounts and commissions and other offering related expenses of $4.8 million.
In June 2015, we received proceeds of $50.2 million in connection with a change in control payment from Auspex Pharmaceuticals, Inc., or Auspex, relating
to the acquisition of Auspex by Teva Pharmaceutical Industries Ltd., or Teva.
In July 2017, the transaction contemplated by the Vertex Agreement closed, as discussed further in Note 12 to the consolidated financial statements appearing
elsewhere in this Annual Report on Form 10-K, and Vertex paid us $160.0 million in cash consideration, with $16.0 million initially held in escrow, which
was released to us in February 2019.
As of December 31, 2019, we had cash and cash equivalents and investments of $106.4 million. Cash in excess of immediate requirements is invested in
accordance with our investment policy, primarily with a view to liquidity and capital preservation.
66
Currently, our funds are held in U.S. government-backed securities and money market mutual funds consisting of U.S. government-backed securities.
Cash flows
The following table sets forth the primary sources and uses of cash for each of the periods presented:
(in thousands)
Net cash (used in) provided by:
Operating activities
Investing activities
Financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Discussion of the years ended December 31, 2019 and 2018
Year ended December 31,
2019
2018
$
$
(48,761) $
82,583
1,451
35,273 $
(48,029)
37,903
(169)
(10,295)
Operating activities. The cash used in operating activities generally approximates our net loss adjusted for non-cash items and changes in operating assets and
liabilities. During the year ended December 31, 2019, we received a $16.0 million payment from Vertex for funds previously held in escrow to secure
potential indemnity claims, as discussed further in Note 12 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
During the year ended December 31, 2019, our operating activities used cash of $48.8 million as compared to cash used by operating activities of $48.0
million during the prior year. The cash used during both 2019 and 2018 was largely driven by our development activities associated with CTP-543 and CTP-
692, our wholly owned development programs.
Investing activities. Net cash used in investing activities consisted of purchases of investments, purchases of fixed assets and proceeds from the maturity of
investments. Net cash used to purchase investments for the years ended December 31, 2019 and 2018 was $97.8 million and $99.4 million, respectively. Net
cash provided by maturities of investments for the years ended December 31, 2019 and 2018 was $181.1 million and $140.2 million, respectively. Purchases
of fixed assets for the years ended December 31, 2019 and 2018 was $0.7 million and $2.9 million, respectively. The decrease in the purchases of fixed assets
during the 2019 period is primarily due to new office and laboratory equipment purchased in 2018 to support our new office and laboratory space, as
discussed further in Note 11 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
Financing activities. During the years ended December 31, 2019 and 2018, our financing activities generated cash of $1.5 million and used cash of $0.2
million, respectively. Cash generated during the year ended December 31, 2019 consisted of $1.1 million of proceeds from the exercise of stock options and
$1.0 million of proceeds from the exercise of warrants, offset by $0.7 million used to pay withholding taxes on behalf of employees in connection with the
vesting and settlement of restricted stock units, in exchange for the surrender of shares of common stock by employees. Cash used during the year ended
December 31, 2018 was attributable to paying $1.2 million of withholding taxes on behalf of employees in connection with the vesting and settlement of
restricted stock units, in exchange for the surrender of shares of common stock by employees, offset by $1.0 million in proceeds from the exercise of stock
options.
Operating capital requirements
We do not anticipate commercializing any of our product candidates for several years. We anticipate that we will continue to generate losses for the
foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates and
begin to commercialize any approved products for which we retain commercialization rights. We are subject to all of the risks incident in the development of
new drug products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our
business, as well as additional risks stemming from the unproven nature of deuterated drugs.
Based on our current expectations, including with respect to our development plans, we believe that our cash and cash equivalents and investments as of
December 31, 2019, together with the net proceeds of the public offering that we received on January 30, 2020, will enable us to fund our operating expenses
and capital expenditure requirements into the second half of
67
2021. However, we will require additional capital for the further development of our existing product candidates and may also need to raise additional funds
sooner to pursue other development activities related to additional product candidates.
To date, we have not generated any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we, or
our collaborators, obtain marketing approval of and commercialize one of our current or future product candidates. Because our product candidates are in
various stages of development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete
development and commercialization of our product candidates or whether or when we will achieve profitability. We anticipate that we will continue to
generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek marketing approvals for, our
product candidates and begin to commercialize any approved products for which we retain commercialization rights.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt
financings, collaboration and licensing arrangements and other sources. Except for any obligations of our collaborators to reimburse us for research and
development expenses or to make milestone payments under our agreements with them, we do not have any additional committed external sources of funds.
Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional funds when needed, we may be required to delay,
limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we
would otherwise prefer to develop and market ourselves. If we raise additional funds through the issuance of additional debt or equity securities, it could
result in dilution to our existing stockholders, increased fixed payment obligations and the issuance of securities with rights senior to those of our common
stock. We may become subject to covenants under any future indebtedness that could limit our ability to take specific actions, such as incurring additional
debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business.
Our expectation with respect to the period of time through which our financial resources will be adequate to support our operations is a forward-looking
statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including those discussed in the "Risk Factors"
section in Part I, Item 1A. of this Annual Report on Form 10-K. We have based this estimate on assumptions that may prove to be wrong, and we could utilize
our available capital resources sooner than we currently expect. If we cannot expand our operations or otherwise capitalize on our business opportunities
because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.
OFF-BALANCE SHEET ARRANGEMENTS
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the
SEC.
ITEM 7A.
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk related to changes in interest rates. Our current investment policy is to maintain a diversified investment portfolio in U.S.
government-backed securities and money market mutual funds consisting of U.S. government-backed securities. Our cash is deposited in and invested
through highly rated financial institutions in North America. As of December 31, 2019 and 2018, we had $106.4 million and $153.3 million of cash, cash
equivalents and investments, respectively. The fair value of cash equivalents and investments is subject to change as a result of potential changes in market
interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of these investments, an immediate 100 basis point change in
interest rates at levels as of December 31, 2019 would not have a material effect on the fair value of our cash equivalents and short-term investments.
We contract with suppliers of raw materials and contract manufacturers internationally. Transactions with these providers are predominantly settled in U.S.
dollars and, therefore, we believe that we have only minimal exposure to foreign currency exchange risks. We do not hedge against foreign currency risks.
Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business,
financial condition or results of operations during the years ended December 31, 2019 or 2018.
68
ITEM 8.
Financial Statements and Supplementary Data
INDEX TO FINANCIAL STATEMENTS
Report of independent registered public accounting firm
Consolidated balance sheets
Consolidated statements of operations and comprehensive loss
Consolidated statements of stockholders’ equity
Consolidated statements of cash flows
Notes to consolidated financial statements
69
70
71
73
74
75
76
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Concert Pharmaceuticals, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Concert Pharmaceuticals, Inc. (the Company) as of December 31, 2019 and 2018, the
related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for each of the two years in the period ended
December 31, 2019, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and
its cash flows for each of the two years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's
internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 27, 2020 expressed an unqualified
opinion thereon.
Adoption of ASU No. 2016-02
As discussed in Note 11 to the consolidated financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of
Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842), and related amendments.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial
statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the Company's auditor since 2007.
Boston, Massachusetts
February 27, 2020
70
CONCERT PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
$
$
$
Assets
Current assets:
Cash and cash equivalents
Investments, available for sale
Marketable equity securities
Interest receivable
Deferred offering costs
Accounts receivable
Contract asset (Note 12)
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Restricted cash
Other assets
Income taxes receivable
Operating lease right-of-use assets, long-term (Note 11)
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued expenses and other liabilities
Income taxes payable
Deferred revenue, current portion
Lease liability, current portion (Note 11)
Total current liabilities
Deferred revenue, net of current portion
Deferred lease incentive, net of current portion
Deferred rent, net of current portion
Lease liability, net of current portion (Note 11)
Total liabilities
Commitments (Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; no shares issued and
outstanding as of December 31, 2019 and 2018, respectively
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 24,065,676 and
23,518,690 shares issued and 23,865,075 and 23,437,587 outstanding as of December 31, 2019
and 2018, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
December 31,
2019
2018
(Amounts in thousands, except
share and per share data)
53,043 $
53,395
5,375
260
143
72
—
4,567
116,855
7,753
1,157
96
2,358
9,252
17,770
135,544
7,525
556
—
15
16,000
2,739
180,149
8,919
1,157
—
2,322
—
137,471 $
192,547
881 $
8,336
—
7,783
268
17,268
2,750
—
—
15,996
36,014
—
24
296,145
(31)
(194,681)
101,457
1,277
5,669
390
1,413
—
8,749
9,120
4,088
2,850
—
24,807
—
23
284,369
(137)
(116,515)
167,740
192,547
$
137,471 $
71
See accompanying notes.
72
CONCERT PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Year ended
December 31,
2019
2018
(Amounts in thousands, except per
share data)
Revenue:
License and research and development revenue
$
Total revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Investment income
Other income
Unrealized loss on marketable equity securities
Loss before income taxes
Provision for income taxes
Net loss
Other comprehensive income:
Unrealized gain on investments, net of tax of $76 in 2018
Comprehensive loss
Net loss attributable to common stockholders - basic and diluted
Net loss per share attributable to common stockholders - basic and diluted
$
$
$
$
1,077 $
1,077
59,816
20,276
80,092
(79,015)
2,987
12
(2,150)
(78,166)
—
(78,166) $
106
(78,060) $
(78,166) $
(3.29) $
10,505
10,505
43,149
22,940
66,089
(55,584)
2,787
12
(2,926)
(55,711)
313
(56,024)
270
(55,754)
(56,024)
(2.40)
Weighted-average number of common shares used in net loss per share attributable
to common stockholders - basic and diluted
23,740
23,370
See accompanying notes.
73
CONCERT PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Common Stock
In Treasury Amount
Additional
paid-in capital
Accumulated other
comprehensive
income
Issued
Accumulated
deficit
Total stockholders’
equity
Balance at December 31, 2017
Exercise of stock options
Release of restricted stock units
Unrealized gain on short-term
investments, net of tax of $76
Stock-based compensation expense
Adoption of ASC 606 as of January
1, 2018
Net loss
Balance at December 31, 2018
Exercise of stock options
Release of restricted stock units
Unrealized gain on short-term
investments
Stock-based compensation expense
Exercise of stock warrants
Proceeds from at-the-market
offering, net of issuance costs
Net loss
Balance at December 31, 2019
23,148
197
174
—
—
—
—
23,519
237
203
—
—
71
36
—
24,066
See accompanying notes.
(in thousands)
8 $
21
52
23 $
—
—
273,059 $
1,016
(1,206)
$
—
—
—
—
81
58
61
—
—
—
—
—
—
—
23
—
1
—
—
—
—
11,500
—
—
1,076
(741)
—
10,326
1,000
—
—
200 $
—
—
24 $
115
—
296,145 $
74
(407) $
—
—
270
—
—
—
(76,243) $
—
—
—
—
15,752
(56,024)
—
—
106
—
—
—
—
(31) $
—
—
—
—
—
—
(78,166)
(194,681) $
196,432
1,016
(1,206)
270
11,500
15,752
(56,024)
167,740
1,076
(740)
106
10,326
1,000
115
(78,166)
101,457
$
284,369
$
(137)
$
(116,515)
$
CONCERT PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation expense
Accretion of premiums and discounts on investments
Amortization of deferred lease incentive
Non-cash license consideration (Note 12)
Non-cash lease expense (Note 11)
Other non-cash items
Unrealized loss on marketable equity securities
Loss on disposal of asset
Changes in operating assets and liabilities:
Accounts receivable
Contract asset (Note 12)
Interest receivable
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other liabilities
Income taxes receivable
Income taxes payable
Deferred rent
Operating lease liabilities (Note 11)
Deferred revenue
Net cash used in operating activities
Investing activities
Purchases of property and equipment
Purchases of investments
Maturities of investments
Net cash provided by investing activities
Financing activities
Proceeds from at-the-market offering, net of issuance costs (Note 13)
Proceeds from warrants exercised
Repurchase of common stock pursuant to share surrender
Proceeds from exercise of stock options
Net cash provided by (used in) financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental cash flow information:
Cash paid for income taxes
Purchases of property and equipment unpaid at period end
Tenant improvements paid by landlord (Note 11)
Public offering costs unpaid at period end
Cash paid included in measurement of lease liabilities (Note 11)
See accompanying notes.
Year ended
December 31,
2019
2018
(in thousands)
$
(78,166) $
1,664
10,326
(1,013)
—
—
226
—
2,150
4
(57)
16,000
296
(1,828)
(96)
(217)
2,984
(36)
(392)
—
(606)
—
(48,761)
(685)
(97,837)
181,105
82,583
115
1,000
(740)
1,076
1,451
35,273
18,927
54,200 $
459 $
4 $
— $
143 $
2,778 $
$
$
$
$
$
$
75
(56,024)
1,247
11,500
(469)
(703)
(10,451)
—
(77)
2,926
52
119
—
72
(953)
34
435
1,265
(76)
344
2,746
—
(16)
(48,029)
(2,869)
(99,435)
140,207
37,903
—
—
(1,206)
1,037
(169)
(10,295)
29,222
18,927
123
188
4,996
—
—
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Nature of Business
Concert Pharmaceuticals, Inc., or the Company, was incorporated on April 12, 2006 as a Delaware corporation and has its operations based in Lexington,
Massachusetts. The Company is a clinical stage biopharmaceutical company that is applying its extensive knowledge of deuterium chemistry to discover and
develop novel small molecule drugs. The Company’s approach typically starts with previously studied compounds, including approved drugs, that the
Company believes may be improved with deuterium substitution. The Company’s pipeline includes multiple clinical stage candidates targeting autoimmune
and CNS disorders, and a number of preclinical compounds that it is currently assessing.
During February 2014, the Company completed its IPO, whereby the Company sold 6,649,690 shares of common stock at a price to the public of $14.00 per
share, raising aggregate net proceeds of $83.1 million. In March 2015, the Company sold 3,300,000 shares of common stock in a public offering at a price to
the public of $15.15 per share, resulting in net proceeds to the Company of approximately $46.7 million after deducting underwriting discounts and
commissions and offering expenses. During January 2020, the Company completed an underwriting public offering pursuant to which it sold 5,735,283 shares
of common stock at the public offering price of $9.92 per share. In addition, the Company sold to a certain existing investor pre-funded warrants to purchase
up to an aggregate of 1,800,000 shares of common stock at a purchase price of $9.919 per pre-funded warrant, which represents the per share public offering
price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The aggregate gross proceeds the Company received from
the public offering was $74.7 million, before deducting underwriting discounts and commissions and other offering related expenses of $4.8 million.
In June 2015, the Company received a one-time payment of $50.2 million from Auspex pursuant to a patent assignment agreement between the Company and
Auspex. The Company became eligible to receive the payment due to a change of control of Auspex, which was acquired by Teva in May 2015.
In March 2017, the Company entered into the Vertex Agreement with Vertex, pursuant to which the Company agreed to sell and assign to Vertex CTP-656,
now known as VX-561, and other cystic fibrosis assets of the Company for up to $250.0 million, subject to the satisfaction of certain closing conditions. In
July 2017, the transaction contemplated by the Vertex Agreement closed, and Vertex paid the Company $160.0 million in cash consideration, with $16.0
million initially held in escrow. In February 2019, the $16.0 million held in escrow was released to the Company. Additional information concerning the sale
of CTP-656 is discussed in Note 12.
The Company had cash and cash equivalents and investments of $106.4 million as of December 31, 2019. The Company believes that its cash and cash
equivalents and investments as of December 31, 2019 will be sufficient to allow the Company to fund its current operating plan for at least the next twelve
months from the date of issuance of the financial statements. The Company may pursue additional cash resources through public or private financings, by
establishing collaborations with or licensing its technology to other companies and through other arrangements.
Since its inception, the Company has generated an accumulated deficit of $194.7 million through December 31, 2019. The Company's operating results may
fluctuate significantly from year to year, depending on the timing and magnitude of clinical trial and other development activities under its current
development programs. Substantially all of the Company's net losses have resulted from costs incurred in connection with its research and development
programs and from general and administrative costs associated with its operations. The Company expects to continue to incur significant expenses and
increasing operating losses for at least the next several years.
The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure or unsatisfactory results of
nonclinical studies and clinical trials, the need to obtain additional financing to fund the future development of its pipeline, the need to obtain marketing
approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key
personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and
ability to transition from pilot-scale manufacturing to large-scale production of products.
Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.
2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation
76
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or
GAAP. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the
chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company's chief
operating decision maker is the Chief Executive Officer. The Company and the Chief Executive Officer view the Company's operations and manage its
business as one operating segment: the development of pharmaceutical products on its own behalf or in collaboration with others. All material long-lived
assets of the Company reside in the United States. The Company does use contract research organizations and research institutions located outside the United
States. Some of these expenses are subject to collaboration reimbursement, which is presented as a component of license and research and development
revenue in the consolidated statements of operations and comprehensive loss.
The accompanying consolidated financial statements include the accounts of Concert Pharmaceuticals, Inc. and its wholly owned subsidiaries. All
intercompany transactions and balances have been eliminated.
The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional
evidence relative to certain estimates or to identify matters that require additional disclosure.
Use of Estimates and Summary of Significant Accounting Policies
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, equity, revenue, expenses and the disclosure of contingent assets and liabilities and the Company's ability to continue as
a going concern. In preparing the consolidated financial statements, management used estimates in the following areas, among others: revenue recognition;
prepaid and accrued research and development expenses; stock-based compensation expense; and the evaluation of the existence of conditions and events that
raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results could differ from those estimates.
Cash, Cash Equivalents and Investments
Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Investments consist of securities with original
maturities greater than 90 days when purchased. The Company classifies these investments as available-for-sale and records them at fair value in the
accompanying consolidated balance sheets. Unrealized gains or losses are included in accumulated other comprehensive income (loss). Premiums or
discounts from par value are amortized to investment income over the life of the underlying investment.
Although available to be sold to meet operating needs or otherwise, securities are generally held through maturity. The Company classifies all investments as
current assets as these assets are readily available for use in current operations. The cost of securities sold is determined based on the specific identification
method for purposes of recording realized gains and losses. During 2019 and 2018, there were no realized gains or losses on sales of investments,
and no investments were adjusted for other than temporary declines in fair value.
The Company reviews available-for-sale securities for other-than-temporary impairment whenever the fair value of an available-for-sale security is less than
the amortized cost and evidence indicates that an available-for-sale security’s carrying amount is not recoverable within a reasonable period of time. Other-
than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the
intent to sell the security or if it is more likely than not that the Company will be required to sell the security before recovery of the amortized cost basis.
Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and the duration
of the impairment and changes in value subsequent to the end of the period.
Deferred Offering Costs
Costs incurred such as legal, accounting and other professional fees incurred in the course of preparing for a capital raise are deferred on the balance sheet
as deferred offering costs. At the time of the completion of the offering, the costs are reclassified as a reduction of the proceeds of the capital raise as part of
additional paid-in capital. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is
terminated.
77
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Marketable Equity Securities
Marketable equity securities consist of the fair value of shares of common stock of Processa held by the Company, as discussed further in Note 12. The
Company recognizes the effects of changes in fair value of equity securities within net income.
The Company reviews investments in marketable securities for other-than-temporary impairment whenever the fair value of the investment is less than the
cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment
is other-than-temporary, the Company considers whether it has an intent to sell, or whether it is more likely than not that the Company will be required to sell,
the investment before recovery of the investment’s cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and
the duration of the impairment and changes in value subsequent to year-end.
Fair Value of Financial Measurements
The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value
hierarchy as described in the accounting standards for fair value measurements:
•
•
•
Level 1—quoted prices for identical instruments in active markets;
Level 2—quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and
model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and
Level 3—valuations derived from valuation techniques in which one or more significant value drivers are unobservable.
For additional information related to fair value measurements, see Note 3.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of money market funds, investments (including
interest receivable) and accounts receivable. The Company's current investment policy is to maintain a diversified investment portfolio in U.S. government-
backed securities and money market mutual funds consisting of U.S. government-backed securities. The Company's cash is deposited in and invested through
highly rated financial institutions in North America.
The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these funds. The
Company has no foreign exchange contracts, option contracts or other foreign exchange hedging arrangements.
As of December 31, 2019 and 2018, substantially all of the Company’s cash was deposited in accounts at two financial institutions, thus limiting the amount
of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits.
Accounts receivable generally represent amounts due from collaboration partners. The Company monitors economic conditions to identify facts or
circumstances that may indicate that any of its accounts receivable are at risk of collection.
Property and Equipment
Property and equipment are recognized at cost and depreciated over their estimated useful lives using the straight-line method. Leasehold improvements are
amortized over the shorter of their useful life or the related lease term. Repair and maintenance costs are expensed as incurred, whereas major improvements
are capitalized as additions to property and equipment. Potential impairment is assessed when there is evidence that events or circumstances indicate that the
carrying amount of an asset may not be recovered. No such impairment losses have been recorded through December 31, 2019.
Rent Expense
Rent expense for the year ended December 31, 2019 consists of the Company's facility at 65 Hayden Avenue, Lexington, Massachusetts. The Company
ceased recognizing rent expense for its previous facility at 99 Hayden Avenue when the lease
78
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
expired on September 30, 2018. The Company began recognizing rent expense for 65 Hayden Avenue on January 1, 2018 when it obtained access to the
premises.
The Company's operating lease for its facility at 65 Hayden Avenue in Lexington, Massachusetts provides for scheduled annual rent increases throughout the
lease term, which expires on January 1, 2029. Additionally, the Company has received certain lease incentives, which are recognized as a reduction to rent
expense over the remaining lease term. Refer to Note 11 for additional details regarding the Company’s operating lease.
Contingencies
The Company records liabilities for legal and other contingencies when information available to the Company indicates that it is probable that a liability has
been incurred and the amount of loss can be reasonably estimated. Legal costs in connection with legal and other contingencies are expensed as costs are
incurred. No liabilities for legal and other contingencies were accrued as of December 31, 2019 and 2018.
Revenue Recognition
The Company has generated revenue through arrangements with collaborators and nonprofit organizations for the development and commercialization of
product candidates, a patent assignment agreement and an asset sale.
On January 1, 2018, the Company adopted FASB ASU 2014-09, Revenue from Contracts with Customers, and all related amendments, which is also referred
to as ASC 606. ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes
most legacy revenue recognition guidance, including industry-specific guidance. ASC 606 is based on the principle that an entity should recognize revenue to
depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for
those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a
customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance
obligations in the contract and (5) recognize revenue when, or as, the entity satisfies a performance obligation. ASC 606 also requires additional disclosure
about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts and costs to obtain or fulfill contracts. The
Company applied ASC 606 on January 1, 2018 to all contracts using the modified retrospective approach. As a result of the adoption, the cumulative effect to
retained earnings at January 1, 2018 was $15.8 million. The comparative information has not been restated and continues to be reported under the accounting
standards in effect for those periods.
The adoption of the new standard had an immaterial impact on the Company’s reported revenues, operating income and changes in operating cash flows for
the twelve months ended December 31, 2018 as compared to what reported amounts would have been under legacy guidance. The cumulative effect of the
changes made to the consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows:
Balance at December 31,
2017
ASC 606 Adjustments
Opening Balance at
January 1, 2018
Assets
Contract asset
Liabilities and Equity
Deferred revenue, current portion
Deferred revenue, net of current portion
Retained earnings
$
$
— $
16,000 $
16,000
1,442 $
8,859
76,243
(14) $
261
15,753
1,428
9,120
60,490
The impact of adopting ASC 606 primarily relates to the treatment of the consideration held in escrow under the Vertex Agreement. Under previous
authoritative guidance, the Company concluded that it would not recognize the Vertex escrow consideration until it was received. However, under ASC 606,
the Vertex escrow consideration represents variable consideration and was included in the transaction price at contract inception, as discussed further in Note
12. There was no material effect on the accounting for income taxes resulting from the adoption of ASC 606.
79
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Research and Development Costs
Research and development costs are expensed as incurred.
Research and development expenses are comprised of costs incurred in providing research and development activities, including salaries and benefits,
facilities costs, overhead costs, contract research and development services and other outside costs. Non-refundable advance payments for goods and services
that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received
rather than when the payment is made.
External research and development expenses associated with the Company’s programs include clinical trial site costs, research compounds and clinical
manufacturing costs, costs incurred for consultants and other outside services, such as data management and statistical analysis support and materials and
supplies used in support of the clinical and nonclinical programs. Internal costs of the Company’s clinical program include salaries, benefits, stock-based
compensation and an allocation of the Company’s facility costs. When third-party service providers’ billing terms do not coincide with the Company’s period-
end, the Company is required to make estimates of its obligations to those third parties, including clinical trial and pharmaceutical development costs,
contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The
Company bases its estimates on its knowledge of the research and development programs, services performed for the period, past history for related activities
and the expected duration of the third-party service contract, where applicable.
Accounting for Stock-Based Compensation
The Company issues stock options and restricted stock units, or RSUs, to certain employees, officers and directors. The Company accounts for stock
compensation using the fair value method, which results in the recognition of compensation expense over the vesting period of the awards. See Note 8 for
additional information.
Income Taxes
Income taxes are recorded in accordance with ASC Topic 740, Income Taxes, or ASC 740, which provides for deferred taxes using an asset and liability
approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the
financial statements or tax returns. The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary
differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in
effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will
more likely than not be realized.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. The Company evaluates tax positions taken, or expected to
be taken, in the course of preparing its tax returns to determine whether the tax positions are “more likely than not” of being sustained by the applicable tax
authority. Tax positions not deemed to meet the more-likely-than-not threshold would be recognized as a tax expense. As of December 31, 2019 or 2018, the
Company did not have any significant uncertain tax positions.
For additional details regarding the accounting for income taxes, see Note 10.
Guarantees
As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was,
serving at the Company’s request in such capacity. The term of the indemnification is for the officer’s or director’s lifetime. The maximum potential amount
of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that limits its
exposure and enables it to recover a portion of any future amounts paid.
The Company leases office space under a non-cancelable operating lease, which is further described in Note 11. The Company has standard indemnification
arrangements under the lease that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities and actions directly
resulting from any breach, violation or non-performance of any covenant or condition of the Company’s lease.
80
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Pursuant to the Vertex Agreement, as discussed further in Note 12, the Company agreed to indemnify Vertex for certain matters, including breaches of
specified representations and warranties, covenants included in the Vertex Agreement and specified tax claims. Representations and warranties, other than
certain fundamental representations and warranties, survived for a period of eighteen months following the closing, and the maximum liability of the
Company for claims by Vertex related to the breaches of such representations and warranties, with limited exceptions, was limited to the escrow amount,
or $16.0 million. In January 2019, the escrow period expired, and the escrow of $16.0 million was released to the Company in February 2019.
As of December 31, 2019 and 2018, the Company had not experienced any material losses related to these indemnification obligations, and no material
claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently,
concluded that the fair value of these obligations is negligible, and no related reserves were established.
Comprehensive Loss
Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions, other events and circumstances from non-
owner sources. Comprehensive loss consists of net loss and other comprehensive loss, which includes certain changes in equity that are excluded from net
loss. Comprehensive loss has been disclosed in the accompanying consolidated statements of operations and comprehensive loss. Accumulated other
comprehensive loss is presented separately on the consolidated balance sheets and consists entirely of unrealized holdings losses on investments as of
December 31, 2019 and 2018.
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet
for the rights and obligations created by all leases with terms of more than 12 months. On January 1, 2019, the Company adopted ASU 2016-02 and all
related amendments. For discussion regarding the impact of this accounting pronouncement, refer to Note 11.
In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, that expands the scope of Topic
718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from non-employees. ASU 2018-07
provides that an entity should apply the requirements of Topic 718 to non-employee awards except for certain exemptions specified in the amendment. The
Company adopted this new standard effective January 1, 2019, and it did not have a material effect on the consolidated financial statements and related
disclosures.
In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the
Company’s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to
interim periods. The Company adopted this new rule beginning with its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
Pending Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. The new standard requires entities to measure all expected credit losses
for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. As a smaller
reporting company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted.
The Company is currently evaluating the impact that ASU 2016-13 will have on its financial statements and related disclosures.
In August 2018, the FASB issued ASU 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for
Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard aligns the requirements for capitalizing
implementation costs in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred for internal-use
software. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized implementation costs and
related amortization expense, and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years beginning after
December 15, 2019, and early adoption is permitted. The Company is currently evaluating the impact that ASU 2018-15 will have on its financial statements
and related disclosures.
81
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
On December 18, 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The standard includes
removal of certain exceptions to the general principles of ASC 740, Income Taxes, and simplification in several other areas. ASU 2019-12 is effective for
public business entities for annual reporting periods beginning after December 15, 2020, and interim periods within those reporting periods, and early
adoption is permitted. The Company is currently evaluating the impact that ASU 2019-12 will have on its financial statements and related disclosures.
3. Fair Value Measurements
The tables below present information about the Company’s financial assets and liabilities that are measured and carried at fair value as of December 31, 2019
and 2018 and indicate the level within the fair value hierarchy where each measurement is classified. The carrying amounts reflected in the consolidated
balance sheets for cash, prepaid expenses and other current assets, restricted cash, accounts payable and accrued expenses approximate their fair values due to
their short-term nature.
Level 1
Level 2
Level 3
Total
December 31, 2019
Cash equivalents:
Money market funds
Government agency securities
Investments, available for sale:
U.S. Treasury obligations
Government agency securities
Marketable equity securities:
Corporate equity securities
Total
December 31, 2018
Cash equivalents:
Money market funds
U.S. Treasury obligations
Investments, available for sale:
U.S. Treasury obligations
Government agency securities
Marketable equity securities:
Corporate equity securities
Total
$
$
$
40,782 $
—
34,499
10,997
5,375
91,653 $
— $
2,000
—
7,899
—
9,899 $
— $
—
—
—
—
— $
40,782
2,000
34,499
18,896
5,375
101,552
Level 1
Level 2
Level 3
Total
7,643 $
1,748
— $
—
34,103
64,733
746
35,962
7,525
—
$
115,752 $
36,708 $
82
— $
—
—
—
—
— $
7,643
1,748
34,849
100,695
7,525
152,460
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
4. Cash, Cash Equivalents, Investments and Marketable Equity Securities
Cash, cash equivalents, available for sale investments and marketable equity securities included the following as of December 31, 2019 and 2018:
December 31, 2019
Cash
Money market funds
Government agency securities
Cash and cash equivalents
U.S. Treasury obligations
Government agency securities
Investments, available for sale
December 31, 2019
Marketable equity securities
December 31, 2018
Cash
Money market funds
U.S. Treasury obligations
Cash and cash equivalents
U.S. Treasury obligations
Government agency securities
Investments, available for sale
December 31, 2018
Marketable equity securities
5. Restricted Cash
Average
maturity
Amortized
cost
Unrealized
gains
Unrealized
losses
Fair
value
$
10,261 $
8 days
40,782
2,000
$
53,043 $
108 days $
74 days
$
34,475 $
18,874
53,349 $
— $
—
—
— $
24 $
22
46 $
— $
—
—
— $
— $
—
— $
10,261
40,782
2,000
53,043
34,499
18,896
53,395
Acquisition
value
Unrealized gains
Unrealized
losses
Fair value
$
10,451 $
— $
(5,076) $
5,375
Average
maturity
Amortized
cost
Unrealized
gains
Unrealized
losses
Fair
value
$
8,379 $
31 days
7,643
1,748
$
17,770 $
151 days $
153 days
34,856 $
100,748
$
135,604 $
— $
—
—
— $
2 $
7
9 $
— $
—
—
— $
(9) $
(60)
(69) $
8,379
7,643
1,748
17,770
34,849
100,695
135,544
Acquisition
value
Unrealized gains
Unrealized
losses
Fair value
$
10,451 $
— $
(2,926) $
7,525
Restricted cash as of December 31, 2019 and 2018 was held as collateral for stand-by letters of credit issued by the Company to its landlords in connection
with the current lease for its principal facilities located at 65 Hayden Avenue, Lexington, Massachusetts. For additional information regarding the Company's
lease, see Note 11. Cash, cash equivalents and restricted cash consisted of the following as of December 31, 2019 and 2018:
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents and restricted cash shown in the statement of cash flows
83
December 31,
2019
December 31,
2018
$
$
53,043 $
1,157
54,200 $
17,770
1,157
18,927
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
6. Property and Equipment
Property and equipment consist of the following as of December 31, 2019 and 2018:
Laboratory equipment
Computer, telephone and office equipment
Software
Leasehold improvements
Less accumulated depreciation and amortization
Estimated useful life
(in years)
December 31,
2019
December 31,
2018
5 $
3
3
Lesser of useful life
or remaining lease term
$
3,736 $
891
122
5,929
10,678
(2,925)
7,753 $
3,484
875
206
5,866
10,431
(1,512)
8,919
Depreciation and amortization expense was charged to operations in the amounts of $1.7 million and $1.2 million for the years ended December 31, 2019 and
2018, respectively.
7. Accrued Expenses and Other Liabilities
Accrued expenses and other liabilities consist of the following as of December 31, 2019 and 2018:
Accrued professional fees and other
Employee compensation and benefits
Research and development expenses
Deferred lease incentive, current portion
8. Stock Compensation
Stock incentive plans
December 31,
2019
December 31,
2018
$
$
862 $
3,222
4,252
—
8,336 $
672
3,067
1,476
454
5,669
The Company previously sponsored an Amended and Restated 2006 Stock Option and Grant Plan, or the 2006 Plan, which provided for the issuance of
shares of common stock in the form of incentive stock options, nonstatutory stock options, awards of stock and direct stock purchase opportunities to
directors, officers, employees and consultants of the Company. The 2006 Plan was replaced by the Company’s 2014 Stock Incentive Plan, or the 2014 Plan,
which became effective in February 2014. The 2014 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards,
restricted stock units, stock appreciation rights and other stock-based awards. In addition, the 2014 Plan includes an “evergreen provision” that allows for an
annual increase in the number of shares of common stock available for issuance under the 2014 Plan. Effective January 1, 2020, 954,603 shares were added to
the 2014 Plan for future issuance pursuant to this evergreen provision.
The 2006 Plan has no shares remaining available for grant, although existing stock options granted under the 2006 Plan remain outstanding. As of December
31, 2019, 1,265,774 shares were available for future grant under the 2014 Plan.
Stock options
Stock options are granted with an exercise price equal to the closing market price of the Company’s common stock on the date of grant. Stock options
generally vest ratably over three or four years and have contractual terms of ten years. Stock options are valued using the Black-Scholes-Merton option
valuation model and compensation cost is recognized based on such fair value over the period of vesting.
The following table provides certain information related to the Company's outstanding stock options as of December 31, 2019 and 2018:
84
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Weighted-average fair value of options granted, per option
Aggregate grant date fair value of options vested during the year
Total cash received from exercises of stock options
Total intrinsic market value of stock options exercised
$
$
$
$
Year ended December 31,
2019
2018
8.94 $
9,354 $
1,076 $
1,277 $
17.74
7,755
1,037
2,599
The weighted-average fair value of options granted in the years ended December 31, 2019 and 2018 reflect the following weighted-average assumptions:
Expected volatility
Expected term
Risk-free interest rate
Expected dividend yield
Year ended December 31,
2019
2018
76.83%
6.0 years
2.16%
—%
77.22%
6.0 years
2.64%
—%
Expected volatility. For the years ended December 31, 2019 and 2018, expected volatility was estimated using a weighted average of the Company's historical
volatility of its common stock and the historical volatility of the common stock of a group of similar companies that were publicly traded. The Company will
continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.
Expected term. The expected term of awards represents the period of time that the awards are expected to be outstanding. The expected term was determined
using the simplified method as prescribed by SAB No. 107, Share-Based Payment, as the Company does not have sufficient historical exercise data to provide
a reasonable basis upon which to estimate the expected term of stock options granted to employees.
Risk-free interest rate. For the years ended December 31, 2019 and 2018, the risk-free interest rate was estimated using an average of treasury bill interest
rates over a period commensurate with the expected term of the option at the time of grant.
Expected dividend yield. The expected dividend yield is zero, as the Company has not paid any dividends to date and has no current intention of paying cash
dividends.
Forfeiture rate. The Company elected to estimate potential forfeiture of stock grants and adjust compensation cost recorded accordingly. The estimate of
forfeitures is adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in
estimated forfeitures are recognized through a cumulative catch-up in the period of change and impact the amount of stock compensation expense to be
recognized in future periods. For the years ended December 31, 2019 and 2018, the Company assumed forfeiture rates of approximately 7%.
85
The following is a summary of stock option activity for the year ended December 31, 2019:
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Outstanding at December 31, 2018
Granted
Exercised
Forfeited or expired
Outstanding at December 31, 2019
Exercisable at December 31, 2019
Vested and expected to vest at December 31, 2019 (1)
Weighted
Average
Exercise
Price per
Share
Weighted
Average
Remaining
Contractual
Term
(In years)
Aggregate
Intrinsic Market
Value
15.26
13.22
7.75
18.02
15.01
14.04
14.98
6.86 $
5.98 $
6.79 $
1,183
1,179
1,182
Number of
Option Shares
3,557,406 $
1,037,750 $
(237,473) $
(245,074) $
4,112,609 $
2,599,751 $
3,989,373 $
(1) Represents the number of vested stock option shares as of December 31, 2019, plus the number of unvested stock option shares that the Company
estimated as of December 31, 2019 would vest, based on the unvested stock option shares as of December 31, 2019 and an estimated forfeiture rate of
7%.
As of December 31, 2019, there was $15.0 million of unrecognized compensation cost related to stock options that are expected to vest. The stock option
costs are expected to be recognized over a weighted-average remaining vesting period of 2.4 years.
Restricted stock units
On July 6, 2017, the Company granted 0.5 million RSUs, or the 2017 RSU grant, to executives and employees. The awards granted to non-executive
employees were service-based, whereas the awards granted to executives were a blend of service-based and performance-based. Assuming all service and
performance conditions were achieved, fifty percent of the RSUs would vest on March 31, 2018, and the remaining fifty percent of the RSUs would vest on
March 31, 2019. Certain executive awards were subject to the achievement of defined performance criteria prior to March 31, 2018, including the closing of
the transaction contemplated by the Vertex Agreement and the institution by the PTAB of the PGR petition filed by the Company against Incyte. In January
2018, the PTAB did not grant the Company's petition to institute the PGR and, as a result, the corresponding performance-based awards did not vest on March
31, 2018.
The Company used the accelerated attribution method to recognize expense over the required service period based on its estimate of the number of
performance-based awards vested. For any change in the estimate of the number of performance-based awards that were probable of vesting, the Company
cumulatively adjusted compensation expense in the period that the change in estimate was made.
On August 15, 2019, the 2019 RSU grant date, the Company granted 0.4 million RSUs, or the 2019 RSU grant, to certain executives and employees. All
awards are service-based and vest annually over two years. On the first anniversary of the 2019 RSU grant date, thirty-five percent of the RSUs will vest. The
remainder of the RSUs will vest on the second anniversary of the 2019 RSU grant date.
RSUs are not included in issued and outstanding common stock until the shares are vested and settled. As of December 31, 2019, all achieved RSUs from the
2017 RSU grant had vested, and no RSUs from the 2019 RSU grant had vested. The fair value of an RSU is measured based on the market price of the
underlying common stock as of the date of grant.
86
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The following is a summary of RSU activity, including both service-based and performance-based RSUs for the year ended December 31, 2019:
Outstanding at December 31, 2018
Granted
Released
Forfeited
Outstanding at December 31, 2019
Number of
RSU Shares
Weighted
Average
Grant Date Fair
Value
228,150 $
412,220 $
(202,550) $
(44,191) $
393,629 $
13.87
10.27
13.87
12.36
10.27
As of December 31, 2019, there was $3.5 million of unrecognized compensation cost related to RSUs that are expected to vest. The RSU costs are expected
to be recognized over a weighted-average remaining vesting period of 1.6 years.
Stock-based compensation expense
Total compensation cost recognized for all stock-based compensation awards in the consolidated statements of operations and comprehensive loss is as
follows for the years ended December 31, 2019 and 2018:
Research and development
General and administrative
Total stock-based compensation expense
For the Year Ended December 31,
2019
2018
5,049 $
5,277
10,326 $
5,221
6,279
11,500
$
$
87
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
9. Loss Per Share
Basic net loss per common share is calculated by dividing net loss allocable to common stockholders by the weighted-average common shares outstanding
during the period, without consideration of common stock equivalents. For purposes of the diluted net loss per share calculation, common stock equivalents
are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are
the same for periods with a net loss.
The following table illustrates the determination of loss per share for the years ended December 31, 2019 and 2018:
Numerator:
Net loss applicable to common stockholders - basic and diluted
$
(78,166) $
(56,024)
Denominator:
Weighted-average shares outstanding - basic and diluted
23,740
23,370
For the Year Ended December 31,
2019
2018
Net loss per share applicable to common stockholders - basic and diluted $
(3.29) $
(2.40)
Anti-dilutive potential common stock equivalents excluded from the
calculation of net loss per share:
Stock options
Restricted stock units
Warrants
232
61
70
666
185
132
88
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
10. Income Taxes
During the year ended December 31, 2019, the Company recorded net loss before taxes of $78.2 million and, since it maintains a full valuation allowance on
its deferred tax assets, the Company did not record an income tax benefit for the year ended December 31, 2019. On July 25, 2017, the transaction
contemplated by the Vertex Agreement closed, as discussed in Note 12, and Vertex paid the Company $160.0 million in cash consideration, with $16.0
million initially held in escrow. For income tax purposes, the $16.0 million held in escrow was recognized under the installment method and therefore
deferred until the cash was received by the Company in February 2019. Under Section 453A of the U.S. Internal Revenue Code, or Code, the Company is
required to recognize interest on the deferred tax liability with respect to the portion of the installment sale outstanding as of the close of each taxable year
that exceeds $5.0 million. As a result, the Company accrued interest of $0.2 million for 2018. The $16.0 million initially held in escrow was released to the
Company in February 2019, and the Company recognized no interest for 2019.
Additionally, during 2019, the Company recorded unrealized gains on its investments in available-for-sale securities in other comprehensive income.
Intraperiod tax allocation rules require the Company to allocate its provision for income taxes between continuing operations and other categories of earnings,
such as other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss from continuing operations and pre-tax income in other
categories of earnings, such as other comprehensive income, the Company must allocate the tax provision to the other categories of earnings. The Company
then records a related tax benefit in continuing operations. As a result of these rules, the Company recorded a benefit of $0.1 million in continuing operations,
with a corresponding reduction in other comprehensive income of $0.1 million, related to its unrealized gains on its investments in available-for-sale
securities during 2018. There was no impact to the Company for 2019 as a result of these rules.
The Tax Cuts and Jobs Act, or TCJA, repealed the corporate alternative minimum tax, or AMT, for years after 2017. Corporations that were previously
subject to the AMT and have AMT tax credit carryforwards as of December 31, 2017, are eligible for a refund of these credits for tax years beginning after
2017 and before 2022. The Company was subject to AMT in the amount of $1.9 million in 2017. Since the AMT paid on its 2017 tax return generated an
AMT credit that will be refundable between 2018 and 2022, the Company recorded a $1.9 million income tax receivable rather than a tax expense for 2017.
Further, the Company also had a deferred tax asset for its AMT credit carryforward related to its AMT liability paid in 2015 in the amount of $0.3 million.
This deferred tax asset was previously offset by a full valuation allowance. As a result of the change in law, the Company reclassified the 2015 AMT credit
carryforward from deferred tax assets to income tax receivable during 2017. As of December 31, 2019, the Company had a $2.3 million income tax
receivable related to AMT taxes in prior years.
The Company’s ability to use its operating loss carryforwards and tax credit carryforwards to offset taxable income is subject to restrictions under
Sections 382 and 383 of the Code. Net operating loss and tax credit carryforwards are subject to an annual limitation in the event of certain cumulative
changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the
Code. Such changes would limit the Company’s use of its operating loss and tax credit carryforwards. In such a situation, the Company may be required to
pay income taxes, even though significant operating loss and tax credit carryforwards exist. Additionally, any future financing could result in a change in
control, as defined by Sections 382 and 383 of the Code, which could further limit the Company's use of its operating loss and tax credit carryforwards. In
determining the tax provisions for 2018, the Company assessed its ability to use its net operating loss carryforwards in accordance with Sections 382 and 383
of the Code.
A reconciliation of the federal statutory income tax rate and the Company’s effective income tax rate is as follows for the years ended December 31, 2019 and
2018:
Federal statutory income tax rate
State income taxes
Change in valuation allowance
Research and development and other credits
Permanent items
Other
Federal rate change
Effective income tax rate
89
Year ended December 31,
2019
2018
21.0 %
6.8 %
(29.8)%
3.2 %
(1.1)%
(0.1)%
— %
— %
21.0 %
6.2 %
(30.9)%
4.0 %
(0.3)%
(0.6)%
— %
(0.6)%
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The significant components of the Company’s net deferred tax assets consist of the following as of December 31, 2019 and 2018:
Deferred tax assets:
Net operating loss carryforwards
Deferred revenue
Research and development and other credit carryforwards
Lease liability
Other
Valuation allowance
Total deferred tax assets, net of valuation allowance
Deferred tax liabilities:
Fixed assets
Right of use asset
Gain deferred under installment method
Total deferred tax liabilities
Net deferred tax assets
December 31,
2019
2018
$
38,544 $
2,878
18,573
4,443
7,508
71,946
(67,737)
4,209 $
1,681 $
2,528
—
4,209 $
— $
$
$
$
$
23,841
2,878
15,597
—
7,985
50,301
(44,453)
5,848
1,477
—
4,371
5,848
—
Subject to the limitations described above and the impacts of the TCJA, as of December 31, 2019, the Company had gross federal net operating loss
carryforwards of $153.0 million and state net operating loss carryforwards of $101.6 million available to reduce future taxable income, of which $54.8
million of the gross federal net operating loss carryforwards and $101.6 million of the state net operating loss carryforwards will expire at various dates
beginning in 2034. Approximately $98.2 million of the federal net operating loss carryforwards will be carried forward indefinitely. The Company also had
federal and state tax credit carryforwards of $14.2 million and $5.5 million, respectively, available to reduce future tax liabilities, which expire at various
dates through 2039.
Realization of the future tax benefits is dependent on many factors, including the Company’s ability to generate taxable income within the carryforward
period. The Company currently has deferred tax assets in excess of its deferred tax liabilities, resulting in the Company having net deferred tax assets. The
Company has evaluated the positive and negative evidence bearing upon the realizability of its net deferred tax assets and concluded that it is more likely than
not that the Company will not realize the benefit of its net deferred tax assets. As a result, the net deferred tax assets have been fully reserved as of December
31, 2019 and 2018.
As of December 31, 2019, the Company had no unrecognized tax benefits. The Company has not conducted a study of its research and development credit
carryforwards. A study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed and
any adjustment is known, no amounts will be presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s
research and development credit carryforwards and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance.
Thus, there would be no impact to the consolidated balance sheet or statement of operations if an adjustment were required.
Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as income tax expense in the statement of operations. As of
December 31, 2019, the Company had no accrued interest related to uncertain tax positions.
The Company is currently open to examination under the statute of limitations by the IRS and state jurisdictions for the tax years ended 2016 through 2018.
Carryforward tax attributes generated in years prior to 2016 may still be adjusted upon future examination if they have or will be used in a future period. The
Company is currently not under examination by the IRS or any other jurisdictions for any tax years. Since the Company is in a loss carryforward position, the
Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is
available.
90
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
11. Commitments
Lease
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which is also referred to as ASC 842. ASC 842 requires lessees to recognize assets
and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than 12 months. ASC 842 also requires certain
qualitative and quantitative disclosures designed to give financial statement users information on the amount, timing and uncertainty of cash flows arising
from leases.
The Company adopted ASC 842 effective January 1, 2019. The Company has elected to employ the transitionary relief offered by the FASB under ASU
2018-11, and implement the new standard without the restatement of comparative periods' financial information. ASU 2018-11 also provides for recognizing
the effects of applying ASC 842 as a cumulative-effect adjustment to retained earnings as of January 1, 2019; however, no such adjustment was required by
the Company.
The Company has elected to employ the package of practical expedients offered under ASC 842, which allow the Company to not reassess the following:
•
•
•
the presence of a lease in any expired or existing contracts;
the lease classification for any expired or existing leases; and
the initial direct costs for any existing leases.
The Company currently has a lease, or the Lease, for approximately 56,000 square feet of office and laboratory space located at 65 Hayden Avenue,
Lexington, Massachusetts, or the Premises, which was classified as an operating lease under the previous leasing standard, ASC 840. The Lease is also
classified as an operating lease under ASC 842 in accordance with the Company's election of the practical expedient under ASC 842. Pursuant to the package
of practical expedients, the Company did not reassess initial direct costs for the Premises. Additionally, the Company made the policy election to adopt the
practical expedient to not separate lease components from non-lease components for the right-to-use asset class of office and laboratory space. This policy
election results in the Company accounting for the lease component, the use of the Premises and the non-lease components, which include the use of the
parking garage, building elevators and HVAC, as a single lease component.
The Company occupied the Premises in the third quarter of 2018; however, the Company gained access to the space on January 1, 2018 in order to start
making certain tenant improvements. Accordingly, the lease commencement date was determined to be January 1, 2018 under the prior guidance of ASC 840,
and therefore the Company began recognizing lease expense as of that date. The Lease term extends ten years following January 1, 2019. The Company is
entitled to two five-year options to extend the Lease; however, these options were not included in the calculation of the Lease asset or liability. The Company
elected to employ the provision under ASC 842 to use hindsight with respect to determining the lease term (i.e., consideration of the actual outcome of lease
renewals, termination options and purchase options) and in assessing any impairment of right-of-use assets for existing leases. The Company notes that no
events such as renewals or termination options have occurred with respect to the Lease for the Premises. Therefore, the hindsight practical expedient under
ASC 842 had no impact on the accounting term as previously determined under ASC 840. As of December 31, 2019, the remaining lease term for the
Premises is 9 years.
The Lease provides for annual base rent of approximately $2.8 million in the first year following the Base Rent Commencement Date of January 1, 2019,
which increases on a yearly basis by 3.0% (subject to an abatement of base rent of approximately $0.5 million at the beginning of the second year of the
Lease term if the Company is not in default under the Lease). There are no variable payments, exercise purchase options, penalties, fees or residual value
guarantees under the Lease. The Company is also obligated to pay the landlord for certain costs, taxes and operating expenses related to the Premises, subject
to certain exclusions; however, the Company concluded that these payments are not in-substance fixed payments and therefore are not included in the
calculation of the related lease liability and asset under ASC 842.
The Company recorded the liability associated with the Lease for the Premises at the present value of the lease payments not yet paid, discounted using the
discount rate for the Lease established at the commencement date. Since the Lease does not provide an implicit rate, the Company had to estimate the
incremental borrowing rate, or IBR, as of the commencement date. The IBR is defined under ASC 842 as the rate of interest that the Company would have to
pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments in a similar economic environment.
The IBR for the Lease was determined by establishing a credit rating of the Company using the Rank Order Model. Based on the established credit rating, the
Company determined a borrowing rate using the Recovery Rate method, adjusted for the risk-free rate, which resulted in an IBR of approximately 13%. The
Company used this IBR of 13% to discount the remaining lease
91
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
payments over the remaining lease term and recorded a lease liability of $16.9 million on January 1, 2019. This lease liability will be amortized over the
remaining lease term in an amount equal to the difference between the cash rent paid and the monthly interest calculated on the remaining lease liability. As
of December 31, 2019, the Company had a current lease liability of $0.3 million and a non-current lease liability of $16.0 million recorded in its consolidated
balance sheets.
The Company received an improvement allowance from the landlord of approximately $5.0 million for certain permitted costs related to the design of the
Company's improvements to the Premises, consisting of normal tenant improvements. The Company is deemed to be the owner of these tenant improvements
during the lease term. These $5.0 million of improvements are included in the Company’s property, plant and equipment balances in its consolidated balance
sheets as of December 31, 2019 and are depreciated over the shorter of their useful life or the related lease term.
On January 1, 2019, the Company recorded a right-of-use asset in the amount of $9.5 million, which represented the lease liability of $16.9 million, adjusted
for previously accrued rent of $2.9 million and previously recorded unamortized lease incentives (the improvement allowance) in the amount of $4.5 million.
The right-of-use asset will be amortized over the remaining Lease term in an amount equal to the difference between the calculated straight-line expense of
the total Lease payments less the monthly interest calculated on the remaining lease liability. As of December 31, 2019, the Company had a long-term lease
asset of $9.3 million recorded in its consolidated balance sheets.
The following table presents a summary of the amount by which each financial statement line item was affected by the adoption of ASC 842:
Prior to Adoption of ASC
842
January 1, 2019
Effect of Adoption
Subsequent to Adoption of
ASC 842
Operating lease right-of-use assets, long-
term
$
Accrued expenses and other liabilities
Lease liability, current portion
Deferred lease incentive, net of current
portion
Deferred rent, net of current portion
Lease liability, net of current portion
Accumulated deficit
— $
5,669
—
4,088
2,850
—
(116,515)
9,478 $
(454)
607
(4,088)
(2,850)
16,264
—
9,478
5,215
607
—
—
16,264
(116,515)
The adoption of ASC 842 did not have a material impact on the consolidated statement of operations and comprehensive loss for the year ended December
31, 2019, or the consolidated statement of cash flows for the year ended December 31, 2019.
The Company will recognize rent expense, calculated as the remaining cost of the Lease allocated over the remaining Lease term, on a straight-line basis.
Rent expense will be presented as part of continuing operations in the condensed consolidated statement of operations and comprehensive loss. For the year
ended December 31, 2019, the Company recognized $2.4 million in rent expense.
For the year ended December 31, 2019, the Company paid $2.8 million in rent relating to the Lease. As a payment arising from an operating lease, the $2.8
million will be classified within operating activities in the consolidated statements of cash flows.
As of December 31, 2019, the discount rate for the Lease was 13.08%, and the remaining Lease term for the Premises was 9 years.
Future minimum lease payments under the Company's non-cancelable operating leases as of December 31, 2019 were as follows:
92
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Maturities of lease liabilities:
For the year ended December
31,
2020 $
2021
2022
2023
2024
Thereafter
Total lease payments $
Less imputed interest $
Total $
2,406
2,969
3,058
3,150
3,244
13,979
28,806
(12,542)
16,264
Prior to the adoption of ASC 842, and pursuant to the legacy guidance within ASC 840, the Company recorded rent expense on a straight-line basis through
the end of the lease term and also recorded deferred rent on the consolidated balance sheets. The Company recorded the tenant improvement allowance as a
deferred lease incentive and was amortizing the deferred lease incentive through a reduction of rent expense ratably over the lease term.
As of December 31, 2018, the future minimum lease payments due under the Lease were as follows:
For the year ended December
31,
2019 $
2020
2021
2022
2023
Greater than 5 years
Total minimum lease payments $
2,776
2,383
2,945
3,034
3,125
17,085
31,348
The Company recorded total rent expense of $3.3 million for the year ended December 31, 2018 pursuant to ASC 840.
12. Revenue
The Company's revenue is generated through collaborative licensing agreements, patent assignments and sales of intellectual property. The Company
generates its revenue through one segment and the revenue recognized under each of the Company's arrangements during the current and prior period is
described below. The terms of these agreements may contain multiple promised goods or services or optional goods and services, including licenses to
product candidates, referred to as exclusive licenses, as well as research and development activities to be performed by the Company on behalf of the
collaboration partner related to the licensed product candidates.
Revenue recognition
Revenue is recognized when control of the promised goods or services are transferred to customers in an amount that reflects the consideration the Company
expects to be entitled to in exchange for transferring those goods or providing services. The Company accounts for a contract when it has approval and
commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability
of consideration is probable.
When determining whether the customer has obtained control of the goods or services, the Company considers the point at which the customer may benefit
from the goods or services. For licenses to product candidates, revenue is recognized upon grant or transfer of the exclusive license, as the Company's
licenses are considered functional in nature. For research, development and manufacturing activities, revenue is recognized as the work is performed using
either the output or input method.
Performance obligations
93
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in ASC 606. A contract’s
transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The
Company's contracts may contain multiple performance obligations if a promise to transfer goods or services is separately identifiable from other promises in
a contract and, therefore, is considered distinct. For contracts with multiple performance obligations, the Company determines the standalone selling price of
each performance obligation and allocates the total transaction price using the relative selling price basis. The Company recognizes performance obligations
based on their nature.
Significant payment terms
The Company’s revenue arrangements include payments to the Company of one or more of the following: a non-refundable, upfront payment; milestone
payments; payment of license exercise or option fees with respect to product candidates; fees for research and development services rendered; and royalties
on commercial sales of licensed product candidates, if any. To date, the Company has received upfront payments, several milestone payments and certain
research and development service payments, but has not received any license exercise or option fees or earned royalty revenue as a result of product sales.
Under ASC 606, the Company estimates the amount of consideration to which it will be entitled in exchange for satisfying performance obligations. Based on
the Company’s current contracts, variable consideration primarily exists in the following forms: development and regulatory milestones, royalties and sales-
based milestones. The Company utilizes the "most likely amount" variable consideration method for estimating development and regulatory milestone
consideration to include in the transaction price. The Company only includes an amount of variable consideration in the transaction price to the extent it is
probable that a significant reversal in the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is
subsequently resolved. The Company refers to this as the variable consideration constraint.
Due to the uncertainty associated with the occurrence of the underlying events which would trigger development and regulatory milestone consideration
under its revenue arrangements, with the exception of those development and regulatory milestones received to date, the Company has concluded the variable
consideration associated with all development and regulatory milestones to be fully constrained as of the ASC 606 transition date and as of December 31,
2019, and therefore has not included such consideration in the transaction price for any of its revenue arrangements. The Company will reassess this
conclusion at each subsequent reporting period and will only include amounts associated with regulatory or development milestones in the transaction price
when, or if, the variable consideration is determined to be released from the constraint.
To date, the Company has not recognized any royalties or sales-based milestones under its licensing and collaboration arrangements. Royalties and sales-
based milestones qualify for the sales-and-usage exemption under ASC 606 as (i) royalties are based strictly on the sales-and-usage by the licensee and (ii) a
license of intellectual property is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned under the
terms of a license agreement in the period the products are sold by the Company's collaborator and the Company has a present right to payment.
In accordance with ASC 606, the Company is required to adjust the transaction price for the effects of the time value of money if the timing of payments
agreed to by the parties to the contract, explicitly or implicitly, provides the Company or its customer with a significant benefit of financing the transfer of
goods or services. The Company concluded that its licensing and collaboration arrangements do not contain a significant financing component because the
payment structure of its agreements arise from reasons other than providing a significant benefit of financing.
Contract assets
The Company did not have a contract asset as of December 31, 2019 as compared to $16.0 million as of December 31, 2018. The decrease in the contract
asset balance is the result of the receipt of the $16.0 million that had initially been held in escrow for indemnification purposes related to the asset purchase by
Vertex, and was released to the Company in February 2019.
Contract liabilities
As of December 31, 2019 and 2018, the Company had $10.5 million in contract liabilities related to unsatisfied performance obligations as well as variable
consideration paid in advance, but currently constrained from recognition. The contract liabilities consist of the following deferred revenue:
•
$7.8 million related to the Company's collaboration with Celgene, $1.4 million of which is attributable to the CTP-730 program and is currently
expected to be recognized as revenue in the next twelve months as the Company satisfies its remaining research and development activities pursuant
to mutually agreed upon development plans, and $6.4 million
94
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
of which is attributable to two additional license programs that the Company will not recognize as revenue unless Celgene exercises its rights with
respect to those programs, or in the second quarter of 2020 at such time that Celgene's rights lapse; and
•
$2.8 million related to a payment received from GSK that the Company will not recognize as revenue until all repayment obligations lapse.
Contract liabilities are presented as deferred revenue and classified as current or non-current based on the timing of when the Company expects to recognize
revenue. During the twelve months ended December 31, 2019, no deferred revenue was recognized into revenue. During the twelve months ended December
31, 2018, $16 thousand of deferred revenue was recognized into revenue.
Revenue arrangements
Vertex
On March 3, 2017, the Company entered into the Vertex Agreement with Vertex pursuant to which the Company agreed to sell and assign to Vertex CTP-656,
now known as VX-561, and other cystic fibrosis assets of the Company. On July 25, 2017, or the Vertex Closing Date, the transaction contemplated by the
Vertex Agreement closed, and Vertex paid the Company $160.0 million in cash consideration, with $16.0 million initially held in escrow, which was released
to the Company in February 2019. In addition, Vertex has agreed to pay the Company an aggregate of up to $90.0 million upon the achievement of certain
milestone events.
As of December 31, 2018, the Vertex indemnification variable consideration represented a contract asset to be released from escrow 18 months following the
Vertex Closing Date and was classified as a current asset in the accompanying consolidated balance sheet. Additionally, the variable consideration related to
the regulatory milestone payments are fully constrained due to the uncertainty associated with the achievement of the respective milestones. Accordingly, no
contract asset was recorded as of December 31, 2019.
Processa
On October 4, 2017, the Company entered into an Option and License Agreement, or the Option Agreement, with Promet Therapeutics, LLC, or Promet,
pursuant to which the Company granted Promet an option to obtain an exclusive license to CTP-499, a deuterated analog of 1-(S)-5-hydroxyhexyl-3,7-
dimethylxanthine, or HDX, an active metabolite of pentoxifylline, provided certain conditions were met. On October 5, 2017, Promet closed an asset
purchase agreement with Heatwurx, Inc., a public company, creating Processa.
On March 19, 2018, the Company entered into an Amendment to the Option Agreement, or the Amendment, and a Securities Purchase Agreement, or the
Securities Agreement, both with Promet and Processa. Pursuant to the Amendment, the Company granted Promet, who then assigned to Processa, an
exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-499, now known as PCS-499. Upon transfer of the license and
as consideration for the license, the Company received 2,090,301 shares of common stock of Processa. In December 2019, Processa implemented a reverse
stock split, and the Company now owns 298,615 shares of common stock of Processa.
The Company is also eligible to receive royalties on worldwide net sales.
The Amendment contained one performance obligation: an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-
499. The Company determined that the transaction price was $10.5 million, which was based on the fair value of the non-cash consideration received on
March 19, 2018, which consisted of 2,090,301 shares of publicly traded common stock of Processa. The transaction price of $10.5 million was allocated to
the single performance obligation. The performance obligation was considered satisfied at contract inception, as the exclusive license transferred control to
the customer at this point in time. Accordingly, revenue of $10.5 million was recognized during the first quarter of 2018.
Subsequent changes to the fair value of the underlying securities are recognized as unrealized gains or losses on marketable equity securities within the
consolidated statement of operations and comprehensive loss.
The Amendment contains consideration that is variable based on royalties upon the customer's commercial success with the licensed product. The
consideration related to royalty payments is considered variable consideration that is fully constrained in
95
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products are sold by
Processa and the Company has a present right to payment.
For the year ended December 31, 2019, the Company recognized $34 thousand in revenue related to intellectual property cost reimbursements. For the year
ended December 31, 2018, the Company recognized $10.5 million in revenue related to the transfer of the license.
Cipla
The Company entered into the Cipla Agreement with Cipla on January 16, 2019, or the Cipla Closing Date, pursuant to which the Company granted Cipla an
exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-354, a novel GABAA receptor subtype-selective modulator.
As consideration for the license, the Company received an upfront payment of $1.0 million.
The Cipla Agreement also provides Cipla the option to purchase the Company’s existing inventory of CTP-354 held as of the effective date, valued in
aggregate at $0.3 million. Additionally, upon the achievement of certain milestone events, Cipla has agreed to pay the Company an aggregate of up to $57.0
million. The first milestone payment the Company may be entitled to receive is $3.0 million when the first IND for the first CTP-354 product goes into effect.
Furthermore, the Company is eligible to receive royalties on worldwide net sales of future product sales at defined percentages ranging from the mid-single to
high-single digits.
The Cipla Agreement contained one performance obligation: an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize
CTP-354, referred to as the Transfer of License Performance Obligation. The Company concluded that the option to purchase existing inventory did not
provide Cipla a material right, and as such, was treated as a separate contract. The transaction price was determined to be $1.0 million based on the upfront
consideration received as of the Cipla Closing Date.
As of the Cipla Closing Date, the Transfer of License Performance Obligation was satisfied, as the control of CTP-354 transferred to Cipla, the customer. As
a result, the full transaction price was recognized as revenue on the Cipla Closing Date. The sale of existing inventory is recognized as goods are transferred
to the customer.
The arrangement with Cipla contains consideration that is variable based on the customer’s achievement of certain development and regulatory milestones in
addition to royalties upon the customer’s commercial success with the licensed product. The next milestone payment the Company may be entitled to receive
of $3.0 million related to the first IND for the first CTP-354 product going into effect is considered variable consideration that is fully constrained due to the
uncertainty associated with the achievement of the development milestone. The consideration related to royalties is also variable consideration that is fully
constrained in accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products
are sold by Cipla and the Company has a present right to payment.
The Company recognized $1.0 million in revenue associated with the sale of existing inventory and the Transfer of License Performance Obligation for the
year ended December 31, 2019.
13. Open Market Sale Agreement
On March 1, 2019, the Company entered into an Open Market Sale Agreement, or the ATM Agreement, with Jefferies LLC, or Jefferies, with respect to an at-
the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par
value $0.001 per share, having an aggregate offering price of up to $50 million, referred to as Placement Shares, through Jefferies as its sales agent. The
Company will pay Jefferies a commission equal to 3.0% of the gross sales proceeds of any Placement Shares sold through Jefferies under the ATM
Agreement, and also has provided Jefferies with customary indemnification and contribution rights. In addition, the Company has agreed to reimburse certain
legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50 thousand, in addition to certain ongoing disbursements of
Jefferies' counsel. As of February 24, 2020, the Company has sold 36,167 shares of its common stock in accordance with the ATM Agreement for net
proceeds of $0.4 million, after payment of cash commissions of 3.0 percent of the gross proceeds to its sales agent. Additionally, the Company incurred
approximately $0.3 million related to legal, accounting and other fees in connection with the ATM Agreement as of December 31, 2019.
96
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
14. 401(k) Retirement Plan
In January 2008, the Company established the Concert Pharmaceuticals 401(k) Retirement Plan, or the 401(k) Plan, in which substantially all of its permanent
employees are eligible to contribute a percentage of base wages up to an amount not to exceed an annual statutory maximum. The Company matches 50% of
the first 6% of an employee’s contributions subject to statutory limits.
The Company made matching contributions under the 401(k) Plan of $0.4 million and $0.3 million for the years ended December 31, 2019 and 2018,
respectively.
15. Warrant to Purchase Redeemable Securities
On June 8, 2017, the Company entered into a Loan Agreement with Hercules Technology Growth Capital, Inc., or Hercules. In connection with the entry into
the Loan Agreement, the Company issued warrants, or the Warrants, to certain entities affiliated with Hercules, exercisable for an aggregate of 61,273 shares
of the Company’s common stock at an exercise price of $12.24 per share. The Warrants have a five-year term, expiring June 8, 2022, and may be exercised on
a cashless basis. The Warrants had a total relative fair value of $0.5 million upon issuance and were recorded as a debt discount.
Pursuant to ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, the Warrants were classified as equity and were
initially measured at relative fair value. Subsequent changes to fair value will not be recognized so long as the instrument continues to be equity classified. To
determine the relative fair value, the Company measured the fair value of the Warrants as of June 8, 2017 using the Black-Scholes-Merton option pricing
model. The significant assumptions used in estimating the fair value of the Warrants include the volatility of the stock underlying the warrants, risk-free
interest rate and estimated life of the warrant. The Company used the following weighted-average assumptions:
Expected volatility
Expected term (in years)
Risk-free interest rate
Expected dividend yield
73.71%
5
1.75%
—%
Consistent with the Company’s weighted-average assumptions used in determining the fair value of options, expected volatility was estimated using a
weighted average of the Company's historical volatility of its common stock and the historical volatility of the common stock of a group of similar companies
that were publicly traded.
16. Quarterly Financial Information (unaudited)
Revenue
Operating expenses
Loss from operations
Other (expense) income, net
Net loss
Net loss per share - basic and diluted
March 31,
2019
June 30,
2019
September 30,
2019
December 31,
2019
Three Months Ended
$
1,005 $
$
$
21,399
(20,394)
(1,432)
(21,826) $
(0.93) $
97
49 $
19,474
(19,425)
757
(18,668) $
(0.78) $
10 $
18,253
(18,243)
1,058
(17,185) $
(0.72) $
13
20,966
(20,953)
466
(20,487)
(0.86)
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
March 31,
2018
June 30,
2018
September 30,
2018
December 31,
2018
Three Months Ended
$
10,479 $
2 $
11 $
14,286
(3,807)
(656)
—
(4,463) $
(0.19) $
14,376
(14,374)
1,329
(280)
(13,325) $
(0.57) $
17,351
(17,340)
(29)
(18)
(17,387) $
(0.74) $
$
$
13
20,076
(20,063)
(771)
(15)
(20,849)
(0.89)
Revenue
Operating expenses
Loss from operations
Other (expense) income, net
Provision for income taxes
Net loss
Net loss per share—basic and diluted
17. Subsequent Events
During January 2020, the Company completed an underwriting public offering pursuant to which it sold 5,735,283 shares of its common stock at the public
offering price of $9.92 per share. In addition, the Company sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 1,800,000
shares of common stock at a purchase price of $9.919 per pre-funded warrant, which represents the per share public offering price for the common stock less
the $0.001 per share exercise price for each pre-funded warrant. The aggregate gross proceeds the Company received from the public offering was $74.7
million, before deducting underwriting discounts and commissions and other offering related expenses of $4.8 million.
ITEM 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
ITEM 9A.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act refers to controls and procedures that are
designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the
Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons
performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily
applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to
provide reasonable assurance of achieving their control objectives.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls
and procedures as of December 31, 2019, the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our Chief
Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as
of such date.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is
defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company’s principal executive
officer and principal financial officer, or persons performing similar functions, and effected by a company’s board of directors, management and other
personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles and includes those policies and procedures that:
98
•
•
•
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of a company’s assets;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that a company’s receipts and expenditures are being made only in accordance with authorizations of the
company’s management and directors; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a
material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the
effectiveness of our internal control over financial reporting as of December 31, 2019 based on the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (2013 framework). Based on this assessment, management
concluded that our internal control over financial reporting was effective as of December 31, 2019.
The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by Ernst & Young LLP, an independent registered
public accounting firm, as stated in their report, which appears herein.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the three months ended December 31, 2019 that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Concert Pharmaceuticals, Inc.
Opinion on Internal Control over Financial Reporting
We have audited Concert Pharmaceuticals, Inc.’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal
Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).
In our opinion, Concert Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of
December 31, 2019, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated
balance sheets of Concert Pharmaceuticals, Inc. as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss,
stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2019, and the related notes and our report dated February 27,
2020 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of
internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility
is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the
PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether effective internal control over financial reporting was maintained in all material respects.
99
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and
evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered
necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over
financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being
made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or
timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 27, 2020
ITEM 9B.
Other Information
None.
100
Item 10. Directors, Executive Officers and Corporate Governance
Part III
The information required by Item 10 will be included in our definitive proxy statement relating to our 2020 Annual Meeting of Stockholders, to be filed no
later than 120 days after December 31, 2019, and is incorporated herein by reference.
Item 11. Executive Compensation
The information required by Item 11 will be included in our definitive proxy statement relating to our 2020 Annual Meeting of Stockholders, to be filed no
later than 120 days after December 31, 2019, and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by Item 12 will be included in our definitive proxy statement relating to our 2020 Annual Meeting of Stockholders, to be filed no
later than 120 days after December 31, 2019, and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by Item 13 will be included in our definitive proxy statement relating to our 2020 Annual Meeting of Stockholders, to be filed no
later than 120 days after December 31, 2019, and is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services
The information required by Item 14 will be included in our definitive proxy statement relating to our 2020 Annual Meeting of Stockholders, to be filed no
later than 120 days after December 31, 2019, and is incorporated herein by reference.
Item 15.
Exhibits and Financial Statement Schedules
(1) Financial Statements
Part IV
Our consolidated financial statements are set forth in Part II, Item 8 of this Annual Report on Form 10-K and are incorporated herein by reference.
(2) Financial Statement Schedules
Schedules have been omitted since they are either not required or not applicable or the information is otherwise included herein.
(3) Exhibits
Exhibit
number
3.1
3.2
3.3
4.1
Description
Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report
on Form 8-K filed on February 20, 2014)
Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on
Form 8-K filed on February 20, 2014)
Amendment to Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant’s
Annual Report on Form 10-K filed on March 6, 2017)
Specimen certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration
Statement on Form S-1 filed on February 3, 2014)
101
4.2
4.3
4.4 *
10.1 #
10.2 #
10.3 #
10.4 #
10.5 #
10.6 #
10.7 #
Form of Warrant Agreement, dated as of June 8, 2017, issued to Hercules Technology II, L.P. and Hercules Technology III, L.P.
(incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on June 12, 2017)
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on
January 28, 2020)
Description of Capital Stock
Amended and Restated 2006 Stock Option and Grant Plan, as amended (incorporated by reference to Exhibit 10.3 to the
Registrant’s Registration Statement on Form S-1 filed on January 13, 2014)
Form of Incentive Stock Option Agreement under 2006 Stock Option and Grant Plan (incorporated by reference to Exhibit 10.4 to
the Registrant’s Registration Statement on Form S-1 filed on January 13, 2014)
Form of Nonstatutory Stock Option Agreement under 2006 Stock Option and Grant Plan (incorporated by reference to Exhibit 10.5
to the Registrant’s Registration Statement on Form S-1 filed on January 13, 2014)
2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1 filed
on February 3, 2014)
Form of Incentive Stock Option Agreement under 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the
Registrant’s Registration Statement on Form S-1 filed on February 3, 2014)
Form of Nonstatutory Stock Option Agreement under 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.8 to the
Registrant’s Registration Statement on Form S-1 filed on February 3, 2014)
Form of Restricted Stock Unit Award Agreement under 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the
Registrant’s Current Report on Form 8-K filed on July 10, 2017)
10.8 #*
Employment Agreement, dated as of October 31, 2018, by and between the Registrant and Roger D. Tung
10.9 #*
Form of Employment Agreement by and between the Registrant and each non-CEO executive officer
10.10 #
10.11 #
Form of Indemnification Agreement by and between the Registrant and each director and executive officer (incorporated by
reference to Exhibit 10.13 to the Registrant’s Registration Statement on Form S-1 filed on January 13, 2014)
Summary of Executive Bonus Program (incorporated by reference to Exhibit 10.19 to the Registrant’s Registration Statement on
Form S-1 filed on January 13, 2014)
10.12 #*
Summary of Non-Employee Director Compensation Program
10.13
10.14 †
10.15
Indenture of Lease, dated as of December 21, 2017, by and between the Registrant and HCP/King Hayden Campus LLC
(incorporated by reference to Exhibit 10.10 to the Registrant’s Annual Report on Form 10-K filed on March 1, 2018)
Development and License Agreement, dated as of February 28, 2012, by and between the Registrant and Avanir Pharmaceuticals,
Inc. (incorporated by reference to Exhibit 10.16 to the Registrant’s Registration Statement on Form S-1 filed on February 3, 2014)
Asset Purchase Agreement, dated as of March 3, 2017, by and among the Registrant, Vertex Pharmaceuticals (Europe) Limited, as
Buyer, and Vertex Pharmaceuticals Incorporated, as Guarantor (incorporated by reference to Exhibit 10.12 to the Registrant’s
Annual Report on Form 10-K filed on March 6, 2017)
21.1 *
Subsidiaries of the Registrant
102
23.1 *
Consent of Ernst & Young LLP
31.1 *
31.2 *
32.1 **
32.2 **
Principal Executive Officer-Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
Principal Financial Officer-Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
Principal Executive Officer-Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002
Principal Financial Officer-Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002
101.INS *
XBRL Instance Document
101.SCH *
XBRL Taxonomy Extension Schema Document
101.CAL *
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF *
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *
XBRL Taxonomy Extension Label Linkbase Document
101.PRE *
XBRL Taxonomy Extension Presentation Linkbase Document
* Filed herewith.
** Furnished herewith.
# Management contract or compensatory plan or arrangement.
† Confidential treatment requested as to certain portions, which portions have been omitted and filed separately with the
Securities and Exchange Commission
Item 16.
Form 10-K Summary
Not applicable.
103
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized, on February 27, 2020.
SIGNATURES
CONCERT PHARMACEUTICALS, INC.
By:
/s/ Roger D. Tung, Ph.D.
Roger D. Tung, Ph.D.
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Roger D. Tung, Ph.D.
Roger D. Tung, Ph.D.
/s/ Marc A. Becker
Marc A. Becker
/s/ Richard H. Aldrich
Richard H. Aldrich
/s/ Thomas G. Auchincloss, Jr.
Thomas G. Auchincloss, Jr.
/s/ Ronald W. Barrett, Ph.D.
Ronald W. Barrett, Ph.D.
/s/ Jesper Høiland
Jesper Høiland
/s/ Peter Barton Hutt
Peter Barton Hutt
/s/ Wilfred E. Jaeger, M.D.
Wilfred E. Jaeger, M.D.
/s/ Christine van Heek
Christine van Heek
President, Chief Executive Officer and Director
(Principal Executive Officer)
February 27, 2020
Chief Financial Officer (Principal Financial and
Accounting Officer)
February 27, 2020
Chairman of the Board
February 27, 2020
Director
Director
Director
Director
Director
Director
104
February 27, 2020
February 27, 2020
February 27, 2020
February 27, 2020
February 27, 2020
February 27, 2020
Exhibit 4.4
DESCRIPTION OF CAPITAL STOCK
The following description of the capital stock of Concert Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”) is a summary
of the rights of our common stock and certain provisions of our restated certificate of incorporation and our amended and restated
by-laws currently in effect. This summary does not purport to be complete and is qualified in its entirety by the provisions of our
restated certificate of incorporation and amended and restated by-laws, each previously filed with the Securities and Exchange
Commission and incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.4 is a part, as
well as to the applicable provisions of the Delaware General Corporation Law (the “DGCL”). We encourage you to read our
certificate of incorporation, by-laws and the applicable portions of the DGCL carefully.
Authorized Capital Stock
Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of
preferred stock, par value $0.001 per share, all of which preferred stock is undesignated.
Common Stock
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do
not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast
by the stockholders entitled to vote on the election. Other matters shall be decided by the affirmative vote of our stockholders
having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter, except as
otherwise disclosed below. Holders of common stock are entitled to receive proportionately any dividends as may be declared by
our board of directors, subject to any preferential dividend rights of outstanding preferred stock.
In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available
for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding
preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights,
preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of
shares of any series of preferred stock that we may designate and issue in the future.
Listing on the Nasdaq Global Market
Our common stock is listed on the Nasdaq Global Market under the symbol “CNCE.”
Authorized but Unissued Shares
The authorized but unissued shares of common stock are available for future issuance without stockholder approval, subject to any
limitations imposed by the Nasdaq Listing Rules. These additional shares may be used for a variety of corporate finance
transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock
could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or
otherwise.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.
Preferred Stock
We may issue shares of our preferred stock from time to time, in one or more series. The rights, preferences and privileges of the
preferred stock could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and the
number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our
common stock. Any issuance of our preferred stock could adversely affect the voting power of holders of our common stock and
the likelihood that such holders would receive dividend payments and payments on liquidation. In addition, the issuance of
preferred stock could have the effect of delaying, deferring or preventing a change of control or other corporate action.
Anti-Takeover Effects of Delaware Law and Our Charter and By-laws
Delaware law and our certificate of incorporation and by-laws contain provisions that could have the effect of delaying, deferring
or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to
discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons
seeking to acquire control of us to first negotiate with our board of directors.
Staggered board; removal of directors. Our certificate of incorporation and by-laws divide our board of directors into three classes
with staggered three-year terms. In addition, a director is only be able to be removed for cause and only by the affirmative vote of
the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in an annual election of directors. Any
vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, is only able to be
filled by vote of a majority of our directors then in office. The classification of our board of directors and the limitations on the
removal of directors and filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party
from seeking to acquire, control of our company.
Stockholder action by written consent; special meetings. Our certificate of incorporation provides that any action required or
permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of such holders and may not
be effected by any consent in writing by such holders. Our certificate of incorporation and by-laws also provide that, except as
otherwise required by law, special meetings of our stockholders can only be called by our chairman of the board, our chief
executive officer or our board of directors.
2
Advance notice requirements for stockholder proposals. Our by-laws establish an advance notice procedure for stockholder
proposals to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to our
board of directors. Stockholders at an annual meeting are only able to consider proposals or nominations specified in the notice of
meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record
date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our
secretary of the stockholder’s intention to bring such business before the meeting. These provisions could have the effect of
delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding
voting securities.
Delaware business combination statute. We are subject to Section 203 of the DGCL. Subject to certain exceptions, Section 203
prevents a publicly held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for
three years following the date that the person became an interested stockholder, unless the interested stockholder attained such
status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A
“business combination” includes, among other things, a merger or consolidation involving us and the “interested stockholder” and
the sale of more than 10% of our assets. In general, an “interested stockholder” is any entity or person beneficially owning 15% or
more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.
Choice of forum. Our by-laws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any
derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim
against us arising pursuant to the DGCL, our certificate of incorporation or our by-laws, or any action asserting a claim against us
that is governed by the internal affairs doctrine. Although our by-laws contain the choice of forum provision described above, it is
possible that a court could rule that such a provision is inapplicable for a particular claim or action or that such provision is
unenforceable.
Amendment of certificate of incorporation and by-laws. The DGCL provides generally that the affirmative vote of a majority of the
shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or by-laws, unless a
corporation’s certificate of incorporation or by-laws, as the case may be, requires a greater percentage. Our by-laws may be
amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of the
votes that all of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the
holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors is
required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation
described above under “—Staggered board; removal of directors” and “—Stockholder action by written consent; special meetings.”
3
Exhibit 10.8
May 16, 2018
Roger D. Tung
c/o
Concert Pharmaceuticals, Inc.
99 Hayden Avenue, Suite 500
Lexington, MA 02421
Dear Dr. Tung:
This agreement revises the terms of your continued employment as President and Chief Executive Officer of Concert
Pharmaceuticals, Inc. (the “Company” or “Concert” and, with you, the “Parties”) reporting directly to the Company’s Board of
Directors (the “Board”), effective as of [_], 2018 (the “Effective Date”). You agree to continue to perform the duties of your position
and such other duties as the Board may reasonably assign to you from time to time.
Although your position is for full-time employment, the Board has agreed that you may maintain up to two advisory or consulting roles
with other organizations, as long as (i) such roles are disclosed to and discussed with the Board’s Compensation Committee (the
“Compensation Committee”) on an annual basis, (ii) the Compensation Committee determines that such roles do not conflict with
your obligations to the Company, and (iii) you do not spend more than 12 days per year in such roles, in the aggregate.
1.
Salary. You will receive annualized base salary of $434,700 per year (as in effect from the Effective Date), payable in
accordance with the regular payroll practices of the Company and less applicable taxes and withholdings, as in effect from time to time.
The base salary shall be subject to increase from time to time by the Compensation Committee of the Board (the “Compensation
Committee”) in its exclusive discretion.
2.
Bonus. During your employment, you may be eligible for an annual discretionary performance bonus in addition to
your base salary. Bonus compensation in any year, if any, will be based on your performance and/or that of the Company, in accordance
with a general bonus program to be established by the Board (and administered by the Compensation Committee) and will be payable
not later than two and one-half months following the calendar year, except as the bonus program may from time to time provide.
3.
Benefits; Vacation. You will be entitled to participate in all employee benefit plans from time to time in effect for
employees of the Company generally. Your participation will be subject to the terms of the applicable plan documents and generally
applicable Company policies. Benefits are subject to change at any time at the Company’s sole discretion. You will remain eligible to
accrue three weeks’ paid vacation in each calendar year (or such greater amount as is generally made available in accordance with the
Company’s policies from time to time in effect), in addition to holidays observed by the Company. Vacation may be taken at such times
and intervals
as you shall determine, subject to the business needs of the Company, and otherwise shall be subject to the policies of the Company, as
in effect from time to time.
4.
Expense Reimbursement. The Company will pay or reimburse you for all and customary reasonable out-of-pocket
business expenses incurred or paid by you in the performance of your duties and responsibilities for the Company, subject to any
maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and
documentation as the Company may specify. Any such reimbursement that would constitute nonqualified deferred compensation
subject to Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A” of the “Code”) shall be subject to the
following additional rules: (i) no reimbursement of any such expense shall affect your right to reimbursement of any other such expense
in any other taxable year; (ii) reimbursement of the expense shall be made, if at all, not later than the end of the calendar year following
the calendar year in which the expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation or exchange
for any other benefit.
5.
Confidentiality Agreement. You represent that you have complied and agree that you will continue to comply with
the Employee Confidentiality, Non-Competition, and Proprietary Information Agreement between the Company and you dated May 17,
2006 (the “Confidentiality Agreement"). It is understood and agreed that a breach by you of the Confidentiality Agreement would be a
material breach of this Agreement.
6.
At-Will; Timing for Termination; Accrued Benefits. This employment letter is not intended to create or constitute
an employment agreement or contract (express or implied) between you and the Company for a fixed term. It is also important for you
to understand that Massachusetts is an “at will” employment state. This means that you will have the right to terminate your
employment relationship with the Company at any time for any reason, although you are requested to give at least two weeks’ notice.
Similarly, the Company will have the right to terminate its employment relationship with you at any time for any reason. You may
terminate your employment hereunder for Good Reason (as defined below) by providing notice to the Company of the condition giving
rise to the Good Reason no later than 90 days following the occurrence of the condition, by giving the Company 30 days to remedy the
condition and by terminating employment for Good Reason within 30 days thereafter if the Company fails to remedy the condition.
Upon your termination, the Company will pay on the date of termination any base salary earned but not paid through the date of
termination and pay for any vacation time accrued but not used to that date. In addition, the Company will pay you any bonus that has
been awarded to you and earned, but not yet paid on the termination of your employment (together with the preceding sentence, the
“Accrued Benefits”). In the event of any termination of your employment, other than a tem1ination under Section 7 or as provided for
COBRA under Section 7(c), the Company shall have no obligation to you under this Agreement other than with respect to the Accrued
Benefits.
7.
Termination without Cause; Termination for Good Reason.
(a) Severance Pay. A termination by you for Good Reason, or any termination of your employment by the Company (other
than for Cause, as defined below, death, or inability to perform as a result of physical or mental infirmity (“disability”) shall entitle you
to 15 months (the
2
“Severance Pay Period”) of severance pay (the “Severance Pay”) and the other compensation provided in this section, as well as to the
Accrued Benefits. The Severance Pay shall be calculated on the basis of your base salary as of the date the Company gives you notice of
your termination and shall be exclusive of any bonus or benefit payments. The Company will provide the Severance Pay in the form of
salary continuation in accordance with the normal payroll practices of the Company, beginning with the Company’s next regular payroll
period following the Effective Release Date (as defined below), with the first payment including any amounts that would have been paid
between the termination date and the Effective Release Date if the payments had commenced on the termination date and with the
remaining payments made proportionately over the remainder of the 15 month severance period. The receipt of any severance benefits
provided for under this Section 7 or otherwise shall be dependent upon your delivery to the Company, within 60 days following the date
of termination of employment, of an effective general release of claims in a form provided by the Company; provided, however, that if
the last day of the 60 day period falls in the calendar year following the year of your date of termination, the severance payments shall be
paid or commence on the first payroll period of such subsequent calendar year following the Effective Release Date. The date on which
your release of claims becomes effective is the “Effective Release Date.”
(b) COBRA. In addition to Severance Pay, if you are participating in the Company’s group health plan and/or dental plan at the
time your employment ends and you exercise the right to continue participation in those plans under the federal law known as COBRA,
or any successor law and if your employment has ended for a reason other than resignation without Good Reason or termination for
Cause, the Company will continue to pay the full premium for such coverage that is applicable for active and similarly-situated
employees who receive the same type of coverage (single, family, or other) until the earlier of (i) the end of the Severance Pay Period
(under either Section 7(a) or (c) as applicable) or (ii) the date your COBRA continuation coverage expires, unless the Company’s
providing payments for COBRA will violate the nondiscrimination requirements of applicable law, in which case this benefit will not
apply.
(c) Effect of Change of Control. If a Change of Control (as defined below) occurs and if, within one year following such
Change of Control, the Company or any successor thereto terminates your employment other than for Cause, or you terminate your
employment for Good Reason, then the Severance Pay Period will be increased by an additional three months and you will also receive
an amount equal to 1.5 times the greater of (i) your then current target bonus or (ii) the actual bonus paid to you for the immediate
preceding calendar year (payable ratably in accordance with the Severance Pay). If the Change of Control is a 409A Change of Control
Event (as defined below), in lieu of installments, the Severance Pay and target bonus multiple will be paid in a single lump sum in the
Company’s next regular payroll period following the Effective Release Date (subject to the same delay provided above where the 60 day
period ends in the following year). A “409A Change of Control Event” is a “change in the ownership or effective control” of the
Company or “change in the ownership of a substantial portion of the assets” of the Company within the meaning of Treasury Regulation
§ 1.409A-3(i)(5). In addition, if a Change of Control occurs and if, within one year following such Change of Control, (a) the Company
or any successor thereto terminates your employment other than for Cause or your employment ends on death or disability, or (b) you
terminate your employment for Good Reason, then all stock options held by you at such time shall immediately vest in full,
notwithstanding any contrary provision in any agreement evidencing any such stock option.
3
(d)
Definitions.
i. For purposes of this Agreement, “Cause” shall include (i) your conviction or plea of guilty or nolo contendere to a
crime involving moral turpitude which adversely affects your ability to perform your obligations to the Company or the
business activities, reputation, goodwill or image of the
Company or to a felony, (ii) your deliberate dishonesty or breach of fiduciary duty which could be reasonably expected to or
does cause material loss, damage or injury to the Company, (iii) your material breach of the terms of this agreement or your
failure or refusal to carry out any material tasks assigned to you by the Company in accordance with the terms hereof, which
breach or failure (only as to those susceptible to cure) continues for a period of more than ten days after your receipt of
·written notice thereof and which could be reasonably expected to or does cause material loss, damage or injury to the
Company, (iv) the commission
by you of any act of fraud, embezzlement or deliberate disregard of a rule or policy of the Company known to you or
contained in a policy and procedure manual provided to you which could be reasonably expected to or does cause material
loss, damage or injury to the Company, or (v) the material breach or threatened breach by you of any of the provisions of the
Confidentiality Agreement which could be reasonably expected to or does cause material loss, damage or injury to the
Company. (“Company,” for purposes of this section, shall include the Company and any Company subsidiary.)
ii. “Good Reason” shall mean, without your consent: (i) material diminution in the nature or scope of your
responsibilities, duties or authority, provided that neither of the following (x) or (y) shall constitute Good Reason: (x) the
Company’s failure to continue your appointment or election as a director or officer of any of its Affiliates nor (y) any
diminution in the nature or scope of
your responsibilities, duties or authority that is reasonably related to a diminution of the business of the Company or any of
its Affiliates, other than any such diminution resulting from the sale or transfer of any or all of the assets of the Company or
any of its Affiliates; (ii) a material reduction in your base salary other than one temporary reduction of not more than 120
days and not in excess of 20% of your base salary in connection with and in proportion to a general reduction of the base
salaries of the Company’s executive officers; (iii) relocation of your office more than 35 miles from Lexington,
Massachusetts; or (iv) material breach by the Company of any material provision of this Agreement or any other service-
providing agreement between the Company or any of its Affiliates and you.
iii. “Change of Control” shall mean (i) the acquisition of beneficial ownership (as defined in Rule 13d-3 under the
Exchange Act) directly or indirectly by any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act),
of securities of the Company representing a majority or more of the combined voting power of the Company’s then
outstanding securities, other than an acquisition of securities for investment purposes pursuant to a bona fide financing of the
Company; (ii) a merger or consolidation of the Company with any other corporation in which the holders of the
4
voting securities of the Company prior to the merger or consolidation do not own more than 50% of the total voting
securities of the surviving corporation; (iii) the sale or disposition by the Company of all or substantially all of the
Company’s assets other than a sale or disposition of assets to an entity whose equity interests are held, directly or indirectly,
entirely by the same persons and in the same proportions as the equity interests of the Company; or (iv) a change in the
composition of the Board that results, during any one year period, in the Continuing Directors’ no longer constituting a
majority of the Board (or, if applicable, the board of directors of a successor corporation to the Company), where the term
“Continuing Director” means at any date a member of the Board (x) who was a member of the Board on January 10, 2014
or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing
Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at
least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided,
however, that there shall be excluded from this clause (y) any individual whose initial assumption of office after January 10,
2014 occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or
other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board.
8.
Withholdings; Section 409A. Anything to the contrary notwithstanding, (a) all payments required to be made by the
Company hereunder to you shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions as
the Company may reasonably determine it should withhold pursuant to any applicable law or regulation, and
(b) if and to the extent any portion of any payment, compensation or other benefit provided to you in connection with your employment
termination is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A and you are a
specified employee as defined in Section 409A(a)(2)(B)(i), as determined by the Company in accordance with its procedures, by which
determination you hereby agree that you are bound, such portion of the
payment, compensation or other benefit shall not be paid before the earlier of (i) the expiration of the six month period measured from
the date of your “separation from service” (as determined under Section 409A) or (ii) the tenth day following the date of your death
following such separation from service (the “New Payment Date”). The aggregate of any payments that otherwise would have been
paid to you during the period between the date of separation from service and the New Payment Date shall be paid to you in a lump sum
in the first payroll period beginning after such New Payment Date, and any remaining payments will be paid on their original schedule.
For purposes of this Agreement, (i) each amount to be paid or benefit to be provided shall be construed as a separate identified payment
for purposes of Section 409A, (ii) neither you nor the Company shall have the right to accelerate or defer any payment or benefit
hereunder unless permitted or required by Section 409A, and (iii) any payments that are due within the “short term deferral period” as
defined in Section 409A or paid in a manner consistent with Treas. Reg. § l.409A- l (b)(9)(iii) shall not be treated as deferred
compensation unless applicable law requires otherwise. The terms of this employment letter are intended to be compliant with, or
exempt from, Section 409A; provided, however, that the Company shall have no liability to you or to any other person in the event that
the employment letter terms are determined not to be so compliant or exempt.
5
9.
Parachute Taxation. The Company will make any payments due to you without regard to whether Section 280G of
the Code would limit or preclude the deductibility of such payments (or any other payments or benefits) and without regard to whether
such payments would subject you to the federal excise tax levied on certain “excess parachute payments” under Section 4999 of the
Code; provided, however, that if the Total After-Tax Payments (as defined below) would be increased by the reduction or elimination of
any payment and/or other benefit (including the vesting of any equity awards), then the amounts payable under this Agreement or
otherwise will be reduced or eliminated as follows, as determined by the Company, in the following order: (i) nonacceleration of any
stock options whose exercise price is at or above the fair market value of the Company’s common stock as determined in the discretion
of the Compensation Committee (taking into account, as appropriate, the proceeds that would be received in connection with the event
covered by Section 4999) (“Underwater Options”), (ii) nonacceleration of any stock options other than Underwater Options, (iii) any
vesting or distribution of restricted stock or restricted stock units, (iv) any other taxable benefits, (v) any nontaxable benefits, and (vi)
the cash severance due under Section 7(a) above. Within each category described in clauses (i), (ii), and (iii), reductions or eliminations
shall be made in reverse order beginning with vesting or distributions that are to be paid the farthest in time from the date of the event
covered by Section 4999. The Company’s independent, certified public accounting firm will determine whether and to what extent
payments or vesting under this Agreement are required to be reduced in accordance with the preceding sentence. If there is an
underpayment or overpayment under this Agreement (as determined after the application of this paragraph), the amount of such
underpayment or overpayment will be immediately paid to you or refunded by you, as the case may be, with interest at the applicable
federal rate provided for in Section 7872(f)(2) of the Code. For purposes of this Agreement, “Total After-Tax Payments” means the
total of all “parachute payments” (as that term is defined in Section 280G(b)(2) of the Code) made to you or for your benefit (whether
made under the Agreement or otherwise), after reduction for all applicable federal taxes (including the tax described in Section 4999 of
the Code).
l 0. Miscellaneous.
(a) Notices. All notices required or permitted under this Agreement must be in writing and will be deemed effective
upon personal delivery or three business days following deposit in a United States Post Office, by certified mail, postage
prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight courier service
addressed in the case of notice to the Company at its then principal headquarters (with copies to the Chairman of the Board and
the Company’s General Counsel, which will not constitute notice), and in the case of notice to you to the current address on file
with the Company. Either Party may change the address to which notices are to be delivered by giving notice of such change to
the other Party in the manner set forth in this Section 10(a).
(b) No Mitigation. You are not required to seek other employment or otherwise mitigate the value of any severance
benefits contemplated by this Agreement, nor will any such benefits be reduced by any earnings or benefits that you may receive
from any other source. Notwithstanding any other provision of this Agreement, any sum or sums paid under this Agreement will be
in lieu of any amounts to which you may otherwise be entitled under the
6
terms of any severance plan, policy, program, agreement or other arrangement sponsored by the Company or an affiliate of the
Company.
(c) Waiver of Jury Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE
WAIVED, THE PARTIES HEREBY WAIVE, AND COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS
PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER
PROCEEDING ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE
RELEASE IT CONTEMPLATES, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN
CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY PARTY MAY FILE A COPY OF THIS
PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR
AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE THEIR RIGHTS TO TRIAL BY JURY IN ANY
PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT OR TO ANY OF THE MATTERS
CONTEMPLATED UNDER THIS AGREEMENT, RELATING TO YOUR EMPLOYMENT, OR COVERED BY THE
CONTEMPLATED RELEASE.
(d) Severability. Each provision of this Agreement is intended to be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such
provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision
or the remaining provisions of this Agreement. Moreover, if an arbitrator or a court of competent jurisdiction determines any of the
provisions contained in this Agreement to be unenforceable because the provision is excessively broad in scope, whether as to
duration, activity, geographic application, subject or otherwise, it will be construed, by limiting or reducing it to the extent legally
permitted, so as to be enforceable to the extent compatible with then applicable law to achieve the intent of the Parties.
(e) Assignment. This Agreement will be binding upon and will inure to the benefit of (i) your heirs, beneficiaries,
executors and legal representatives upon your
death and (ii) any successor of the Company. Any such successor of the Company will be treated as substituted for the Company
under the terms of this Agreement for all
purposes. The Company may assign this Agreement without your consent, and such an assignment will not terminate your
employment for purposes of triggering your entitlement to severance. You specifically agree that any assignment may include rights
under the Confidentiality Agreement without requiring your consent. As used herein, “successor” will mean any person, firm,
corporation or other business entity that at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or
substantially all of the assets or business of the Company and its subsidiaries. None of your rights to receive any form of
compensation payable under this Agreement will be assignable or transferable except through a testamentary disposition or by the
laws of descent and distribution upon your death or as provided in Section 10(k). Any attempted assignment, transfer, conveyance or
other disposition of any interest in your rights to receive any form of compensation hereunder, except as provided in the preceding
sentence, will be null and void.
7
(f) No Oral Modification, Waiver, Cancellation or Discharge. This Agreement may only be amended, canceled or
discharged or any obligations thereunder waived through a writing signed by you and the Board or any duly authorized executive
officer of the Company.
(g) No Conflict of Interest. You confirm that you have fully disclosed to the Company and its affiliates, to the best of your
knowledge, any circumstances under which you, your immediate family and other persons who reside in your household have or
may have a conflict of interest with the Company. You further agree to fully disclose to the Company any such circumstances that
might arise during your employment upon your becoming aware of such circumstances.
(h) Other Agreements. You hereby represent that your performance of all the terms of this Agreement and the
performance of your duties as an employee of the Company does not and will not breach any agreement to keep in confidence
proprietary information, knowledge or data acquired by you in confidence or in trust prior to your employment with the Company.
You also represent that you are not a party to or subject to any restrictive covenants, legal restrictions, policies, commitments or
other agreements in favor of any entity or person that would in any way preclude, inhibit, impair or limit your ability to perform
your obligations under this Agreement, including noncompetition agreements or nonsolicitation agreements, and you further
represent that your performance of the duties and obligations under this Agreement does not violate the
terms of any agreement to which you are a party. You agree that you will not enter into any agreement or commitment or agree to
any policy that would prevent or unreasonably hinder your performance of duties and obligations under this Agreement.
(i) Disclosure of this Agreement. You acknowledge that the Company may provide persons or entities who may employ
or engage you with a copy of the Confidentiality Agreement (or portions thereof) to highlight your continuing obligations to the
Company. You also acknowledge that the Company may be obligated to disclose this Agreement or any portion thereof to satisfy
applicable laws and regulations.
(j) Survivorship. The respective rights and obligations of the Company and you hereunder will survive any termination of
your employment to the extent necessary to preserve the intent of such rights and obligations.
(k)
Beneficiaries. You will be entitled, to the extent applicable law permits, to select and change the beneficiary or
beneficiaries to receive any compensation or benefit payable hereunder upon your death by giving the Company written notice
thereof in a manner consistent with the terms of any applicable plan documents. If you die, severance then due or other amounts due
hereunder will be paid to your designated beneficiary or beneficiaries or, if none are designated or none survive you, your estate.
(I) Company Policies. References in this Agreement to Company policies and procedures are to those policies and
procedures in effect at the Effective Date, as the Company may amend them from time to time.
(m)
Governing Law; Dispute Resolution. This Agreement must be construed, interpreted, and governed in
accordance with the laws of the Commonwealth of Massachusetts without reference to rules relating to conflict of law. You and the
Company (a) hereby irrevocably submit to the exclusive jurisdiction of the state courts of The Commonwealth of
8
Massachusetts or the United States District Court located in The Commonwealth of Massachusetts for the purpose of any action
between the Company and you arising in whole or in part under or in connection with this Agreement, (b) hereby waive, to the
extent not prohibited by applicable law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action, any
claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that any such action brought in one of the above-named courts should be dismissed on grounds of forum
non conveniens, should be transferred or removed to any court other than one of the above-named courts, or should be stayed by
reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this
Agreement or the subject matter hereof may not be enforced in or by such court, and (c) hereby agree not to commence any such
action other than before one of the above-named courts. Notwithstanding the previous sentence, the Company or you may
commence any action in a court other than the above-named courts solely for the purpose of enforcing an order or judgment issued
by one of the above-named courts. In the event of a final judgement in the Company’s favor, the Company shall be entitled to
recover all of its reasonably incurred costs and attorney’s fees in enforcing its rights hereunder.
(n)
Interpretation. The parties agree that this Agreement will be construed without regard to any presumption or rule
requiring construction or interpretation against the drafting party. References in this Agreement to “include” or “including” should
be read as though they said “without limitation” or equivalent forms. References to “day” or “days” are to calendar days, unless the
Agreement specifically refers to “business” days.
(o)
Entire Agreement. This Agreement and any documents referred to herein, including the Confidentiality
Agreement, represent the entire agreement of the Parties and will supersede any and all previous contracts, arrangements or
understandings between the Company and you relating to matters covered by this Agreement, including specifically your prior
employment agreement dated as January 21, 2008 and amended as of December 30, 2008 and the version of this Agreement entered
into as of January 10, 2014.
Agreed and Accepted:
Signature:
/s/ Roger D. Tung
Roger D. Tung
Very truly yours,
/s/ Nancy Stuart
Nancy Stuart
Chief Operating Officer
10/31/2018
Date:
9
Exhibit 10.9
[Date]
[Name and Address]
Dear [Name]:
This agreement [revises/defines] the terms of your [continued] employment as __________ of Concert Pharmaceuticals, Inc. (the “Company” or
“Concert” and, with you, the “Parties”) reporting to the Company’s Chief Executive Officer, effective as of __________ (the “Effective Date”). You agree to
continue to perform the duties of your position and such other duties as the Board may reasonably assign to you from time to time.
1. Salary. You will receive annualized base salary of $__________ per year (as in effect from the Effective Date), payable in accordance with the
regular payroll practices of the Company and less applicable taxes and withholdings, as in effect from time to time. The base salary shall be subject to
increase from time to time by the Compensation Committee of the Board (the “Compensation Committee”) in its exclusive discretion.
2. Bonus. During your employment, you may be eligible for an annual discretionary performance bonus in addition to your base salary. Bonus
compensation in any year, if any, will be based on your performance and/or that of the Company, in accordance with a general bonus program to be
established by the Board (and administered by the Compensation Committee) and will be payable not later than two and one-half months following the
calendar year, except as the bonus program may from time to time provide.
3. Benefits; Vacation. You will be entitled to participate in all employee benefit plans from time to time in effect for employees of the Company
generally. Your participation will be subject to the terms of the applicable plan documents and generally applicable Company policies. Benefits are subject to
change at any time at the Company’s sole discretion. You will remain eligible to accrue three weeks’ paid vacation in each calendar year (or such greater
amount as is generally made available in accordance with the Company’s policies from time to time in effect), in addition to holidays observed by the
Company. Vacation may be taken at such times and intervals as you shall determine, subject to the business needs of the Company, and otherwise shall be
subject to the policies of the Company, as in effect from time to time.
4. Expense Reimbursement. The Company will pay or reimburse you for all and customary reasonable out-of-pocket business expenses incurred or
paid by you in the performance of your duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such
expenses set by the Company and to such reasonable substantiation and documentation as the Company may specify. Any such reimbursement that would
constitute nonqualified deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A” of the “Code ”)
shall be subject to the following additional rules: (i) no reimbursement of any such expense shall affect your right to reimbursement of any other such expense
in any other taxable year; (ii) reimbursement of the expense shall be made, if at all, not later than the end of the calendar year following the calendar year in
which the expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for any other benefit.
5. Confidentiality Agreement. You represent that you have complied and agree that you will continue to comply with the Employee Confidentiality,
Non-[Competition/Solicitation], and Proprietary Information Agreement between the Company and you dated __________ (the “Confidentiality
Agreement”). It is understood and agreed that a breach by you of the Confidentiality Agreement would be a material breach of this Agreement.
6. At-Will; Timing for Termination; Accrued Benefits. This employment letter is not intended to create or constitute an employment agreement or
contract (express or implied) between you and the Company for a fixed
1
term. It is also important for you to understand that Massachusetts is an “at will” employment state. This means that you will have the right to terminate your
employment relationship with the Company at any time for any reason, although you are requested to give at least two weeks’ notice. Similarly, the Company
will have the right to terminate its employment relationship with you at any time for any reason. You may terminate your employment hereunder for Good
Reason (as defined below) by providing notice to the Company of the condition giving rise to the Good Reason no later than 90 days following the
occurrence of the condition, by giving the Company 30 days to remedy the condition and by terminating employment for Good Reason within 30 days
thereafter if the Company fails to remedy the condition. Upon your termination, the Company will pay on the date of termination any base salary earned but
not paid through the date of termination and pay for any vacation time accrued but not used to that date. In addition, the Company will pay you any bonus that
has been awarded to you and earned, but not yet paid on the termination of your employment (together with the preceding sentence, the “Accrued Benefits”).
In the event of any termination of your employment, other than a termination under Section 7 or as provided for COBRA under Section 7(c), the Company
shall have no obligation to you under this Agreement other than with respect to the Accrued Benefits.
7. Termination without Cause; Termination for Good Reason.
(a) Severance Pay. A termination by you for Good Reason, or any termination of your employment by the Company (other than for Cause, as
defined below, death, or inability to perform as a result of physical or mental infirmity (“disability”) shall entitle you to 12 months of severance pay (the
“Severance Pay”) and the other compensation provided in this section, as well as to the Accrued Benefits. The Severance Pay shall be calculated on the
basis of your base salary as of the date the Company gives you notice of your termination and shall be exclusive of any bonus or benefit payments. The
Company will provide the Severance Pay in the form of salary continuation in accordance with the normal payroll practices of the Company, beginning
with the Company’s next regular payroll period following the Effective Release Date (as defined below), with the first payment including any amounts
that would have been paid between the termination date and the Effective Release Date if the payments had commenced on the termination date and
with the remaining payments made proportionately over the remainder of the 12 month severance period. The receipt of any severance benefits
provided for under this Section 7 or otherwise shall be dependent upon your delivery to the Company, within 60 days following the date of termination
of employment, of an effective general release of claims in a form provided by the Company; provided, however, that if the last day of the 60 day
period falls in the calendar year following the year of your date of termination, the severance payments shall be paid or commence on the first payroll
period of such subsequent calendar year following the Effective Release Date. The date on which your release of claims becomes effective is the
“Effective Release Date.”
(b) COBRA. In addition to Severance Pay, if you are participating in the Company’s group health plan and/or dental plan at the time your
employment ends and you exercise the right to continue participation in those plans under the federal law known as COBRA, or any successor law and
if your employment has ended for a reason other than resignation without Good Reason or termination for Cause, the Company will continue to pay the
full premium for such coverage that is applicable for active and similarly-situated employees who receive the same type of coverage (single, family, or
other) until the earlier of (i) the end of the 12th month after your employment ends or (ii) the date your COBRA continuation coverage expires, unless
the Company’s providing payments for COBRA will violate the nondiscrimination requirements of applicable law, in which case this benefit will not
apply.
(c) Effect of Change of Control. If a Change of Control (as defined below) occurs and if, within one year following such Change of Control, the
Company or any successor thereto terminates your employment other than for Cause, or you terminate your employment for Good Reason, then, in
addition to the Severance Pay, you will receive an amount equal to the greater of (i) your then current target bonus or (ii) the actual bonus paid to you
for the immediate preceding calendar year (payable ratably in accordance with the Severance Pay). If the Change of Control is a 409A Change of
Control Event (as defined below), in lieu of installments, the Severance Pay will be paid in a single lump sum in the Company’s next regular payroll
period following the Effective Release Date (subject to the same delay provided above where the 60 day period ends in the following year). A “409A
Change of Control Event” is a “change in the ownership or effective control” of the Company or “change in the ownership of a substantial portion of
the assets” of the
2
Company within the meaning of Treasury Regulation § 1.409A-3(i)(5). In addition, if a Change of Control occurs and if, within one year following such
Change of Control, (a) the Company or any successor thereto terminates your employment other than for Cause or your employment ends on death or
disability, or (b) you terminate your employment for Good Reason, then all stock options held by you at such time shall immediately vest in full,
notwithstanding any contrary provision in any agreement evidencing any such stock option.
(d) Definitions.
i. For purposes of this Agreement, “Cause” shall include (i) your conviction or plea of guilty or nolo contendere to a crime involving moral
turpitude which adversely affects your ability to perform your obligations to the Company or the business activities, reputation, goodwill or image
of the Company or to a felony, (ii) your deliberate dishonesty or breach of fiduciary duty which could be reasonably expected to or does cause
material loss, damage or injury to the Company, (iii) your material breach of the terms of this agreement or your failure or refusal to carry out any
material tasks assigned to you by the Company in accordance with the terms hereof, which breach or failure (only as to those susceptible to cure)
continues for a period of more than ten days after your receipt of written notice thereof and which could be reasonably expected to or does cause
material loss, damage or injury to the Company, (iv) the commission by you of any act of fraud, embezzlement or deliberate disregard of a rule or
policy of the Company known to you or contained in a policy and procedure manual provided to you which could be reasonably expected to or
does cause material loss, damage or injury to the Company, or (v) the material breach or threatened breach by you of any of the provisions of the
Confidentiality Agreement which could be reasonably expected to or does cause material loss, damage or injury to the Company. (“Company” for
purposes of this section, shall include the Company and any Company subsidiary.)
ii. “Good Reason” shall mean, without your consent: (i) material diminution in the nature or scope of your responsibilities, duties or
authority, provided that neither of the following (x) or (y) shall constitute Good Reason: (x) the Company’s failure to continue your appointment
or election as a director or officer of any of its Affiliates nor (y) any diminution in the nature or scope of your responsibilities, duties or authority
that is reasonably related to a diminution of the business of the Company or any of its Affiliates, other than any such diminution resulting from
the sale or transfer of any or all of the assets of the Company or any of its Affiliates; (ii) a material reduction in your base salary other than one
temporary reduction of not more than 120 days and not in excess of 20% of your base salary in connection with and in proportion to a general
reduction of the base salaries of the Company’s executive officers; (iii) relocation of your office more than 35 miles from Lexington,
Massachusetts; or (iv) material breach by the Company of any material provision of this Agreement or any other service-providing agreement
between the Company or any of its Affiliates and you.
iii. “Change of Control” shall mean (i) the acquisition of beneficial ownership (as defined in Rule 13d-3 under the Exchange Act) directly
or indirectly by any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), of securities of the Company representing a
majority or more of the combined voting power of the Company’s then outstanding securities, other than an acquisition of securities for
investment purposes pursuant to a bona fide financing of the Company; (ii) a merger or consolidation of the Company with any other corporation
in which the holders of the voting securities of the Company prior to the merger or consolidation do not own more than 50% of the total voting
securities of the surviving corporation; (iii) the sale or disposition by the Company of all or substantially all of the Company’s assets other than a
sale or disposition of assets to an entity whose equity interests are held, directly or indirectly, entirely by the same persons and in the same
proportions as the equity interests of the Company; or (iv) a change in the composition of the Board that results, during any one year period, in
the Continuing Directors’ no longer constituting a majority of the Board (or, if applicable, the board of directors of a successor corporation to the
Company), where the term “Continuing Director” means at any date a member of the Board (x) who was a member of the Board on __________
or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of
such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were
3
Continuing Directors at the time of such nomination or election; provided, however , that there shall be excluded from this clause (y) any
individual whose initial assumption of office after January 10, 2014 occurred as a result of an actual or threatened election contest with respect to
the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the
Board.
8. Withholdings; Section 409A. Anything to the contrary notwithstanding, (a) all payments required to be made by the Company hereunder to you
shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions as the Company may reasonably determine it should
withhold pursuant to any applicable law or regulation, and (b) if and to the extent any portion of any payment, compensation or other benefit provided to you
in connection with your employment termination is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A and
you are a specified employee as defined in Section 409A(a)(2)(B)(i), as determined by the Company in accordance with its procedures, by which
determination you hereby agree that you are bound, such portion of the payment, compensation or other benefit shall not be paid before the earlier of (i) the
expiration of the six month period measured from the date of your “separation from service” (as determined under Section 409A) or (ii) the tenth day
following the date of your death following such separation from service (the “New Payment Date”). The aggregate of any payments that otherwise would
have been paid to you during the period between the date of separation from service and the New Payment Date shall be paid to you in a lump sum in the first
payroll period beginning after such New Payment Date, and any remaining payments will be paid on their original schedule. For purposes of this Agreement,
(i) each amount to be paid or benefit to be provided shall be construed as a separate identified payment for purposes of Section 409A, (ii) neither you nor the
Company shall have the right to accelerate or defer any payment or benefit hereunder unless permitted or required by Section 409A, and (iii) any payments
that are due within the “short term deferral period” as defined in Section 409A or paid in a manner consistent with Treas. Reg. § 1.409A-1(b)(9)(iii) shall not
be treated as deferred compensation unless applicable law requires otherwise. The terms of this employment letter are intended to be compliant with, or
exempt from, Section 409A; provided, however, that the Company shall have no liability to you or to any other person in the event that the employment letter
terms are determined not to be so compliant or exempt.
9. Parachute Taxation. The Company will make any payments due to you without regard to whether Section 280G of the Code would limit or
preclude the deductibility of such payments (or any other payments or benefits) and without regard to whether such payments would subject you to the federal
excise tax levied on certain “excess parachute payments” under Section 4999 of the Code; provided, however, that if the Total After-Tax Payments (as defined
below) would be increased by the reduction or elimination of any payment and/or other benefit (including the vesting of any equity awards), then the amounts
payable under this Agreement or otherwise will be reduced or eliminated as follows, as determined by the Company, in the following order: (i)
nonacceleration of any stock options whose exercise price is at or above the fair market value of the Company’s common stock as determined in the discretion
of the Compensation Committee (taking into account, as appropriate, the proceeds that would be received in connection with the event covered by Section
4999) (“Underwater Options”), (ii) nonacceleration of any stock options other than Underwater Options, (iii) any vesting or distribution of restricted stock or
restricted stock units, (iv) any other taxable benefits, (v) any nontaxable benefits, and (vi) the cash severance due under Section 7(a) above. Within each
category described in clauses (i), (ii), and (iii), reductions or eliminations shall be made in reverse order beginning with vesting or distributions that are to be
paid the farthest in time from the date of the event covered by Section 4999. The Company’s independent, certified public accounting firm will determine
whether and to what extent payments or vesting under this Agreement are required to be reduced in accordance with the preceding sentence. If there is an
underpayment or overpayment under this Agreement (as determined after the application of this paragraph), the amount of such underpayment or
overpayment will be immediately paid to you or refunded by you, as the case may be, with interest at the applicable federal rate provided for in Section
7872(f)(2) of the Code. For purposes of this Agreement, “Total After-Tax Payments” means the total of all “parachute payments” (as that term is defined in
Section 280G(b)(2) of the Code) made to you or for your benefit (whether made under the Agreement or otherwise), after reduction for all applicable federal
taxes (including the tax described in Section 4999 of the Code).
10. Miscellaneous.
4
(a) Notices. All notices required or permitted under this Agreement must be in writing and will be deemed effective upon personal delivery or
three business days following deposit in a United States Post Office, by certified mail, postage prepaid, or one business day after it is sent for next-
business day delivery via a reputable nationwide overnight courier service addressed in the case of notice to the Company at its then principal
headquarters (with copies to the Chairman of the Board and the Company’s General Counsel, which will not constitute notice), and in the case of notice
to you to the current address on file with the Company. Either Party may change the address to which notices are to be delivered by giving notice of
such change to the other Party in the manner set forth in this Section 10(a)
(b) No Mitigation. You are not required to seek other employment or otherwise mitigate the value of any severance benefits contemplated by this
Agreement, nor will any such benefits be reduced by any earnings or benefits that you may receive from any other source. Notwithstanding any other
provision of this Agreement, any sum or sums paid under this Agreement will be in lieu of any amounts to which you may otherwise be entitled under
the terms of any severance plan, policy, program, agreement or other arrangement sponsored by the Company or an affiliate of the Company.
(c) Waiver of Jury Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, THE PARTIES
HEREBY WAIVE, AND COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY
RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER PROCEEDING ARISING IN WHOLE OR IN PART UNDER OR IN
CONNECTION WITH THIS AGREEMENT OR THE RELEASE IT CONTEMPLATES, WHETHER NOW EXISTING OR HEREAFTER
ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY PARTY MAY FILE A
COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR
AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE THEIR RIGHTS TO TRIAL BY JURY IN ANY PROCEEDING
WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT OR TO ANY OF THE MATTERS CONTEMPLATED UNDER THIS
AGREEMENT, RELATING TO YOUR EMPLOYMENT, OR COVERED BY THE CONTEMPLATED RELEASE.
(d) Severability. Each provision of this Agreement is intended to be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. Moreover, if an
arbitrator or a court of competent jurisdiction determines any of the provisions contained in this Agreement to be unenforceable because the provision is
excessively broad in scope, whether as to duration, activity, geographic application, subject or otherwise, it will be construed, by limiting or reducing it
to the extent legally permitted, so as to be enforceable to the extent compatible with then applicable law to achieve the intent of the Parties.
(e) Assignment. This Agreement will be binding upon and will inure to the benefit of (i) your heirs, beneficiaries, executors and legal
representatives upon your death and (ii) any successor of the Company. Any such successor of the Company will be treated as substituted for the
Company under the terms of this Agreement for all purposes. The Company may assign this Agreement without your consent, and such an assignment
will not terminate your employment for purposes of triggering your entitlement to severance. You specifically agree that any assignment may include
rights under the Confidentiality Agreement without requiring your consent. As used herein, “successor” will mean any person, firm, corporation or
other business entity that at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or
business of the Company and its subsidiaries. None of your rights to receive any form of compensation payable under this Agreement will be assignable
or transferable except through a testamentary disposition or by the laws of descent and distribution upon your death or as provided in Section 10(k).
Any attempted assignment, transfer, conveyance or other disposition of any interest in your rights to receive any form of compensation hereunder,
except as provided in the preceding sentence, will be null and void.
5
(f) No Oral Modification, Waiver, Cancellation or Discharge. This Agreement may only be amended, canceled or discharged or any obligations
thereunder waived through a writing signed by you and the Board or any duly authorized executive officer of the Company.
(g) No Conflict of Interest. You confirm that you have fully disclosed to the Company and its affiliates, to the best of your knowledge, any
circumstances under which you, your immediate family and other persons who reside in your household have or may have a conflict of interest with the
Company. You further agree to fully disclose to the Company any such circumstances that might arise during your employment upon your becoming
aware of such circumstances.
(h) Other Agreements. You hereby represent that your performance of all the terms of this Agreement and the performance of your duties as an
employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by
you in confidence or in trust prior to your employment with the Company. You also represent that you are not a party to or subject to any restrictive
covenants, legal restrictions, policies, commitments or other agreements in favor of any entity or person that would in any way preclude, inhibit, impair
or limit your ability to perform your obligations under this Agreement, including noncompetition agreements or nonsolicitation agreements, and you
further represent that your performance of the duties and obligations under this Agreement does not violate the terms of any agreement to which you are
a party. You agree that you will not enter into any agreement or commitment or agree to any policy that would prevent or unreasonably hinder your
performance of duties and obligations under this Agreement.
(i) Disclosure of this Agreement. You acknowledge that the Company may provide persons or entities who may employ or engage you with a
copy of the Confidentiality Agreement (or portions thereof) to highlight your continuing obligations to the Company. You also acknowledge that the
Company may be obligated to disclose this Agreement or any portion thereof to satisfy applicable laws and regulations.
(j) Survivorship. The respective rights and obligations of the Company and you hereunder will survive any termination of your employment to
the extent necessary to preserve the intent of such rights and obligations.
(k) Beneficiaries. You will be entitled, to the extent applicable law permits, to select and change the beneficiary or beneficiaries to receive any
compensation or benefit payable hereunder upon your death by giving the Company written notice thereof in a manner consistent with the terms of any
applicable plan documents. If you die, severance then due or other amounts due hereunder will be paid to your designated beneficiary or beneficiaries
or, if none are designated or none survive you, your estate.
(l) Company Policies. References in this Agreement to Company policies and procedures are to those policies and procedures in effect at the
Effective Date, as the Company may amend them from time to time.
(m) Governing Law; Dispute Resolution. This Agreement must be construed, interpreted, and governed in accordance with the laws of the
Commonwealth of Massachusetts without reference to rules relating to conflict of law. You and the Company (a) hereby irrevocably submit to the
exclusive jurisdiction of the state courts of The Commonwealth of Massachusetts or the United States District Court located in The Commonwealth of
Massachusetts for the purpose of any action between the Company and you arising in whole or in part under or in connection with this Agreement, (b)
hereby waive, to the extent not prohibited by applicable law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action,
any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or
execution, that any such action brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be
transferred or removed to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding
in any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by such
court, and (c) hereby agree not to commence any such action other than before one of the above-named courts. Notwithstanding the previous sentence,
the Company or you may commence any action in a court other than the above-named courts solely for the purpose of enforcing an order or judgment
issued by one of the above-named courts. In the event of a final judgement in the
6
Company’s favor, the Company shall be entitled to recover all of its reasonably incurred costs and attorney’s fees in enforcing its rights hereunder.
(n) Interpretation. The parties agree that this Agreement will be construed without regard to any presumption or rule requiring construction or
interpretation against the drafting party. References in this Agreement to “include” or “including” should be read as though they said “without
limitation” or equivalent forms. References to “day” or “days” are to calendar days, unless the Agreement specifically refers to “business” days.
(o) Entire Agreement. This Agreement and any documents referred to herein, including the Confidentiality Agreement, represent the entire
agreement of the Parties and will supersede any and all previous contracts, arrangements or understandings between the Company and you relating to
matters covered by this Agreement[, including specifically your prior employment agreement dated as of __________].
Agreed and Accepted:
Signature:
[Name]
Very truly yours,
Roger D. Tung
President and Chief Executive Officer
Date:
7
Exhibit 10.12
Summary of Non-Employee Director Compensation Program
The Board of Directors (the “Board”) of Concert Pharmaceuticals, Inc. (the “Company”) has approved the following non-
employee director compensation program.
Each non-employee director will receive a cash retainer for service on the Board and for service on each committee of which
the director is a member. The Chairman of the Board and the chair of each committee will receive higher retainers for such service.
These fees are payable quarterly in arrears. The fees paid to non-employee directors for service on the Board and for service on
each committee of the Board of which the director is a member are as follows:
Board of Directors
Audit Committee
Compensation Committee
Nominating and Corporate Governance Committee
Member
Annual
Retainer
Chair
Annual
Retainer
40,000
10,000
7,500
5,000
70,000
20,000
15,000
10,000
Non-employee directors may elect to receive all or a portion of their cash retainer in the form of a stock option award. The
number of shares subject to the option will be calculated using the fair value of a share of the Company’s common stock on the date
of grant. Each of these options will vest in equal quarterly installments over a one-year period measured from the date of grant, or,
if earlier, will vest in full on the date of the Company’s annual meeting of stockholders held in the year following the date of grant,
subject to the director’s continued service as a director.
In addition, each new non-employee director elected to the Board will receive an option to purchase 25,000 shares of the
Company’s common stock. Each of these options will vest in equal quarterly installments over a three-year period measured from
the date of grant, subject to the director’s continued service as a director, and will become exercisable in full upon a change in
control of the Company. Further, on the date of the first Board meeting held after each annual meeting of stockholders, each non-
employee director that has served on the Board for at least six months will receive an option to purchase 10,000 shares of the
Company’s common stock. Each of these options will vest in equal quarterly installments over a one-year period measured from
the date of grant, subject to the director’s continued service as a director, and will become exercisable in full upon a change in
control of the Company.
The exercise price of all options granted to non-employee directors will equal the closing market price of the Company’s
common stock on the date of grant.
The Company will also reimburse non-employee directors for reasonable travel and out-of-pocket expenses incurred in
connection with attending Board and committee meetings.
Subsidiaries of the Registrant
Exhibit 21.1
Name
Concert Pharmaceuticals Securities Corp.
Concert Pharma U.K. Ltd
Concert Pharma Ireland Limited
Jurisdiction of Organization
Massachusetts
United Kingdom
Ireland
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333-223334) of Concert Pharmaceuticals, Inc. and the related Prospectus;
(2) Registration Statement (Form S-8 No. 333-195125) pertaining to the Amended and Restated 2006 Stock Option and Grant Plan and 2014 Stock
Incentive Plan of Concert Pharmaceuticals, Inc.;
(3) Registration Statement (Form S-8 No. 333-202453) pertaining to the 2014 Stock Incentive Plan of Concert Pharmaceuticals, Inc.;
(4) Registration Statement (Form S-8 No. 333-209841) pertaining to the 2014 Stock Incentive Plan of Concert Pharmaceuticals, Inc.;
(5) Registration Statement (Form S-8 No. 333-216459) pertaining to the 2014 Stock Incentive Plan of Concert Pharmaceuticals, Inc.;
(6) Registration Statement (Form S-8 No. 333-223335) pertaining to the 2014 Stock Incentive Plan of Concert Pharmaceuticals, Inc.; and
(7) Registration Statement (Form S-8 No. 333-229932) pertaining to the 2014 Stock Incentive Plan of Concert Pharmaceuticals, Inc.;
of our reports dated February 27, 2020, with respect to the consolidated financial statements of Concert Pharmaceuticals, Inc. and the effectiveness of internal
control over financial reporting of Concert Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Concert Pharmaceuticals, Inc. for the year
ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 27, 2020
CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 31.1
I, Roger D. Tung, certify that:
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Concert Pharmaceuticals, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Date: February 27, 2020
/s/ Roger D. Tung, Ph.D.
Roger D. Tung, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 31.2
I, Marc A. Becker, certify that:
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Concert Pharmaceuticals, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Date: February 27, 2020
/s/ Marc A. Becker
Marc A. Becker
Chief Financial Officer
(Principal Financial Officer)
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.1
In connection with the Annual Report on Form 10-K of Concert Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2019, as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roger D. Tung, President and Principal Executive Officer of the
Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 27, 2020
/s/ Roger D. Tung, Ph.D.
Roger D. Tung, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
A signed original of this written statement required by Section 906 has been provided to Concert Pharmaceuticals, Inc. and will be retained by Concert
Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.2
In connection with the Annual Report on Form 10-K of Concert Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2019, as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), I, Marc A. Becker, Principal Financial Officer of the Company, hereby
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 27, 2020
/s/ Marc A. Becker
Marc A. Becker
Chief Financial Officer
(Principal Financial Officer)
A signed original of this written statement required by Section 906 has been provided to Concert Pharmaceuticals, Inc. and will be retained by Concert
Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.